National Academies Press: OpenBook

Biologic Markers in Urinary Toxicology (1995)

Chapter: REFERENCES

« Previous: 7 CONCLUSIONS AND RECOMMENDATIONS
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

REFERENCES

Abrahamsson, P.A., L.B. Wadstrom, J. Aluments, S. Falkmer, and L. Grimelius. 1987. Peptide-hormone-and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol. Res. Pract. 182:298–307.

Abrahamsson, P.A., S. Falkmer, K. Falt, and L. Grimelius. 1989. The course of neuroendorcrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an endocrine marker. Pathol. Res. Pract. 185:373–380.

Acara, M.A., R.J. Mazurchuk, P.A. Nickerson, and R.J. Fiel. 1991. Magnetic resonance imaging and histopathology of hydronephrosis in the rat. Magnetic Resonanace Imaging 9:89–92.

Akaza, H., S. Kameyama, and Y. Aso. 1987. Significance of tumor markers in the treatment of urological malignancies [in Japanese]. Gan to Kagaku Ryoho 14:3034–3040.

Åkerström, B., and L. Lögdberg. 1990. An intruguing member of the lipwcalin protein family: α1-microglobin. Trends Biochem. Sci. 15:240–243.

Akimoto, S., K. Akakura, and J. Shimazaki. 1988. Prostatic acid phosphatse (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer [in Japanese], Hinyokika Kiyo (Acta. Urol. Jpn.) 34:1389–1396.

al-Abadi, H., and R. Nagel. 1988. Prognostic relevance of ploidy and proliferative activity of renal cell carcinoma. Eur. Urol. 15:271–276.

Alden, C.L. 1986, A review of unique male rat hydrocarbon nephropathy. Toxicol. Pathol. 14:109–111.

Alden, C.L. 1989. Male rat specific alpha2u globulin nephropathy and renal tumorigenesis. Pp. 535–541 in Nephrotoxicity. In Vitro to In Vivo. Animals to Man. P.H. Bach, and E.A. Lock, eds. New York: Plenum Press.

Alden, C.L., and C.H. Frith. 1991. Urinary system. Pp 315 in Handbook of Toxicologic Pathology, W.M. Haschek, and C.G. Rousseaux, eds. San Diego: Academic Press.

Alden, C.L., R.L. Kanerva, G. Ridder, and L.C. Stone. 1984. The pathogenesis of the nephrotoxocity of volatile hydrocarbons in the male rat. Pp. 107–120 in Advances in Modern Environmental Toxicology. Vol. III. Renal Effects of Petroleum

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Hydrocarbons. M.A. Mehlman, G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers, Inc.

Aleo, M.D., and R.G. Schnellman, 1992a. The neurotoxicants strychnine and biculline protect renal proximal tubules from mitochondrial inhibitor-induced cell death. Life Sci. 51:1783–1787.

Aleo, M.D., and R.G. Schnellman. 1992b. Regulation of glycolytic metabolism during long-term primary culture of renal proximal tubule cells. Am. J. Physiol. 262:F77F85.

Aleo, M.D., M.L. Taub, P.A. Nickerson, and P.J. Kostyniak. 1989. Primary cultures of rabbit renal proximal tubule cells: I. Growth and biochemical characteristics. In Vitro Cell. Dev. Biol. 25:776–783.

Alfrey, A.C., and R.C. Tomford. 1982. Phosphate and prevention of renal failure. Pp. 31–38 in Prevention of Kidney Disease and Long-Term Survival, M.M. Avram, ed. New York: Plenum.

Allen, B.C., and J.W. Fisher. 1993. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Analysis 13:71–86.

Allen, B.C., K.S. Crump, and A.M. Shipp. 1988. Correlation between carcinogenic potency of chemicals in animals and humans. Risk Anal. 8:531–544.

Allen, J.K., E.A. Krauss, and E.G. Deeter. 1991. Dipstick analysis of urinary protein. A comparison of Chemstrip-9 and Multistix-10SG. Arch. Path. Lab. Med. 115:34–37.

Allison, M.E., E.M. Lipham, W.E. Lassiter, and C.W. Gottschalk. 1973. The acutely reduced kidney. Kidney Int. 3:354–363.

Almeder, R. and J. Humber. 1987. Introduction to Quantitative Risk Assessment. Biomedical Ethics Reviews, 1986. J. Humbar, R. Almeder, eds. Clifton, N.J.: Humana Press.

Almeida, A.R.P., D. Bunnachak, M. Burnier, J.F.M. Wetzels, T.J. Burke, and R.W. Schrier. 1992. Time-dependent protective effects of calcium channel blockers on anoxia and hypoxia-induced proximal tubule injury. J. Pharmacol. Exp. Ther. 260:526–532.

Ambrose, S.S. 1983. Ureterosigmoidostomy. Pp. 511–520 in Urologic Surgery, 3rd edition, J.F. Glenn, ed. Philadelphia: Lippincott.

Ambrurn, J.L., C.M. Ambrus, P. Forgach, S. Stadler, J. Haplern, S. Sayyid, P. Niswander, and C. Toumbis. 1992. Studies on tumor induced angiogenesis. EXS 61:436–444.

Ames, B.N., and L.S. Gold. 1990. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 249:970–971.

Amico, S., J.C. Liehn, B. Desoize, H. Larbre, G. Deltour, and J. Valeyre. 1991 Comparison of phophotase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin. Nucl. Med. 16:643–648.

Anders, M.W. 1980 Metabolism of drugs by kidney. Kidney Int. 18:636–647.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Anders, M.W., ed. 1985. Bioactivation of Foreign Compounds. New York: Academic Press.

Anders, M.W. 1989. Biotransformation and bioactivation of xenobiotics by the kidney. Pp. 81–97 in Intermediary Xenobiotic Metabolism in Animals: Methodology, Mechanisms and Significance. D.H. Hutson, J. Caldwell, and G.D. Paulson, eds. London: Taylor & Francis.

Anders, M.W., L.H. LAsh, W. Dekant, A.A. Elfarra, and D.R. Dohn. 1988 Biosynthesis and metabolism of glutathione conjugates to toxic forms. CRC Crit. Rev. Toxicol. 18:311–341.

Anderson, R.L. 1985. Some changes in gastro-intestinal metabolism and in the urine and bladders of rats in responce to sodium saccharin ingestion. Fd. Chem. Toxic 23:457–463.

Anderson, R.L. 1988. An hypothesis of the mechanism of urinary tumorigenesis in rats ingesting sodium sacchrin. Fd. Chem. Toxic 26:637–644.

Anderson, R.L. 1991. Early indicators of bladder carcinogenesis produced by non-genotoxic agents. Mut. Res. 248:261–270.

Anderson, R.L., and C.L. Alden. 1989. Risk assessment for nitrilotriacetic acid (NTA). Pp. 390–426 in The Risk Assessment of Environmental Hazards. A Textbook of Case Studies. D.J. Paustenbach, ed. New York: John Wiley & Sons.

Anderson, P.M., and M.O. Schultze. 1965. Cleavage of S-(1,2-dichlorovinyl)-L-cysteine by and enzyme of bovine origin. Arch. Biochem. Biophys. 111:593–602.

Anderson, E., and the Carcinogen Assessment Group of the U.S. Environmental Protection Agency. 1983. Quantitative approaches in use to assess cancer risk. Risk Analysis 3:277–295.

Anderson, R.L., W.E. Bishop, and R.L. Campbell. 1985. A review of the environmental and mammalian toxicology of nitrolotriacetic acid. CRC Crit. Rev. Toxicol. 15:1–102.

Anderson, R.L., R.L. Kanerva, F.R. Lefever, and W.R. Francis. 1986a. Effect of N-nitrose-n-butyl-(4-hydroxybutyl)amine exposure on the changes in mineral deposition caused by trisodium nitrilotriacetate. Fd. Chem. Toxic 24:229–235.

Anderson, S., H.G. Rennke, and B.M. Brenner. 1986b. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invset. 7:1993–2000.

Anderson, R.L., F.R. Lefever, and J.K. Maurer. 1988. The effect of various sacchrin forms on gastro-intertinal tract, urine and bladder on male rats. Fd. Chem. Toxic. 26:665–669.

Andersson, G., and E. Jennische. 1988. IGF-I immunoreactivity is expressed by regenerating renal tubular cells after ischaemic injury in the rat. Acta. Physiol. Scand. 132:4653–457.

Andersson, G.L., A. Skottner, and E. Jennische. 1988. Immunocytochemical and

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

biochemical localization of insulin-like growth factor I in the kidney of rats before and after uninephrectomy. Acta. Endocrinol. 119:555–560.

Anglard, P., K. Tory, H. Brauch, G.H. Weiss, F. Latif, M.J. Merino, M.I. Lerman, B. Zbar, and W.M. Linehan. 1991. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res. 51:1071–1077.

Annab, L.A., J.T. Dong, P.A. Futreal, H. Satoh, M. Oshimura, and J.C. Barrett. 1992. Growth and transformation suppressor genes for BHK Syriam hamster cells on human chromosomes 1 and 11. Mol. Carcinog. 6:280–288.

Anonymous. 1985. Acid phosphatases and other tumor markers in the management of prostatic cancer. Proceedings of the Workshop of the Scandinavian Prostatic Cancer Group, Scandinavian Committee on Enzymes. Copenhagen, March 1985. Scand. J. Clin. Lab. Invest. Suppl. 179:1–117.

Anonymous. 1990. Bladder cancer screening in high-risk groups. Proceedings of the International Conference. September 13–14, 1989. J. Occup. Med. 32:787–945.

Arndt, R. J. Durkopf, H. Huland, F. Donn, T. Loening, and H. Kalthoff. 1987. Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. J. Urol. 137:758–763.

Ash, S.R., and F.E. Cuppage. 1970. Shift toward anaerobic glycolysis in the regererating rat kidney. Am. J. Pathol. 60:385:402.

Askergren, A., L.G. Allgen, and J. Berstrom. 1981. Studies on kidney function in subjects exposed to organic solvents. 1. Excretion of albumin and beta2-microglobulin in the urine. Acta. Med. Scand. 209:479–483.

Askergren, A. 1984. Urinary protein and cell excretion in constructions workers exposed to organic solvents.

Asselin, C., and K.B. Marcus. 1989. Mode of c-myc gene regulation in folic acid-induced kidney regeneration. Oncogene Res. 5:67–72.

Aten, J., C.B. Bosman, J. Rozing, T. Stynen, P. Hoedemacker, and J.J. Weening. 1988. Mercuric chloride-induced autoimmunity in the Brown Norway Rat. Am. J. Path. 133:127–138.

Aulizky, W.K., P.N. Schlogel, D. Wu, C.Y. Cheng, C.C. Chen, P.S. Li, M. Goldstein, M. Reidenberg, and C.W. Bardin. 1992. Measurement of urinary clusterin as an index of nephrotoxicity. Proc. Soc. Exp. Biol. Med. 199:93–96.

Azzopardi, J.G., and D.J. Evans. 1971. Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium. J. Pathol. 104:247–251.


Baisch, H., U. Otto, and G. Kloppel. 1986. Malignancy index based on flow cytonetry and histology for renal cell carcinomas and its correlation to prognosis. Cytometry 7:200–204.

Baisch, H., G. Kloppel, and U. Otto. 1990. Pp. 249–260 in DNA analysis in relan neoplasia. New York: Churchill Livingstone.

Balitskaia, O.V., N.K. Berdinskikh, and N.G. Kononenko. 1992. The possibilities of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

using the free polyamines of the peripheral blood as biochemical tumor markers in nephroblastoma in children [in Russian]. Vopr. Onkol. 38:674–682.

Ballardi, F.W., ed. 1992. Autoimmunity in Nethritis. Chur, Switzerland: Harwood Academic Publishers.

Ballatori, N., R. Jacob, C. Barrett, and J.L. Boyer. 1988. Biliary catabolism of glutathione and differential reabsorption of its amino acids constituents. Am. J. Physiol. 254:G1–G7.

Bander, N.H., C.L. Finstad, C. Cordon-Cardo, R.D. Ramsawak, E.D. Vaughan, W.F. Whitmore, H.F. Oettgen, M.R. Melames, and L.J. Old. 1989. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res. 49:6774–6780.

Bandyk, M., I. Sawczuk, C.A. Olsson, A.E. Katz, and R. Buttyan. 1990. Characterization of the products of a gene expressed during androgen-programmed cell death and their potential use as a marker of urogenital injury.

Banki, K., and M.W. Anders. 1989. Inhibition of rat kidney mitochondrial DNA, RNA and protein synthesis by halogenated cystein S-conjugates. Carcinogenesis 10:767–772.

Baretton, G., B. Kuhlmann, R. Krech, U. Lohrs. 1991. Intratumoural heterogeneity of nuclear DNA-content and proliferation in clear cell type carcinomas of the kidney. Virchows Arch B: Cell Pathol. Mol. Pathol. 61:57–63.

Baricordi, O.R., A. Sensi, C. DeVinci, L. Melchorri, G. Fabris, E. Marchette, F. Corrado, P.L. Mattiuz, and G. Pizza. 1985. A monoclonal antibody to human transitional cell carcinoma of the bladder cross reaction with a differentiation antigen of neutrophilic lineage. Int. J. Cancer 35:781–786.

Barrett, J.C., and J.E. Huff. 1991. Cellular and molecular mechanisms of chemically induced renal cancinogenesis in nephretoxicity. Pp. 287–306 in Mechanisms, Early Diagnosis, and Therapeutic Management . P.H. Bach, N.J. Gregg, M.F. Wiks, and L. Delactuz, eds. New York: Marcel Dekker, Inc.

Balslov, J.T., and H.E. Jorgensen. 1963. A survey of 499 patients with acute anuric renal insufficience. Causes, treatment, complications, and mortality. Am. J. Med. 34:75.

Bass, R.A., G. Hemstreet, N.A. Honker, R.E. Hurst, R.S. Doggett. 1987. DNA cytometry and cytology by quantitative fluorescence inage analysis in sympltomatic bladder cancer patients. Int. J. Cancer 40(5):698–705.

Basta, M.T., A.M. Attallah, M.N. Seddek, H. el-Mohamady, E.S. Al-Hilaly, N. Atwaan, and M. Ghoneim. 1988. Cytokeratin shedding in urine: A biological marker for bladder cancer? Br. J. Unol. 61:116–121.

Bauer, H.W. 1988. Acid phosphatase, alkaline phosphatase and prostate-specific antigen—usefulness in the diagnosis of netastatic disease and follow-up. Prog. Clin. Biol. Res. 269:33–42.

Bauer, D., Müller, J. Reich, H. Riedel, V. Ahrenkiel, P. Warthoe, and M. Strauss.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1993. Indentification of differentially expressed mRNA species by an improver display technique (DDRT-PCR). Nucleic Acids Res. 21:4272–4280.

Beckett, M.L., G.B. Lipford, C.L. Haley, P.F. Schellhammer, and G.L. Wright. 1991. Monoclonal antibody PD41 recognizes and antigen restricted to prostate adencarcinomas. Cancer Res. 51:1326–1333.

Beer, D.G., K.A. Zweifel, D.P. Simpson, and H.C. Pitot. 1987. Specific gene expression during compensatory renal hypertrophy in the rat. J. Cell Physiol. 131:29–35.

Beggard, I., and A.G. Bearn. 1968. Isolation and properties of a low molecular weight β2-globulin occuring in human biological fluids. J. Biol. Chem. 243:4095–4103.

Bethrens, M.T., A.L. Corbin, and M.K. Hise. 1989. Epidermal growth factor receptor regulation in rat kidney: Two models of renal growth. Am. J. Physiol. 257:4095–4103.

Beirne, G.J., J.T. Brennan. 1972. Glomerulonephritis associated with hydrocarbon solvents. Arch. Environ. Health 24:365–369.

Bell, G.M., D. Doig, D. Thompson, J.L. Anderton, and J.S. Robson. 1985. End-stage renal disease associated with occupational exposure to organic solvent. Proc EDTA-ERA 22:725–729.

Bell, G.I., N.M. Fong, M.M. Stempien, M.A. Wormsted, D. Caput, L. Ka, M.S. Urdea, L.B. Rall, and R. Sanchez-Pescador. 1986. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res. 14:8427–8446.

Ben-Aissa, H., S. Paulie, and H. Koho. 1985. Specificities and binding properties of two monoclonal antibodies against carcinoma cells of the human urinary bladder. Br. J. Cancer 52:65–72.

Bennett, W.M., L.W. Elzinga, and G.A. Porter. 1991 Tubulointerstitial disease and toxic nephropathy. Pp. 1430–1496 in the Kidney. B.M. Brenner, F.C. Rector, and W.B. Saunders, eds. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo.

Bennington, J.K., and J.B. Beckwith. 1975. Tumors of the Kidney, Renal Pelvis, and Ureter. Pp. 93–199 in Atlas of Tumor Pathology. Second Series, Fascicle 12. Washington, D.C.: Armed Forces Institute of Pathology.

Benson, M.C., I.S. Whang, C.A. Olsson, D.J. McMahon, And W.H. Cooner. 1992a. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147:813–821.

Benson, M.C., I.S. Whang, A. Pantuckk, K. Ring, S.A. Kaplan, C.A. Olsson, and W.H. Cooner. 1992b. Prostate specific antigen density: A means of distinuishing benign prostatic hypetrophy and prostate cancer. J. Urol. 147:815–816.

Bergerheim, U., M. Nordenskjold, and V.P. Collins. 1989. Deletion mapping in human renal cell carcinoma. Cancer Res. 49:1390–1396.

Bergerheim, U.S., K. Kunimi, V.P. Collins, and P. Ekman. 1991. Deletion mapping of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

chromosomes 8, 10, and 16 in human prostatic cancinoma. Genes Chromosom. Cancer 3(3):215–220.

Berggard, I. 1970. Plasma proteins in normal human urine. Pp. 7–19 in Proteins in Normal and Pathological Urine. Y. Manuel, J.P. Revillard, and H. Betuel. eds. S. Karger, Basel.

Berlyne, G.M. 1984. Toxic nephropathies and current methods for early dection of the toxicity of the kidney. Pp. 173–184 in Renal Effects of Petroleum Hydrocarbons. Advances in Moderm Environmental Toxicology, Vol. VII. M.A. Mehlman, C.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers.

Berman, J., J. Seidman, R. Yetter, adn G. Moore. 1991. Clear cell dysplasia of the bladded. Report of a case with flow cytometric analysis. Anal. Quant. Cytol. Histol. 13(6):391–394.

Bernard, A., A. Vyskocyl, P. Mahieu, and R. Lauwerys. 1988. Effect of renal insufficiency on the concentration of free retinol-binding protein in urine and serum. Clin. Chim. Acta. 171:85–93.

Bernard, A.M., R.R. Lauwerys, A. Nöel, B. Vandeleene, and A. Lambert. 1989. Urine protein 1: A sex dependent marker of tubular or glomerular dysfunction. Clin. Chem. 35:2141–2142.

Berndt, W.O. 1981. Use of renal function tests in the evaluation of nephrotoxic effects. Pp. 1–29 in Toxicology of the Kidney, J.B. Hook, ed. New York: Raven.

Berrozpe, G., R. Miro, M.R. Caballin, J. Salvador, and J. Egozcue. 1990. Trisomy 7 may be a primary change in noninvasive transitional cell cancinoma of the bladded. Cancer Genet. Cytogenet. 50:9–14.

Bertani, T., M. Livio, D. Maconi, M. Morigi, G. Bisogno, C. Patrono, and G. Remuzzi. 1987. Platelet activating factor (PAF) as the mediator of injury in nephrotoxic nephritis. Kidney Int. 31:1248–1256.

Bi, W., J.Y. Rao, G.P. Hemstreet P. Fang. N.R. Asal, M. Zang, K.W. Min , Z. Ma, P. Fang, E. Lee, G. Li, R.E. Hurst, W. Wu, R.B. Bonner, Y. Wang, Y. Fradet, and S. Yin. 1993. Field molecular epidemiology: Feasibility of monitering for the malignant bladder cell phenotype in a benzidine exposed occupational cohort. J. Occup. Med. 35(1):20–27.

Birk, H.W., S. Piberhofer, G. Schutterle, W. Haase, J. Kotting, and H. Koepsell. 1991. Analysis of Na+-D-glucose cotransporter and other renal brush border proteins in human urine. Kidney Int. 40:823–837.

Blais, A., F. Jalal, P. Crine, J. Paiement, and A. Bertloot. 1992. Increased functional differentiation of rabbit proximal tubule cells cultured in glucose-free media. Am. J. Physiol. 263:F152–F162.

Blay, J.Y., S. Negrier. V. Combaret, S. Attali, E. Goillot, Y. Merrouche, A. Mercatello, A. Ravault, J.M. Tourani, J.F. Moskovtchenko, T. Phillip, and M. Favrot. 1992.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Serum level of interieukin 6 as a prognosis factor in metastatic renal cell cercinoma. Cancer Res. 52:3317–3322.

Blouin, P., M.C. Guiot, and S. Jothy. 1989. Definition of the human renal cell carcinoma phenotype using monoclonal and polyclonal antibodies: A tumor marker study. Exp. Pathol. 36:147–163.

Boag, A.H., and I.D. Young. 1992. Type IV collagenase expression in prostatic adenocarcinoma [abstract]. Mad. Pathol. 5:51A.

Bodenstab, W., J. Kaufman, and C.L. Parsons. 1983. Inactivation of antoadherence effect of bladder surface glycusaminoglycan by a complete urinary carcinogen (N-methyl-N-nitrosourea). J. Urol. 129.

Boehm, T., I. Lavenir, A. Forster, R.B. Wadey, J.K. Cowell, J. Harbott, F. Lampert, J. Waters, P. Sherrington, and P. Couillin. 1988. The T-ALL specific t(11;14)(p13;q11) translocation breakpoint cluster region is locatid near tho the Wilms'tumour prodisposition locus. Oncogene 3:691–695.

Boileau, M., D. Swartz, K. Schmidt, and W. Schmidt. 1987. Bladder cancer dection and surceillance: Carcinoembryonic antigen as a monitor of newplastic transformation. J. Surg. Oncol. 35:120–123.

Boldog, F., K. Arheden, S. Imreh, B. Strombeck, L. Szekely, R. Erlandsson, Z., Marcsek, J. Sumegi, F. Mitelman, and G. Klein. 1991. Involvement of 3p deletions in sporatic and hereditary forms of renal cell cancinoma. Genes Chromosomes Cancer 3:403–406.

Bombassei, G.J., and A. E. Kaplan. 1992. The association between hydrocarbon exposure and antiglomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am. J. Indust. Med. 21:141–153.

Bonner, R.B., G.P. Hemstreet, Y. Fradet, J.Y. Rao, K.W. Min, and R.E. Hurst. 1993. Bladder cancer risk assessment with quantitative fluoroscence image analysis of tumor markers in exfoliated bladder cells. Cancer 72:2461–2469.

Boogaard, P.J., J.N.M. Commandeur, G.J. Mulder, N.P.E. Vermeulen, and J.F. Nagelkerke. 1989. Toxicity of cystein S-conjugates and mercapturic acids of four structurally related difluoroethylenes in isolated proximal tubular cells from rat kidney: Uptake of the conjugates and activation to toxic metabolites. Biochem. Pharmacol. 38:3731–3741.

Boogaard, P.J., J.P. Zoeteweij, T.J.C. van Berkel, J.M. van't Noorkende, G.J. Mulder, and J.F. Nagelkerke. 1990. Primary culture of proximal tubular cells from normal rat kidney as an in vitro model to study mechanisms of nephrotoxicity: Toxicity of nephrotoxicants at low concentrations during prolonged exposure. Biochem. Pharmacol. 39:1335–1345.

Bookstein, R., D. MacGrogan, S.G. Hilsenbeck, F. Sharkey and D.C. Allred. 1993. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:3369–3373.

Borghoff, S.J., B.G. Short, and J.A. Swenberg. 1990. Biochemical mechanisms and

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

pathobiology of α2u-giobulin nephropathy. Ann. Rev. Pharmacol. Toxicol. 30:349–367.

Borghoff, S.J., A.B. Miller, J.P. Bowen, and J.A. Swenberg. 1991 Characteristics of chemical binding to α2u-globulin in vitro—evaluation structure-activity relationships. Toxicol. Appl. Pharmacol. 107:228–238.

Borland, R., C. Brendler, and W.B. Isaacs. 1992. Molecular biology of bladder cancer. Hematol. Oncol. Clin. NorthAm. 6(1):31–39.

Bortz, J.D., P. Rotwein, D. DeVol, et al. 1988. Focal expression of insulin-like growth factor I in rat kidney collection duct. J. Cell Biol. 107:811–819.

Bostwick, D.G. 1989. The pathology, of early prostate cancer. Cancer J. Clin. 39:376–393.

Bostwick, D.G, 1989. Varients of prostatic carcinoma. Pp. 95–133 in Pathology of the Prostate, D.G. Bostwick, ed. New York: Churchill Livingstone.

Bostwick, D.G., Graham, P. Napalkov, P.A. Abrahamsson, P.A. di Sant'Agnese, F. Algaba, P.A. Hoisaeter, F. Lee, P. Littrup, and F.K. Mostofi. 1993. Staging of early prostate cancer: A proposed tumor volume-based prognostic index. Urology 41:403–411.

Boswell, J.M., M.A. Yui, D.W. Burt, and V.E. Kelley. 1988. Increased tumor necrosis factor and IL-1β gene expression in the kidneys of mice with lupus nephritis. J. Immunol. 141:3050–3054.

Bot, F.J., J.C. Godschalk, K.K. Krishnadath, T.H. van der Kwast, and F.T. Bosman. 1994. Prognostic factors in renal-cell carcinoma: Immunohistochemical detection of p53 protein versus clinico-pathological paramenter. Int. J. Cancer 57:634–637.

Boucher, A., D. Droz, E. Adafer, and L-H. Noël. 1986. Characterization of mononuclear cellsubsets in renal cellular interstitial infiltrates. Kidney Int. 29:1043–1049/

Boffioux, C.R. 1980. Etiological and epidemiological considerations in prostatic cancer. Scand. J. Urol. Nephrol., Suppl. 55;9–16.

Bowers, M.A., L.D. Aicher, H.A. Davis, and J.S. Woods. 1992. Quantitative determination of porphyrins in rat and human urine and evaluation of urinary porphyrin profiles during mercury and lead exposures. J. Lab. Clin. Med. 120:272–281.

Boyce, N.W. P.G. Tipping, and S.R. Holdsworth. 1989. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int. 35:778–782.

Boyle, E. 1970. Biological patterns in hypertension by race, sex, body weight and skin color. JAMA 213:1637–1643

Brady, H.R. B.C. Kone, M.E. Stromski, M.L. Zeidel, G. Giebisch, and S.R. Gullans. 1990, Mitochondrial injury: An early event in cisplatin toxicity to renal proximal tubules. Am. J. Physiol. 258:F1181–F1187.

Brauch, H. K. Tory, W.M. Linehan, D.J. Weaver, M.A. Lovell, and B. Zbar. 1990.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Molecular analysis of the sort arm of chromosome 3 in five renal oncocytomas. J. Urol. 143:622–624.

Braver, D.J., M. Modan, A Chetrit, A. Lucky, and Z. Braf. 1987. Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer. J. Natl. Cancer Inst. 78:437–440.

Brazy, P.C., L.J. Mandel, S.R. Gullans, and S.P. Soltoff. 1984. Interactions between phosphate and oxidative metabolism in proximal renal tubules. Am. J. Physiol. 247:F575–F581.

Brenner, B.M., and S. Anderson. 1989. Filtration surface area, salt intake, and hypertension. Pp. 45–59 in The Progressive Nature of Renal Disease: Myths and Facts. Contributions in Nephrology, Vol. 75, L. Oldrizzi, G. Maschio, and C. Rugiu, eds. Basel: Karger.

Brenner, B.M., and F.C. Rector, eds. 1986. The Kidney, 3rd edition. Philadelphia: W.B. Saunders Company.

Brenner, B.M., T.W. Meyer, and T.H. Hostetter. 1982. Dietary protein intake and the progressive nature of kidney disease. N. Engl. J. Med. 307:652–659.

Bretton, P.R., A. Myc, C. Cordon-Cardo, P. DeAngelis, W.R. Fair, and M.R. Melamed. 1989. Initial evaluation of a new epithelial antigen (TI 6) for bivariate flow cytometry of bladder irrigation specimens. Cytometry 10:339–344.

Breysse, P., W.G. Couser, C.E. Alpers, K. Nelson, L. Gaur, and R.J. Johnson . 1994. Membranous nephropathy and formaldehyde exposure.

Bringuier, P.P., R. Umbas, H.E. Schaafsma, H.F.M. Karthaus, F.M. J. DeBruyne, and J.A. Schalken. 1993. Decreased e-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53:3241–3245.

Bringuier, P.P., R. Bouvier, N. Berger, E. Piaton, J.P. Revillard, P. Perrin, and M. Devonec. 1993. DNA ploidy status and DNA content instability within single tumors in renal cell carcinoman. Cytometry 14:559–564.

Brochard, P., J. DePalmas, M. Martini, M. Bondet, and G. Largue. 1984. Etude de la prevalence des proteinuries dipistees chex des sujets exposes professionnellment aux solvants. XXI Int. Congr. Occup. Health, Dublin.

Broder, L.E., B.D. Weintraub, S.W. Rosen, M.H. Cohen, and F. Tejada. 1977. Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 40:211–216.

Brooks, D.E. 1987. The major androgen-regulated secretory proteins of the rat epidiymis bear sequence homology with members of the α 2u-globulin superfamily. Biochem. Int. 14:235–240.

Brooks, J.D., G.S. Bova, F.F. Marshall, and W.B. Isaacs. 1993. Tumor suppressor gene allelic loss in human renal cancers. J. Ruol. 150:1278–1283.

Bruner, R.H. 1984. Pathologic findings in laboratory animals exposed to hydrocarbon fuels of military interest. Pp. 133–140 in Advances in Modern Environmental Toxicology. Vol. Vii. Renal Effects of Petroleum Hydrocarbons. M.A. Mehlman,

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton: Princeton Scientific Publishers, Inc.

Bucher, N.L.R., and R.A. Malt. 1971. Regeneration of liver and kidney. Boston: Little, Brown.

Buchet, J.P., R. Lauwerys, H. Roels, A. Bernard, P. Bruaux, F. Claeys, G. Ducofere, P. De Plaen, J. Staessen, A. Amery, P. Lijnen, L. Thijs, D. Rondia, F. Sartor, A. Saint Remy, and L. Nick. 1990. Renal effects of cadmium body burden of the general populatoin. The Lancet 335:699–762.

Bullock, A.D., J.J. Becich, C.G. Klutke, and T.L. Ratliff. 1992. Experimental autoimmune cystitis: A potential murine model for ulcerative interstitial cystitis. J. Urol. 148:1951–1956.

Burg, M. b., and M.A. Knepper. 1986. Single ruble perfusion techniques. Kidney Int. 30:166–170.

Burns, C.P., and E. Rozengurt. 1984. Extracellular Na+ and initiation of DNA synthesis: Role of intracellular pH and K+. J. Cell Biol. 98:1082–1089.

Burton, B.T. and G.H. Hirschman. 1979. Demographic analysis: End-stage renal disease and its treatment in the United States. Clin. Nephrol. 11:47–51.

Bussemakers, M.J.G., W.B. Isaacs, B.S. Carter, W. Van de Ven, F.M.J. DeBruyne, and J.A. Schalken. 1991. Ecahedrin is a candidate trumor suppressor gene implicated in prostate cancer. J. Urol. 145:294A.

Buttyan, R., C.A. Olsson, J. Pintar, C. Chang, M. Bandyk, P. Ng., and I.S. Sawczuk. 1989. Induction of the TRPM-2 gene in cells undergoing programmed death. Molec. and Cell Biol. 9:3473–3481.

Byrne, C., J. Nedelman, and R.G. Luke. 1994. Race, socioeconomic status, and the development of end-stage renal disease. Amer. J. Kidney Dis. 23:16–22.


Cagnoli, L., S. Casanova, S. Pasquali, U. Donini, and P. Zucchelli. 1980. Relation between hydrocarbon exposure and the nephrotic syndrome. BMJ 280:1068–1069.

Cairns, P., A.J. Proctor, and M.A. Knowles. 1991. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6:2305–2309.

Cantrell, B.B., D.P. DeKlerk, J.C. Eggleston, J.K. Boitnott, and P.C. Walsh. 1981. Pathological factors that influence prognosis in state A prostatic cancer: The influence of extent versus grade. J. Urol. 125:516–520.

Capella, C., L. Usellini, R. Buffa, B. Frigerio, and e. Solcia. 1981. The endocrine component of prostatic carcinomas, mixed adenocarcinoid tumours and non-tumour prostate: Histochemical and ultrastructural identification of the endocrine cells. Histopathology 5:175–192.

Carbin, B.E., P. Ekman, P. Eneroth, and B. Nilsson. 1989. Urine-TPA (tissue polypeptide antigen), flow cytometry and cytology as markers for furnor invasiveness in urinary bladder carcinoma. Urol. Res. 17:269–272.

Carlisle, E.J., S.M. Donnelly, S. Vasuvattakul, K.S. Kamel, S. Tobe, and M.L. Halperin.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1991. Glue-sniffing and distal renal tubular acidosis: Sticking to the facts [review]. J. Amer Soc. Nephrol. 1:1019–1027.

Carter, H., S. Piantadosi, and J. Isaacs. 1990 Clinical evidence for an implications of the multistep development of prostate cancer. J. Ruol. 143(4):742–746.

Carter, B.S., T.H. Beaty, G.D. Steinberg, B. Childs, and P.C. Walsh. 1992. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 89(8):3367–3371.

Cartwright, R.A. 1986. Screening workers exposed to suspect bladder carcinogens. J. Occup. Med. 28(10):1017–1019.

Casalone, R., P. Granata Casalone, E. Minelli, P. Portentoso, R. Righi, E. Meroni, A. Guidici, D. Donati, C. Riva, and S. Salvatore. 1992. Siginificance of the clonal and sporadic chromosome abnormalities in non-neoplastic renal tissue. Hum. Genet. 90:71–78.

Catalona, W.J. 1992. Urothelial Tumors of the Urinary Tract. Pp. 1094–1158 in Campbell's Urology, Vol 2., P.C. Walsh, A.B. Retik, T.A. Stamye, and E. Darracott Vaughan, Jr., eds. W. B. Saunders Company.

Catalona, W.J. 1994. Screening for prostate cancer. Lancet 343:1436–1437.

Catalona, W.J., D.S. Smith, T.L. Ratliff, K.M. Dodds, D.E. Coplen, J.J. Yan, J.A. Petros, and G.L. Andriole. 1991. Measurement of prostate-specific antigen in serum as a screening test for rpostate cancer published erratum appears in N. Engl. J. Med. 1991 Oct 31. 325(18):1324 [see comments]. N. Engl. J. Med. 324:1156–1161.

Catalona, W.J., J.P. Richie, F.R. Ahmann, M.A. Hudson, P.T. Scardino, R.C. Flanigan, J.B. deKernion, T.L. Ratliff, L.R. Kavoussi, B.L. Dalkin, W.B. Waters, M.T. MacFarlane, and P.C. Southwick. 1994. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J. Urol. 151:1283–1290.

Catalona, W.J., D.S. Smith, T.L. Ratliff, and J.W. Basler. 1993. Detection of organ-confined prostate cancer is increased through prostate-specific santigen-gased screening. J. Am. Med. Assoc. 270(8):948–954.

Cattell, V., T. Cook, and S. Moncada. 1990. Glomeruli synthesize nitrate in experimental nephrotoxic nephritis. Kisney Int. 38:1056–1060.

Chamberlin, M.E., A. LeFurgey, and L.J. Mandel. 1984. Suspension of medullary thick ascending limb tubules from the rabbit kidney. Am. J. Physiol. 247:F955–F964.

Charbonneau, M., J. Strasser, E.A. Lock, M.J. Turner, and J.A. Swenberg. 1989. Involvement of reversible binding to α2u-globulin in 1,4 dichlorobenzene-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 99:122–132.

Chasseaud, L.F. 1979. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res. 29:175–274.

Chatterjee, B., W.F. Demyan, C.S. Song, B.D. Garg, and A.K. Roy. 1989. Loss of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

androgenic induction of α2u-globulin gene family in the liver of NIH black rats. Endrocrinology 125:1385–1388.

Chavers, B.M., R.W. Bilous, E.E. Ellis, M.W. Steffes, and S.M. Mauer. 1989. Glomerular lesions and urinary albumin exretion in Type I diabetes without overt proteinuria.

Chen, Q., T.W. Jones, P.C. Brown, and J.L. Stevens. 1990a. The mechanisms of cysteine conjugate cytotoxicity in renal epithelial cells: Covalent binding leads to thiol depletion and lipid peroxidation. J. Biol. Chem. 265:21603–21611.

Chester, A.C., T.A. Rakowski, W.P. Argy, A. Giacalone, and G.E. Schreiner. 1979. Hemodialysis in the eight and ninth decade of life. Arch. Intern. Med. 139:1001–1005.

Cheung, C.K., and R. Swaminathan. 1989. Automated immunoturbidometric methods for the determination of retinol binding protein, prealbumin and transferrin in urine. Clin. Biochem. 22:425–427.

Chi, S.G., R.W. DeVere White, F.J. Meyers, D.B. Siders, F. Lee, and P.H. Gumerlock. 1994. Prostate cancer: Frequent expressed transition mutations. J. Nat. Cancer Inst. 86:926–933.

Chin, T.Y., R.W. Tyl, J.A. Popp, and H. d'A. Heck. 1981. Clinical urolithiasis. 1. Characteristics of bladder stone induction by terephthalic acid and dimethyl terephthate in weanling Fischer-344 rats. Toxicol. Appl. Pharmacol. 58:307–321.

Chopin, D.K., J.B. deKernion, D.L. Rosenthal, and J.L. Fahey. 1985. Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing. J. Urol. 134:260–265.

Chow. N.H., T.S. Tzai, S.N. Lin, S.H. Chan, and M.J. Tang. 1993. Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. Eur. Urol. 24:140–143.

Chowdhury, A., G.J. Harber, and D.P. Chopra. 1989. Characterization and serial propagation of mouse prostate epithelial cells in serum-free medium. Biol. Cell 67:281–287.

Chung, S.D., N. Alavi, D. Livingston, S. Hiller, and M. Taub. 1982. Characterization of primary rabbit kidney cultures that express proximal tubule functions in a hormonally defined medium. J. Cell Biol. 95:118–126.

Cisternino, A., F. Argona, A. Garbeglio, A. Ranieri, P. Bassi, and V. Pergoraro. 1986. CEA and ABO antigens as early signs of malignancy in urotheliomas of the upper urinary tract [in Spanish]. Arch. Esp. Urol. 39:529–533.

Clar-Blanch, F., L. Morell-Quadreny, B. Fenollosa-Entrena, P. Chuan-Nuez, M. Gil-Salom, P. Carretero-Gonzalez, and A. Liombart-Bosch. 1992. Correlation between serum values of prostatic acid phosphatase and morphometric analysis in the cytologic diagnosis of prostatic carcinoma. Eur. Urol. 21 Suppl. 1:75–78.

Clarke, A.R., C.A. Purdie, and D.J. Harrison. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849–852.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Clevenger, C., A. Epstein, and K. Bauer. 1987a. Quantitative analysis of a nuclear antigen in interphase and mitotic cells. Cytometry 8:280–286.

Clevenger, C., A. Epstein, and K. Bauer. 1987b Modulation of the nuclear antigen P105 as a function of cell-cycle progression. J. Cell. Physiol. 130:336–343.

Cockroft, D.W., and M.H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41.

Cohen, C., P.A. McCue, and P.B. Derose. 1988. Histogenesis of renal cell carcinoma and renal oncocytoma. An immunohistochemical study. Cancer 62:1946–1951.

Cohen, G.M. 1986. Basic principles of target organ toxicity. Pp. 1–6 in Target Organ Toxicity, Vol. 1, G.M. Cohen, ed. Boca Raton, Fla: CRC Press.

Cohen, R., G.S. Bedi, and M.E. Neider. 1990. Tissue distribution of an inducible cystatin in isoproterenal-treated rats. Lab. Invest. 62:452–457.

Cohen, S.M., and L.B. Ellwein. 1991. Genetic erros, cell proliferation, and carcinogenesis. Cancer Res. 51:6493–6505.

Cohen, P., D. Peehl, G. Lamson, and R. Rosenfeld. 1991a. Insulin-like growth factors (IGSs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 73:401–407.

Cohen, S.M., L.B. Ellwein, T. Okamura, T. Masui, S.L. Johansson, R.A. Smith, J.M. Wehner, M. Khachob, C.I. Chappel, G.P. Schoenig, J.L. Emerson, and E.M. Garland. 1991b. Comparative bladder tumor promoting activity of sodium saccharin, sodium ascorbate, related acids, and calcium salts in rats. Cancer Res. 51:1766–1777.

Cohen, M.B., F.M. Waldman, P.R. Carroll, R. Kerschmann, K. Chew, and B.H. Mayall. 1993. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum. Pathol. 24:772–778.

Cojocel, C., K. Maita, D.A. Pasino, C.-H. Kuo, and J.B. Hook. 1983. Metabolic heterogeneity of the proximal and distal kidney tubules. Life Sci. 33:855–861.

Cole, P., and R. Hoover. 1971. Comments on turmor of the urinary bladder: An analysis of the occupation sof 1030 patients in Leeds, England. J. Nat. Cancer Inst. 46:1111–1113.

Cole., P., R.R. Monson, H. Haning, and G.H. Friedell. 1971. Smoking and cancer of the lower urinary tract. N. Eng. J. Med. 284:129–134.

Colle, A., C. Tonnelle, T. Jarry, C. Coirre, and Y. Manual. 1984. Isolation and characterization of post gamma globulin in mouse. Biochem. Biophys. Res. Comm. 122:111–115.

Commandeur, J.N.M., and N.P.E. Verneulen. 1990. Molecular and biochemical mechanisms of chemically induced nephrotoxicity: A review. Chem. Res. Toxicol. 3:171–194.

Committee on Biological Markers of the National Research Council. 1987. Biological Markers in environmental health research. Environ. Health Perspect. 74:3–9.

Connolly, J., and D. Rose. 1990. Production of epidermal growth factor and

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16:209–218.

Connolly, J., and D. Rose. 1992. Interactions between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line. Prostate 20:151–158.

Cook, H.T., J. Smith, J.A. Salmon, and V. Cattell. 1987. Functional characteristics of macrophages in glomerulonephritis in the rat: O2-generation, MHC class II expressive and eicosanoid synthesis. Am. J. Pathol. 134:431–437.

Coombes, R.C., P.B. Greenberg, C. Hillyard, and I. Maclntyre. 1974. Plasma immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet 1:1080–1083.

Coombs, L.M., D.A. Pigott, E. Sweeney, A.J. Proctor, M.E. Eydmann, C. parkinson, and M.A. Knowles. 1991. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 63:601–608.

Cordon-Cardo, C., Z. Fuks. M. Drobnjak, C. Moreno, L. Eisenbach, and M. Feldman. 1991. Expression of HLA-A,B,C antigens in primary and metastic tumor cell populations of human carcinomas. Can. Res. 51:6372–6380.

Cordon-Cardo, C., D.D. Wartinger, M.R. Melamed, W. Fair, and Y. Fradet. 1992. Immunopathologic analysis of human urinary bladder cancer. Characterization of two new antigens associated with low-grade superficial bladder tumors. Am. J. Pathol. 140:375–385.

Cornelius, C.E., A.S. Mia, and S. Rosenfield. 1965. Ruminant urolithiasis VII. Studies on the origin of Tamm-Horsfall urinary mucoprotein and its presence of ovine calculus matrix . Invest. Urol. 2:453–457.

Cowley, B.D., F.L. Smardo, J.J. Grantham, and J.P. Calvet. 1987. Elevated c-myc oncogene expression in autosomal recessive polycystic kidney disease. Proc. Natl. Acad. Sci. U.S.A. 84:8394–8398.

Cowley, B.D., L.J. Chadwick, J.J. Grantham, and J.P. Calvet. 1989. Sequential proto-oncogene expression in regenerating kidney following acute renal injury. J. Biol. Chem. 264:8389–8393.

Crump, K.S., 1984. An improved procedure for low-dose carcinogenic risk assessment from animal data. J. Environ. Pathol. Toxicol. 5:339–348.

Crump, K.S., B. Allen, and A. Shipp. 1989. Choice of dose measure for extrapolating carcinogenic risk from animals to humans: An empirical investigation of 23 chemicals. Health Physics 57(Suppl. 1): 387–393.

Cunningham, E.E., M.A. Zielezny, and R.C. Venuto. 1983. Heroin-associated nephropathy: A nationwide problem. J. Amer. Med. Assoc. 250:2935–2936.


Dal Cin, P., J. Gaeta, and R. Huben. 1989. Cytogenic characterization. Am. J. Clin. Pathol. 92:408–414.

Dal Cin, P., M.S. Aly, J. Delabie, J.J. Ceuppens, S. Van Gool, B. Van Damme, L. Baert, H. Van Poppel, and H. Van den Berghe. 1992. Trisomy 7 and trisomy 10

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

characterize subpopulations of tumor-infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. Proc. Nat. Acad. Sci. U.S.A. 89:9744–9748.

Darmady, E.M., J. Offer, and M.A. Woodhouse. 1973. The parameters of the aging kidney. J. Pathol. 109:195–207.

Das, G. and R.W. Glashan. 1988. Correlation of urine cytology with ABO(H) antigenicity in transitional cell carcinoma of the bladder. J. Clin. Pathol. 41:538–539.

Das, G., N.J. Buxton, P.A. Stewart, and R.W. Glashan. 1986. Prognostic significance of ABH antigenicity of mucosal biopsies in superficial bladder cancer. J. Urol. 136:1194–1196.

Da Silva, J.L., C. Lancombe, P. Bruneval, N. Casadevall, M. Leporrier, J.P. Camilleri, J. Bariety, P. Tamourin, and B. Varet. 1990. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood & 5:577–582.

Daugaard, G., N.H. Holstein-Rathlou, and P.P. Leyssac. 1988. Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. J. Pharmacol. Exp. Ther. 244:1081–1085.

Davies, P., C.L. Eaton, T.D. France, and M.E.A. Phillips. 1988. Growth factor receptors and oncogene expression in prostate cells. Am. J. Clin. Oncol. 11:S1–S7.

Davis, L.M., B. Zabel, G. Senger, H.J. Ludecke, B. Matzroth, K. Call, D. Housman, U. Claussen, B. Horsthemke, and T.B. Shows. 1991. A tumor chromosome rearrangement further defines the 11p13 Wilms tumor focus. Genomics 10:588-592.

DeCaprio, J.A., J.W. Ludlow, D. Lynch, and Y. Furukawa. 1989. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element . Cell 58:1085–1095.

Decken, K., B. Schmitz-Drager, D. Rohde, S. Nakamura, T. Ebert, and R. Ackermann. 1992. Monoclonal antibody Due ABC 3 directed against transitional cell carcinoma. I. Production, specificity analysis, and preliminary characterization of the antigen. J. Urol. 147(1):235–241.

Deen, W.M. D.A. Maddox, C.R. Robertson, and B.M. Brenner. 1974. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. Am. J. Physiol. 227:556–562.

Dekant, W., A. Schulz, M. Metzler, and D. Henschler. 1986a. Absorption, elimination and metabolism of trichloroethylene: A quantitative comparison between rats and mice. Xenobiotica 16:143–152.

Dekant, W. M. Metzler, and D. Henschler. 1986b. Identification of S-(1,1,2-tricholorovinyl)-N-acetylcysteine as a urinary metabolite of tetrachloroethylene: Bioactivation through glutathione conjugation as a possible explanation for its nephrocarcinogenecity. J. Biochem. Toxicol. 1:57–72.

Dekant, W., and D. Henschler. 1986c. Identification of S-(1,2-dichloroviny)-N-

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

acetylcysteine as a urinary metabolite of trichloroethylene: A possible explanation for its nephrocarcinogenicity in male rats. Biochem. Pharmacol. 35:2455–2458.

Dekant, W., G. Martens, S. Vamvakas, M. Matzler, and D. Henschler. 1987a. Bioactivation of tetrachloroethylene: Role of glutathione S-transferase-catalyzed conjugation versus cytochrome P-450 dependent phospholipid alkylation. Drug Metab. Dispos. 15:702–709.

Dekant, W., L.H. Lash, and M.W. Anders. 1987b. Bioactivation of the cytotoxic and mephrotoxic S-conjugate S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine. Proc. Natl. Acad. Sci. U.S.A. 84:7443–7447.

Dekant, W., L.H. Lash, and M.W. Anders. 1988a. Fate of glutathione conjugates and bioactivation of cysteine S-conjugates by cysteine conjugate by-lyase. Pp. 415–557 in Glutathione Conjugation: Its Mechanism and Biological Significance. H. Sies, and B. Ketterer, eds. London: Academic Press, Orlando.

Dekant, W., D. Schrenk, S. Vamvakas, and D. Henschler. 1988b. Metabolism of hexachloro-1,3-butadiene in mice: In vivo and in vitro evidence for activation by blutahtione conjugation. Xenobiotica 18:803–816.

Dekant, W., K. Berthold, S. Vamvakas, and D. Henschler. 1988c. Thioacylating agents as ultimate intermediates in the b-lyase catalyzed metabolism of S-(pentachlorobutadienyl)-L-cysteine. Chem. Biol. Interact. 67:139–148.

Dekant, W., K. Berthold, S. Vamvakas, D. Henschler, and M.W. Anders. 1988d. Thioacylating intermediates as metabolites of S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2,2-trichlorovinyl)-L-cysteine formed by cysteine conjugate b-lyase. Chem. Res. Toxicol. 1:175–178.

Delaere, K., M. van Dieijen-Visser, A. Gijzen, and P. Brombacher. 1988. Is prostate-specific antigen the most useful marker for screening in prostate cancer? Am. J. Clin. Oncol. 11 (Suppl 2): S65–S67.

Delahunt, B., P.B. Bhetwaite, J.N. Nacey, and J.L. Ribas. 1993. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: Comparison with tumor grade, mitotic index, and silver-staining nucleolar organizer region numbers. J. Pathol. 179:471–477.

D'Ercole, A.J., D. Stiles, and L.E. Underwood. 1984. Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad. Sci. U.S.A. 81:935–939.

De Riese, WT., W.N. Crabtree, E.P. Allholff, M. Werner, S. Liedke, G. Lenis, J. Atzpodien, and H. Kirchner. 1993. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J. Clin. Oncol. 11:1804–1808.

Detrisac, C.J., M.A. Sens, A.J. Garvin, S.S. Spicer, and D.A. Sens. 1984. Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int. 25:383–390.

Diamond, J.R., and I. Pesek. 1991. Glomerular tumor necrosis factor and interleukin-

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1, during acute amino-nucleoside nephrosis: An immuno-histochemical study. Lab. Invest 64:21–28.

Dickman, K.G., and L.J. Mandel. 1989. Glycolytic and oxidative metabolism in primary renal proximal tubule cultures. Am. J. Physiol. 258:C333–C340.

Dickman, K.G., and L.J. Mandel. 1990. Differential effects of respiratory inhibitors on glycolysis in proximal tubules. Am. J. Physiol. 258:F1608–F1615.

Dieperink, H., H. Starkling, and P.P. Leyssac. 1983. Nephrotoxicity of cyclosporin A—An animal model. A study of the nephrotoxic effect of cyclosporin on overall renal and tubular function in conscious rats. Transplant Proc. 15(Suppl. 1):2736–2741.

Dierick, A.M., M. Praet, H. Roels, P. Verbeeck, C. Robyns, and W. Oosterlinck. 1991. Vimentin expression of renal cell carcinoma in relation to DNA content and histological grading: A combined light microscopic, immunocytochemical and cytophotometrical analysis. Histopathology 18:315–322.

Dietrich, P.Y., and J.P. Droz. 1992. Renal cell cancer: Oncogenes and tumor suppressor genes [in French]. Rev. Prat. 42:1236–1240.

Dietrich, D.R., and J.A. Swenberg. 1990. Lindane induces nephropathy and renal accumulation of α2u-globulin in male but not in female Fischer 344 rats or male NBR rats. Toxicol. Lett. 53:179–181.

Dietrich, D.R., and J.A. Swenberg. 1991. The presence of α2u-globulin is necessary for d-limonene promotion of male rat kidney tumors. Cancer Res. 51:3512–3421.

Ding, Z., N. Sumrani, and J.H. Hong. 1991. Effect of timing of cyclosporine administration on recovery from renal ischemia in rats . J. Surg. Res. 51:341–343.

di Sant'Agnese, P.A. 1988. Neuroendocrine differentiation and prostatic carcinoma: The concept comes of age. Arch. Pathol. Lab. Med. 112:1097–1099.

di Sant'Agnese, P.A. 1992. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70:254–268.

di Sant'Agnese, P.A., and K.L. de Mesy Jensen. 1987. Neuroendocrine differentiation in prostatic carcinoma. Hum. Pathol. 18:849–856.

Doctor, V.M., A.R. Sheth, M.M. Shimha, N.J. Arbatti, and J.P. Aaveri. 1986. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign, and malignant prostates. Br. J. Cancer 53:547–554.

Dohn, D.R. and M.W. Anders. 1982. The enzymatic reaction of chlorotrifluoroethylene with glutathione. Biochem. Biophys. Res. Commun. 109:1339–1345.

Dohn, D.R., A.J. Quebbemann, R.F. Borch, and M.W. Anders. 1985a. Enzymatic reaction of chlorotrifluoroethylene with glutathione: 19F NMR evidence for stereochemical control of the reaction. Biochemistry 24:5137–5143.

Dohn, D.R., J.R. Leininger, L.H. Lash, A.J. Quebbemann, and M.W. Anders. 1985b. Nephrotoxicity of S-(2-chloro-1,1,2-trifluoroethyl) glutathione and S-(2-chloro-

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1,1,2-trifluoroethyl)-L-cysteine, the glutathione and cysteine conjugates of chlorotrifluoroethene. J. Pharmacol. Exp. Ther. 235:851–857.

Dominick, M.A., D.G. Robertson, M.R. Bleading, R.E. Sigler, W.F. Bobrowski, and A.W. Gough. 1991. α-2u Globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(amino methyl) cyclohexareactic acid. Toxicol. Appl. Pharmacol. 111:375.

Dosquet, C., A. Schaetz, C. Faucher, E. Lepage, J.L. Wautier, F. Richard, and J. Cabane. 1994. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur. J. Cancer 30A: 162–167.

Drabkin, H.A., C. Bradley, I. Hart, J. Bleskan, F.P. Li, and D. Patterson. 1985. Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8) p14.2;q24.13) chromosomal translocation. Proc. Nat. Acad. Sci. U.S.A. 82:6980–6984.

Droz, D., D. Zachar, L. Charbit, J. Gogusev. Y. Chretein, and L. Iris. 1990. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am. J. Pathol. 137–895–905.

Dubach, U.C. and M. Le Hir. 1984. Critical evaluation of the diagnostic use of urinary enzymes. Contrib. Nephrol. 42: 74–80.

Dubach, U.C., M. Le Hir, and R. Gandhi. 1989. Use of urinary enzymes as markers of nephrotoxicity. Toxiol. Lett. 46:193–196.

Dubey, C., B. Bellon, F. Hirsch, J. Kuhn, M.C. Viol, M. Goldman, and P. Druet. 1991. Increased expression of class 11 major histocompatibility complex molecules on B cells in rats susceptible or resistant to HgCl2-induced autoimmunity. Clin. Exp. Immunol. 86:118–123.

Duvall, E. and A.H. Wyllie. 1986. Death and the cell. Immunol. Today 7:115–119.


Easterling, R.E. 1977. Racial factors in the incidence and causation of end-stage renal disease (ESRD). Trans. Am. Soc. Artif. Intern. Organs 23:28.

Eaton, C.L., P. Davids, and M.E.A. Phillips. 1988. Growth factor involvement and oncogene expression in prostatic tumours. J. Steroid Biochem. 30:341–345.

Ebihara, I., P. Kellen, G. Laurie, T. Huang, Y. Yamoda, G. Martin, and K. Brown. 1981. Altered mRNA expression of basement membrane components in a murine model of polycystic kidney disease. Lab. Invest. 58:262–269.

Eble, J.N. and J.I. Epstein. 1990. Stage A carcinoma of the prostate. Pp. 61–82 in Pathology of the Prostate, D.G. Bostwick, ed. New York: Chruchill Livingstone.

Eguchi, J., K. Nomata, S. Kanda, T. Igawa, M. Taide, S. Koga, F. Matsuya, H. Kanetake, and Y. Saito. 1992. Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma . Biochem. Biophys. Res. Comm. 183:937–944.

Eklöv, S., K. Funa, H. Nordgren, A. Olofsson T. Kanzaki, K. Miyazono, and S. Nilsson. 1993. Lack of the latent transforming growth factor β binding protein in malignant, but not benign prostatic tissue. Cancer Res. 53:3193–3197.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Ekstrom, B. and I. Berggard. 1977. Human α1-microglobulin: purification procedure, chemical and physicochemical properties. J. Biol. Chem. 252:8048–8057.

El-Aaser, A.A., M.M. el-Merzabani, and F.A. Abu-Bedair. 1985. Serum estrogen level in Egyptian breast cancer patients. Tumori 71:293–295.

Elfarra, A.A. and M.W. Anders. 1984. Renal processing of glutathione conjugates: Role in nephrotoxicity. Biochem. Pharmacol. 33:3729–3732.

Elfarra, A.A., I. Jakobson, and M.W. Anders. 1986a. Mechanism of S-(1,2-dichlorovinyl)glutathione-induced nephrotoxity. Biochem. Pharmacol. 35:283–288.

Elfarra, A.A., L.H. Lash, and M.W. Anders. 1986b. Metabolic activation and detoxication of nephrotoxic cysteine and homocysteine S-conjugates. Proc. Natl. Acad. Sci. U.S.A. 83:2667–2671.

Elfarra, A.A., L.H. Lash, and M.W. Anders. 1987. a-Ketoacids stimulate rat renal cysteine conjugate b-lyase activity and potentiate the cytotoxicity of S-(1,2-dichlorovinyl)-L-cysteine. Mol. Pharmacol. 31:208–212.

Elgebaly, S.A., M.E. Allam, M.P. Walzak, D. Oselinsky, C. Gillies, and H. Yamase. 1992. Urinary neutrophil chemotactic factors in interstitial cystitis patients and a rabbit model of bladder inflammation. J. Urol. 147:1382–1387.

Elinder, C.G., C. Edling, E. Lindberg, B. Kagedal, and O. Vesterberg. 1985. β2-microglobulinuria among workers previously exposed to cadmium: Follow-up and dose-response analyses. Am. J. Ind. Med. 8:553–564.

Elliget, K.A. and B.F. Trump. 1991. Primary cultures of normal rat kidney proximal tubule epithelial cells for studies of renal cell injury. In Vitro Cell. Dev. Biol. 27A:739–748.

Ellis, W.J., K.D. Bauer, R. Ovasu, and K.T. McVary. 1992. Flow cytometric analysis of small renal tumors. J. Urol. 148:1774–1777.

el-Mohamady, H., M.T. Basta, M.N. Seddek, H. Helmy, E. al-Hilaly, A.M. Attallah, and M.A. Ghoneim. 1991. UNME/K1: An IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma. Urol. Res. 19:145–150.

el-Naggar, A.K., H.D. van Dekken, L.G. Ensign, and S. Pathak. 1994. Interphase cytogenetics in paraffin-embedded sections front renal cortical neoplasms. Correlation with cytogenetic and flow cytometric DNA ploidy analyses. Cancer Genet. Cytogenet. 73:134–141.

El Nahas, A.M., J.E. Le Carpertier, A.H. Bassett, and D.J. Hill. 1989. Dietary protein and insulin-like growth factor-I content following unilateral nephrectomy. Kidney Int. 36 (Suppl. 27):S15–S19.

Emami, A., J.H. Schwartz, and S.C. Borkan. 1991. Transient ischemia or heat stress induces a cryoprotectant protein in rat kidney. Am. J. Physiol. 260:F479–F485.

Emanuel, A., S. Szucs, H.U. Weier, and G. Kovacs. 1992. Clonal aberrations of chromosomes X, Y, 7 and 10 in normal kidney tissue of patients with renal cell tumors. Genes Chromosomes Cancer 4:75–77.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Enomoto, T., J.M. Ward, and A.O. Perantoni. 1990. H-ras activation and ras p21 expression in bladder tumors induced in F3444/NCr rates by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 11:2233–2238.

EPA (U.S. Environmental Protection Agency). 1991 a. Report of the EPA peer review workshop on alpha2u-globulin: Association with renal toxicity and neoplasia in the male rat. EPA/625/3–91/021. August 1991. 78 pp.

EPA (U.S. Environmental Protection Agency). 1991 b. Alpha2u-globulin: Association with renal toxicity and neoplasia in the male rat. EPA/625-3-91/019F.

EPA (U.S. Environmental Protection Agency). 1991c. Response to issues and data submissions on the carcinogenicity of tetrachloroethylene (perchloroethylene). EPA/600/6-91/002F.

Epstein, M. 1979. Effects of aging on the kidney. Fed. Proc. 38:168–172.

Epstein, J.I., and J.M. Woodruff. 1986. Adenocarcinoma of the prostate with endometrioid features. Alight microscopic and immunohistochemical study of ten cases. Cancer 57:111–117.

Epstein, J.I. and P.H. Lieberman. 1985. Mucinous adenocarcinoma of the prostate gland. Am. J. Surg. Pathol. 9:299–306.

Ercole, C.J., Ph.H. Lange, M. Mathisen, R.K. Chious, P.K. Reddy, and R.L. Vessella. 1987. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J. Urol. 138: 1181–1184.

Erlandsson, R., U.S. Bergerheim, F. Boldog, Z. Marcsek, K. Kunimi, B.Y. Lin, S. Ingvarsson, J.S. Castresana, W.H. Lee, and E. Lee. 1990. A gene near the D3FI5S2 site on 3p is expressed in normal human kidney but not or only at a severely reduced level in 11 of 15 primary renal cell carcinomas (RCC). Oncogene 5:1207–1211.

Erlandsson, R., F. Boldog, B. Persson, E.R. Zabarovsky, R.L. Allikmets, J. Sumegi, G. Klein, and H. Jornvall. 1991a. The gene from the short arm of chromosome 3, at D3FI5S2, frequently deleted in renal cell carcinoma, encodes acylpeptide hydrolase. Oncogene 6:1293–1295.

Erlandsson, R., J. Szpirer, M.Q. Islam, F. Boldog, G. Klein, and S. Ingvarsson. 1991b. The most frequently lost allelic site in human renal cell carcinoma (D3F15S2) on the short arm of chromosome 3 has homologous sequences on rat chromosome 8. Cytogenet. Cell Genet. 57:149–150.

Eryigit, M., and Z. Kirkali. 1990. HLA antigens and transitional cell carcinoma of the bladder. Urol. Int. 45:75–77.

Escudero Barrilero, a., E. Fernandez, E. Garcia Cuerpo, F. Lovaco, and S. Navio. 1991. Infiltrating transitional cancer of the bladder (2). Prognostic value of the stage (Its influence on the therapeutic decision) [in Spanish]. Acta Urol. Esp. 15(3):213–230.

Eskelinen, M., P. Lipponen, R. Majapuro, K. Syrjanen, and S. Nordling. 1991. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma. Eur. Urol.20:62–66.

Esnard, A., F. Esnard, and F. Gauthier. 1988. Purification of the cystatin C-like

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

inhibitors from urine of nephropathic rats. Bioch. Chem. Hoppe-Seyler 369:S219–222.

Evan, G.I., A.H. Wyllie, and G.S. Gilbert. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119–128.

Evans, R.W., C.R. Blagg, and F.A. Bryan. 1981. Implications for health care policy: A social and demographic profile of hemodialysis patients in the United States. JAMA 345:487.

Eveloff, J., W. Haase, and R. Kinne. 1980. Separation of renal medullary cells: Isolation of cells from the thick ascending limb of Henle's loop. J. Cell Biol. 87:672–681.

Evrin, P.E., and L. Wibell. 1972. The serum levels and urinary excretion of β2-microglobulin in apparently healthy subjects. Scand. J. Clin. Lab. Invest. 29:6–74.


Fagin, J.A., and S. Melmed. 1987. Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology 120:718–724.

Fanning, P., K. Bulovas, K.S. Saini, ).A. Libertino, A.D. Joyce, I.C. Summerhayes. 1992. Elevated expression of pp60c-src in low grade human bladder carcinomas. Cancer Res. 52:1457–1462.

Farrow, G.M. 1990. Urine cytology in the detection of bladder cancer: A critical approach. J. Occup. Med. 32:817–821.

Fauler, J., A. Wiemeyer, K.H. Marx, K. Kühn, K.M. Koch, and J.C. Frölich. 1989. LTB4 in nephrotoxic serum nephritis in rats. Kidney Int. 36:46–50.

Fearon, E.R., A.P. Feinberg, S.H. Hamilton, and B. Vogelstein. 1985. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318:377–380.

Feigelson, P., and D.T. Kurtz. 1977. Hormonal modulation of specific messenger RNA species in normal and neoplastic rat liver. Adv. Enzymol. 47:275–312.

Fekete, M., T.W. Redding, A.M. Comaru-Schally, J.E. Pontes, R.W. Connelly, g. Srkalovic, and A.V. Schally. 1989. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 14:191–208.

Feldman, H.K., M.J. Klag, A.P. Chiapelle, and P.K. Whelton. 1992. End-stage renal disease in U.S. minority groups. Amer. J. Kidney Dis. 19:397–410.

Fernandez-Repollet, E., S. Opava-Stitzer, and M. Martiez-Maldonado. 1992. Renal hemodynamics and urinary concentrating capacity in protein deprivation: Role of antidiuretic hormone. Am. J. Med. Sci.

Filmer, R.B., and J.R. Spencer. 1990. malignancies in bladder augmentations and intestinal conduits. J. Urol. 143:671–678.

Fine, L.G. 1986. The biology of renal hypertrophy. Kidney Int. 29:619–634.

Fine, L.G., B. Badie-Dezfooly, A.G. Lowe, A. Hamzeh, J. Wells, and S. Salehmoghaddam. 1985. Stimulation of Na+/H+ antiport is an early event in

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

hypertrophy of renal proximal tubular cells. Proc. Natl. Acad. Sci. U.S.A. 82:1736–1740.

Finn, W.F. 1982. Compensatory renal hypertrophy in Sprague-Dawley rats: Glomerular ultrafiltration dynamics. Renal Physiol. 5:222–234.

Finn, W.F. 1983. Compensatory hypertrophy of single nephrons following ischemic injury in the rat. Clin. Exp. Dial. Apheresis 7:101–114.

Finver, S.N., C. Martiniere, J. Kagan, W. Cavenee, and c.M. Croce. 1989. The chromosome 11 region flanking the t(11:14) breakpoint in human T-ALL is deleted in Wilms' tumor hybrids. Oncogene Res. 5:143–148.

Fiorelli, G., A. De Bellis, A. Longo, S. Giannini, A. Natali, A. Constantini, and G. Vannelli. 1991a. Insulin-like growth factor-I-receptors in human hyperplastic prostate tissue: Characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab. 72:740–746.

Fiorelli, G., A. De Bellis, A. Longo, P. Pioli, A. Constantini, S. Giannini, G. Forti, and M. Serio. 1991b. Growth factors in the human prostate. J. Steroid Biochem. Mol. Biol. 40:199–205.

Fisher, C.C., and B.M. Brenner, eds. 1989. Renal Pathology. Philadelphia: J.B. Lipincott.

Fisher, D.A., E.C. Salido, and L. Barajas. 1989. Epidermal growth factor and the kidney. Annu. Rev. Physio. 51:67–80.

Fjellestad-Paulsen, A., P.A. Abrahamsson, A. Bjartell, M. Grino, L. Grimelius, and H. Hedeland. 1988. Carcinoma of the prostate with Cushing's syndrome: a case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol. (Copenh) 119:506–516.

Flamm, W.G. and L.D. Lehman-McKeeman. 1991. The human relevance of the renal tumor-inducing potential of d-limonene in male rats: Implications for risk assessment. Reg. Toxicol. Pharmacol. 13:70–86.

Fletcher, A.P., J.E. McLaughlin, W.A. Ratcliffe, and D.A. Woods. 1970. The chemical composition and electron microscope appearance of a protein derived from urinary casts. Biochim. Biophys. Acta 214:299–308.

Floege, J., R.J. Johnson, K. Gordon, H. lida, P. Pritzl, A. Yoshimura, C. Campbell, C.E. Alpers, and W.G. Couser. 1991. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 40:477–488.

Floege, J., M.W. Burns, C.E. Alpers, A. Yoshimura, P. Pritzl, K. Gordon, R. Seifert, D.F. Bowen-Pope, W.G. Couser, and R.J. Johnson. 1992a. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 41:297–309.

Floege, J., C. Alpers, M. Burns, P. Pritzl, K. Gordon, W.G. Couser, and R.J. Johnson.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1992b. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab. Invest. 66:485–497.

Flyvbjerg, A., K.E. Bornfeldt, S.M. Marshall, H.J. Arnqvist, and H. Ørskov. 1990. Kidney IGF-1 mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 33:334–338.

Ford, S.M., and J.B. Hook. 1984. Biochemical mechanisms of toxic nephropathies . Semin. Nephrol. 4:88–106.

Fournet, J.C., C. Beroud, E. Austruy, C. Leonard. 1992. Genetic aspects of renal tumors in adults [review] [in French]. Arch. Anat. Cytol. Pathol. 40:301–306.

Fowler, B.A. 1982. Ultrastructural and biochemical localization of organelle damage from nepbrotoxic agents. Pp. 315–330 in Nephrotoxic Mechanisms of Drugs and Environmental Toxins, G.A. Porter, ed. New York: Plenum.

Fowler, B.A., and G.E. Duval. 1991. Effects of lead on the kidney: Roles of high-affinity lead-binding proteins. Environ. Hlth. Perspec. 91:77–80.

Fowler, J.J., W. Lynes, J. Lau, L. Ghosh, and A. Mounzer. 1988. Interstitial cystitis is associated with intraurothelial Tamm-Horsfall protein. J. Urol. 140:1385–1389.

Fowler, B.A., M.W. Kahng, and D.R. Smith. 1994. Role of lead-binding proteins in renal cancer. Environ. Health Perspect. 102(Suppl. 3):115–116.

Fox, S., P. Raj, J. Royds, R. Kore, P. Silcocks, and C. Collins. 1993. p53 and c-myc expression in stage Al prostatic adenocarcinoma: useful prognostic determinants? J. Urol. 150:490–494.

Fradet, Y., C. Cordon-Cardo, T. Thomson, M.E. Daly, W.F. Whitmore, K.O. Lloyd, M.R. Melamed, and L.J. Old. 1984. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 81:224–228.

Fradet, Y., C. Cordon-Cardo, W.F. Whitmore, M.R. Melamed, L.J. Old. 1986. Cell surface antigens of human bladder tumors: Definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. Cancer Res. 46:5183–5188.

Fradet, Y., N. Islam, L. Boucher, C. Parent-Vaugeois, and M. Tardif. 1987. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 84:7227–7231.

Fradet, Y., H. LaRue, C. Parent-Vaugeois, A. Bergeron, C. Dufour, L. Boucher, and L. Bernier. 1990a. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int. J. Cancer 46(6):990–997.

Fradet, Y., M. Tardif, L. Bourget, J. Robert, and the Laval University Urology Group. 1990b. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res. 50(2):432–437.

Franchini, I., A. Cavatorta, M. Falzoi, S. Lucertini, and A. Mutti. 1983. Early

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

indicators of renal damage in workers exposed to organic solvents, Int. Arch. Occup. Environ. Health 52:1–9.

Frederick, C.B., K.L. Dooley, R.L. Kodell, W.G. Sheldon, and F.F. Kadlubar. 1989. The effect of lifetime sodium saccharin dosing in mice initiated with the carcinogin 2-acetylaminofluorene. Fund. Appl. Toxicol. 12:346–357.

Friberg, L. 1948. Proteinuria and kidney injury among workmen exposed to cadmium and nickel dust. J. Indust. Hyg. Toxicol. 30:32–36.

Friedman, S.A., A.E. Raizner, H. Rosen, N.A. Solomon, and W. Sy. 1972. Functional defects in the aging kidney. Ann. Intern. Med. 76:41–45.

Fries, J.W.U., and T. Collins. 1992. Platelet-derived growth factor expression in a transgenic model. Kidney Int. 41:584–589.

Fuhrman, S.A., L.C. Lasky, and C. Limas. 1982. Prognostic significance of morphologic and parameters in renal cell carcinoma. Am. J. Surg. Path. 6:655–663.

Fujimoto, K., Y. Ichimori, T. Kakizoe, E. Okajima, H. Sakamoto, T. Sugimura, and M. Terada. 1991. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem. Biophys. Res. Comm. 180:386–392.

Fujimoto, K., Y. Yamada, E. Okajima, T. Kakizoe, H. Sasaki, T. Sugimura, and M. Terada. 1992. Frequent association of p53 gene mutation in invasive bladder cancer . Cancer Res. 52:1393–1398.

Fukatsu, A., S. Matsuo, H. Tamai, N. Sakamoto, T. Matsuda, and T. Hirano. 1991. Distribution of interleukin 6 in normal and diseased human kidney. Lab. Invest. 65:61–66.

Fukutani, K., J.M. Libby, W.B. Panko, and P.T. Scardino. 1983. Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter, and kidney. J. Urol. 129:74–77.

Fuse, H., K. Umeda, I. Mizuno, and T. Katayama. 1991. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen. Int. Urol. Nephro. 23:455–463.

Fuse, H., I. Mizuno, M. Sakamoto, and T. Katayama. 1992. Epidermal growth factor in urine from the patients with urothelial tumors. Urol. Int. 48:261–264.

Fuzesi, L., M. Cober, and C. Mittermayer. 1992. Collecting duct carcinoma: Cytogenetic characterization . Histopathology 21:155–160.


Galand, P., and C. Degraef. 1989. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections form animal and human tissues. Cell Tissues Kinet. 22:383–392.

Gardiner, R.A., M.L. Samaratunga, M.D. Walsh, G.J. Seymour, and M.F. Lavin. 1992. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelia) bladder cancer. Urol. Res. 20:117–120.

Gardner, K.D., J.S. Burnside, L.W. Elzinga, and R.M Locksley. 1991. Cytokines in fluids from polycystic kidneys. Kidney Int. 39:718–724.

Garg, B.D., M.J. Olson, W.F. Demyan, and A.K. Roy. 1988. Rapid post exposure

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

decay of α2u-globulin and hyaline droplets in the kidneys of gasoline-treated male rats. J. Toxicol. Env. Health 24:145–160.

Garg, B.D., M.J. Olson, L.C. Li, and A.K. Roy. 1989a. Phagolysosomal alterations induced by unleaded gasoline in epithelial cells of the proximal convoluted tubules of male rats: Effect of dose and treatment duration . J. Toxicol. Env. Health 26:101–118.

Garg, B.D., M.J. Olson, L.C. Li, M.A. Mancini, and A.K. Roy. 1989b. Estradiol pretreatment of male rats inhibits gasoline-induced renal hyaline droplet and alph-2u-globulin accumulation. Research Publication, General Motors Research Laboratories. GMR-6557. March 1989.

Gattone, V.H., G.K. Andrews, N. Fu-Wen, L.J. Chadwick, R.M. Klein, J.P. Calvet. 1990. Defective epidermal growth factor gene expression in mice with polycystic kidney disease. Dev. Biol. 138:225–230.

Gemmill, R.M., J. Coyle-Morris, L. Ware-Uribe, N. Pearson, F. Hecht, R.S. Brown, F.P. Li, and H.A. Drabkin. 1989. A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. Genomics 4:28–35.

Gerber, W., P. Lenahen, A. Kendall, and W. Mercer. 1991. Computer-assisted microfluorometric detection of individual malignant bladder cells. Urology 38(5):466–472.

Gesek, F.A., D.W. Wolff, and J.W. Strandhoy. 1987. Improved separation method for rat proximal and distal renal tubules. Am. J. Physiol. 253:F358–F365.

Gesualdo, L., M. Pinzani, J.J. Floriano, M. Hassan, N.U. Nagy, F.P. Schena, S.N. Emancipator, and H.E. Abhoud. 1991. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab. Invest. 65:160–167.

Gesualdo, L., S.N. Emancipator, C. Kesselheim, and M.E. Lamm. 1992. Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int. 42:106–114.

Ghadirian, P., M. Cadotte, A. Lacroix, and C. Perret. 1991. Family aggregation of cancer of the prostate in Quebec: The tip of the iceberg. Prostate 19(1):43–52.

Ghiggeri, G.M., G. Candiano, G. Delfino, and C. Queirolo. 1985, Electrical charge of serum and urinary albumin in normal and diabetic humans. Kidney Int. 28:168–177.

Giampetro, O., and A. Clerico. 1990. Microalbuminuria in diabetes: Which method to employ, which sample to collect. J. Nucl. Med. Allied. Sci. 34:111–120.

Gietl, Y.S., and M.W. Anders. 1991. Biosynthesis and biliary excretion of S-conjugates of hexachlorobuta-1,3-diene in the perfused rat liver. Drug Metab. Dispos. 19:274–277.

Gittes, R.F. 1987. Prostate-specific antigen [editorial]. N. Engl. J. Med. 317:954–955.

Gleason, D.F. 1990. Histologic grading of prostatic carcinoma. Pp. 83–93 in Pathology of the Prostate, D.G. Bostwick, ed. New York: Churchill Livingstone.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Glenn, G.M., L.N. Daniel, P. Choyke, W.M. Linehan, E. Oldfield, M.B. Gorin, S. Hosoe, F. Latif, G. Weiss, and M. Walther. 1991. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more that one mutant allele at the VHL locus. Hum. Genet. 87:207–210.

Gnarra, J.R., K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, P. Latif, S. Liu, F. Chen, F.-M. Duh, I. Lubensky, R. Duan, C. Florence, R. Pozzatti, M.M. Walther, N.H. Bander, H.B. Grossman, H. Brauch, S. Pomer, J.D. Brooks, W.B. Isaacs, M.I. Lerman, B. Zbar, and W.L. Linehan. 1994. Mutation of the VHL tumor suppressor gene in renal carcinoma. Nature Genetics 7:85–90.

Goering, P.L., B.R. Fisher, P.P. Chaudhary, C.A. Dick. 1992. Relationship between stress protein induction in rat kidney by mercuric chloride and nephrotoxicity. Toxicol. and Appl. Pharmacol. 113:184–191.

Gohji, K., M. Ishii, H. Nagata, O. Matsumoto, and S. Kamidono. 1990. Serum basic fetoprotein in patients with renal cell carcinoma. Cancer 65:1405–1411.

Goldsworthy, T.L., and J.A. Popp. 1987. Chlorinated hydrocarbon-induced peroxisomal enzyme activity in relation to species and organ carcinogenicity. Toxicol. Appl. Pharmacol. 88:225–233.

Goldsworthy, T.L., O. Lyght, V.L. Burnett, and J.A. Popp. 1988a. Potential role of α-2u-globulin, protein droplet accumulation, and cell replication in the renal carcinogenicity of rats exposed to trichloroethylene, perchloroethylene, and pentachloroethane. Toxicol. Appl. Pharmacol. 96:367–379.

Goldsworthy, D.W., T. Smith-Oliver, D.J. Loury, J.A. Popp, and B.E. Buttherworth. 1988b. Assessment of chlorinated hydrocarbon-induced genotoxicity and cell replication in rat kidney cells. Env. Mol. Mutagen. 11(Suppl. 11):39.

Gomella, L.G., E.R. Sargent, T.P. Wade, P. Anglard, W.M. Linehan, and A. Kasid. 1989. Expression of transforming growth factor alpha on normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res. 49:6972–6975.

Goodrich, D.W., Y. Chen, P. Scully, and W.H. Lee. 1992. Expression of the retinoblastorna gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res. 52:1968–1973.

Goodyer, P.R., Z. Kachra, C. Bell, and R. Rozen. 1988. Renal tubular cells are potential targets for epidermal growth factor. Am. J. Physiol. 255:F1191–F1196.

Gospodarowicz, D. 1991. Biological activities of fibroblast growth factors. Ann. N.Y. Acad. Sci. 638:1–8.

Grafström, R., K. Ormstad, P. MoldÄus, and S. Orrenius. 1979. Paracetamol metabolism in the isolated perfused rat liver with further metabolism of a biliary paracetamol conjugate by the small intestine. Biochem. Pharmacol. 28:3573–3579.

Gram, T.E., L.K. Oldne, and R.A. Gram. 1986. The metabolism of xenobiotics by certain extrahepatic organs and its relation to toxicity. Annu. Rev. Pharmacol. Toxicol. 26:259–291.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Grasso, R. 1952. Sobre las celulas argentafines de la uretra y de la glandula prostatica. (About the agrentaffin cells of the urethra and the prostrate gland.) Arch. Histol. Normal Pathol. 5:227–270.

Green, T., and J. Odum. 1985. Structure/activity studies of the nephrotoxic and mutagenic action of cysteine conjugates of chloro-and fluoroalkenes. Chem.-Biol. Interact. 54:15–31.

Green, T., J. Odum, and J.K. Foster. 1990. Perchloroethylene-induced rat kidney tumors: An investigation of the mechanisms involved and their relevance to humans. Toxicol. Apl. Pharmacol. 103:77–89.

Green, T., J. Odum, and J.R. Yates. 1994. Loss of heterozygosity on chromosone 16p13.3 in hamartomas from tuberous sclerosis patients. Nature Genetics 6:193–196.

Gregg, N.J., M.M. Elseviers, M.E. DeBroe, and P.H. Bach. 1989. Epidemiology and mechanistic basis of analgesic nephropathy. Toxicol. Lett. 46:141–151.

Grignon, D.J., M. Abdel-Malak, W.C. Mertens, W.A. Sakr, and R.R. Shepherd. 1994. Glutathione S-transferase expression in renal cell carcinoma: A new marker of differentiation. Mod. Pathol. 7:186–189.

Grignon, D.J., A. el-Naggar, L.K. Green, A.G. Ayala, J.Y. Ro, D.A. Swanson, P. Troncoso, D. McLemore, G.G. Giacco, V.F. Guinee. 1989. DNA flow cytometry as a predictor of outcome of stage I renal cell carcinoma. Cancer 63:1161–1165.

Grimmond, S.M., D. Raghavan, and P.J. Russell. 1992. Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. Urol. Res. 20:121–126.

Groeneveld, A.B.J., D.D. Tran, and J. van der Meulen. 1991. Acute renal failure in the medical intensive care unit: Predisposing, complicating factors and outcome. Nephron. 59.602.

Grollino, M.G., D. Cavallo, F. Di Silverio, M. Rocchi, and R. De Vita. 1993. Interphase cytogenetics and flow cytometry analyses of renal tumours. Anticancer Res. 13:2239–2244.

Gröne, H.J., K. Weber, E. Gröne, U. Helmchen, and M. Osborn. 1987. Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. Am. J. Path. 129:1–8.

Grundy, P.E., P.E. Telezerow, N. Breslow, J. Moksness, V. Huff, and M.C. Paterson. 1994. Loss of heterozygosity for chroniosones 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res. 54:2331–2333.

Gu, F.L., S.L. Cai, B.J. Cai, and C.P. Wu. 1991. Cellular origin of renal cell carcinoma--an immunohistological study on monoclonal antibodies. Scand. J. Urol. Nephrol. Suppl. 138:203–206.

Guarnieri, G., M. lanche, and S. Lin. 1979. Renal enzyme and protein excretion after induction of diuresis. Br. Med. J. 2(6181):50–51.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Guder, W.G., and B.D. Ross. 1984. Enzyme distribution along the nephron. Kidney Int. 26: 101–111.

Guder, W.G., and W. Hofmann. 1991. Future markers for the diagnosis of renal lesions. Pp. 575–580 in Nephrotoxicity. Mechanisms, Early Diagnosis and Therapeutic Management. P.H. Bach, N.J. Gregg, M.F. Wilks, and L. Delacruz, eds. Marcel Dekker.

Guinan, P., M. Shaw, P. Targonski, V. Ray, M. Rubenstein. 1989. Evaluation of cytokeratin markers to differentiation between benign and malignant prostatic tissue. J. Surg. Oncol. 42(3):175–180.

Gullans, S.R., P.C. Brazy, S.P. Soltoff, V.W. Dennis, and L.J. Mandel. 1982. Metabolic inhibitors: Effects on metabolism and transport in the proximal tubule. Am. J. Physiol. 243:F133–F140.

Gullans, S.R., S.I. Harris, and L.J. Madel. 1984a. Glucose-dependent respiration in suspensions of rabbit cortical tubules. J. Membr. Biol. 78:257–262.

Gullans, S.R., P.C. Brazy, V.W. Dennis, and L.J. Madel. 1984b. Interactions between gluconeogenesis and sodium transport in rabbit proximal tubule. Am. J. Physiol. 246:F859–F869.

Guo, Y. 1992. Production and characterization of a group of monoclonal antibodies to human transitional cell carcinoma [in Chinese]. Zhonghua Waike Zazhi (Chung Hua Wai Ko Tsa Chih) 29:777–780.

Gupta, R.K., J. van der Meulen, and K.V. Johny. 1991. Oliguric acute renal failure due to glue sniffing. Scand. J. Urol. Nephrol 25:247–250.


Haber, D.A., and D.E. Housman. 1992. The genetics of Wilms' tumor. Adv. Cancer Res. 59:41–68.

Haber, D.A., and A.J. Buckler. 1992. WT1: A novel tumor supressor gene inactivated in Wilms' tumor [review]. New Biologist 4:97–106.

Hagen, T.M., T.Y. Aw, and D.P. Jones. 1988. Glutathione uptake and protection against oxidative injury in isolated kidney cells. Kidney Int.34:74–81.

Hagood, P.G., F.E. Johnson, C.W. Bedrossian, and A.B. Silverberg. 1991. Small cell carcinoma of the prostate. Cancer 67:1046–1050.

Halder, C.A., T.M. Warne, and N.S. Hatoum. 1984. Renal toxicity of gasoline and related petroleum napthas in male rats. Pp. 73–88 in Advances in Modern Environmental Toxicology. Vol. VII. Renal Effects of Petroleum Hydrocarbons. M.A. Mehlman, G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton, New Jersey: Princeton Scientific Publishers, Inc.

Halliburton, I.W., and R.Y. Thomson. 1965. Chemical aspects of compensatory renal hypertrophy. Cancer Res. 25:1882–1887.

Halloran, P., J. Urmson, V. Ramassae, C. Laskin, and P. Autenreid. 1988. Increased class I and class II MHC products and mRNA in kidneys of MRL/1pr mice during autoimmune nephritis and inhibition by cyclosporine. J. Immunol. 141:2303–2312.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Hammerman, M.R. 1989. The growth hormone-insulin-like growth factor axis in kidneys. Am. J. Physiol. 257(4 Pt. 2):F503–F514.

Hammerman, M.R., and S. Rogers. 1987. Distribution of IGF receptors in the plasma membrane of proximal tubular cells. Am. J. Physiol. 253:F841–F847.

Hankin, J.H., L. Zhao, L. Wilkens, and L. Kolonel. 1992. Attributable risk of breast, prostate, and lung cancer in Hawaii due to standard fat. Cancer Causes Control 3(1):17–23.

Hard, G.C. 1987. Chemically induced epithelia tumors and carcinogenesis of the renal parenchyma. Pp. 211–250 in Nephrotoxicity in the Experimental and the Clinical Situation, Part I. P.H. Bach and E.A. Lock, eds. Martinus Nijhoff Publishers, Lancaster.

Hard, G.C. 1990. Tumors of the kidney, renal pelvis and ureter. Pp. 301–344 in Pathology of Tumours in Laboratory Animals. Vol. 1-Tumours of the Rat. Second Edition. V.S. Turusov and U. Mohr, eds. International Agency for Research on Cancer, Lyon. IARC Scientific Publications No. 99.

Hard, G.C., and J. Whysner. 1994. Risk assessment of d-Limonene. An example of male rat-specific renal tumorigens. CRC Crit. Rev. Toxicol. 24:231–254.

Hard, G.C., I.S. Rodgers, K.P. Baetcke, W.L. Richards, R.E. McGaughy, and L.R. Valcovic. 1993. Hazard evaluation of chemicals that cause accumulation of 2α2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats. Environ. Health Perspect. 99:313–.

Hargrove, J.L., and F.H. Schmidt. 1989. The role of mRNA and protein stability in gene expression. FASEB J. 3:2360–2370.

Hargus, S.J., and M.W. Anders. 1991. Immunochemical detection of covalently modified kidney proteins in S-(1,1,2,2-tetrafluoroethyl)-L-cysteine-treated rats. Biochem. Pharmacol. 42:R17–R20.

Harney, J.V., M. Liebert, S.P. Ethier, J.A. Stein, G.A. Wedemeyer, and R. Washington. 1991a. Down regulation of epidermal growth factor receptor in cultured human normal urothelial cells and in low and high grade human bladder cancer cell lines. J. Urol. 145:311A.

Harney, J.V., M. Liebert, G. Wedemeyer, R. Washington, J. Stein, D. Buchsbaum, Z. Steplewski, and H.B. Grossman. 1991b. The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphy. J. Urol. 146:227–231.

Harper, M.E., L. Goddard, E. Glynne-Jones, D.W. Wilson, M. Price-Thomas, W.B. Peeling, and K. Griffiths. 1993. An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate 23:9–23.

Harrington, D.S., M. Fall, and S.L. Johansson. 1990. Interstitial cystitis: Bladder mucosa lymphocyte immunophenotying and peripheral blood flow cytometry analysis. J. Urol. 144:868–871.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Harris, C.C. 1993. p53. At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980–1981.

Harris, J.W. and M.W. Anders. 1991a. In vivo metabolism of the hydrochlorofluorcarbon 1,1-dichloro-1-fluoroethane (HCFC-141b). Biochem. Pharmacol. 41:R13–R16.

Harris, J.W. and M.W. Anders. 1991b. Metabolism of hydrochlorofluorocarbon 1,2-dichloro-1,1-difluoroethane. Chem. Res. Toxicol. 4:180–186.

Harris, C.C. and M. Hollstein. 1993, Clinical implications of the p53 tumor-supressor gene. N. Engl. J. of Med. 329:1318–1327.

Harris, C.C., A. Weston, J.C. Willey, G.E. Trivers, and D.L. Mann. 1987. Biochemical and molecular epidemiology of human cancer: Indicators of carcinogen exposure, DNA damage, and genetic predisposition. Environ. Health Perspect. 75:109–119.

Harris, J.W., W. DeKant, and M.W. Anders. 1992. In vivo detection and characterization of protein adducts resulting from bioactivation of haloethene cystein S-conjugates by 19F-NMR: Chlorotrifluoroethene and tetrafluoroethene. Chem. Res. Toxicol. 5:34–41.

Hasegawa, R., and S.M. Cohen. 1986. The effect of different salts of saccharin on the rat urinary bladder . Cancer Lett. 30:261–268.

Hashimura, T., R.R. Tubbs, R. Connelly, M.J. Caulfield, C.S. Trindade, J.T. McMahon, T.P. Galetti, M. Edinger, A.A. Sandberg, and P. Dal Cin. 1989. Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res. 49:7064–7071.

Hasui, Y., K. Marutsuka, J. Suzumiya, S. Kitada, Y. Osada, and A. Sumiyoshi. 1992. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer 50:871–873.

Hata, M. 1989. The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 80:1558–1565.

Hattori, K., K. Uchida, T. Shimazui, R. Nemoto, K. Koiso, and M. Harada. 1988. Cell cycle kinetics of human bladder tumor in situ measured by bromodeoxyuridine (BrdU) [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 79:1811–1817.

Haugen, A., D. Ryberg, I.L. Hansteen, and P. Amstad. 1990. Neoplastic transformation of a human kidney epithelial cell line transfected with v-Ha-ras oncogene. Int. J. Cancer 45:572–577.

Hayden, P.J. C.J. Welsh, Y. Yang, W.H. Schaeffer, A.J.I. Ward, and J.L. Stevens. 1992. Formation of mitrochondrial phospholipid adducts by nephrotoxic cysteine conjugate metabolites. Chem. Res. Toxicol. 5:231–237.

Hayslett, J.P. 1979. Functional adaptation to reduction in renal mass. Physiol. Rev. 59:137–164.

HEI (Health Effects Institute). 1985. Gasoline Vapor Exposure and Human Cancer:

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Evaluation of Existing Scientific Information on Recommendations for Further Research. Health Effects Institute, Report of the Institute's Health Review Committee, September 1985.

HEI (Health Effects Institute). 1988. An Update on Gasoline Vapor Exposure and Human Cancer: An Evaluation of Scientific Information Published between 1985 and 1987. Health Effects Institute, Report of the Institute's Health Review Committee, January 6, 1988.

Heim, M., B. Conte-Devolx, G. Pin, J.C. Manelli, G. Rougon-Rapuzzi, and A. Lagier. 1977. Syndrome de secretion in appropriee de vasopressine: A propos de trois observations. Sem. Hop. Paris 53:155–159; 1977.

Held, P.J., P.M. Hanno, A.J. Wein, M.V. Pauly, and M.A. Cann. 1990. Epidemiology of interstitial cystitis. Pp. 29–48 in Interstitial Cystitis. P. Hanno, D.R. Staskin, R.J. Krane, and A.J. Wein, eds. New York: Springer-Verlag.

Helmy, H., M.N. Seddak, M.T. Basta, A. Shaaban, M. el-Baz, S. el-Masry, E.S. Al-Hilaly, and M.A. Ghoneim. 1991. Cytokeratin shedding in urine as a biological marker for bladder cancer: Monoclonal antibody-based evaluation. Br. J. Urol. 68:248–253.

Helpap, B. 1980. The biological significance of atypical hyperplasia of the prostate. Virchows Arch. (A) 387:307–313.

Helpap, B. 1988. Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology 13:203–211.

Hemminki, K. 1993. DNA adducts, mutations and cancer. (Commentary) Carcinogenisis 14:2007–2012.


Iesato, K., M. Wakastin, and Y. Wakastin. 1977. Renal tubular dysfunction in Minimata disease. Ann. Intern. Med. 86:731–733.

Iida, H., R. Seifert, C.E. Alpers, R. Gronwald, P.E. Phillips, P. Pritzl, K. Gordon, A.M. Gown, R. Ross, D. Bowel-Pope, and R.J. Johnson. 1991, Platelet-derived growth factor (PDGF) and PDGF receptor are induced in inesangial proliferative nephritis in the rat. Proc. Natl. Acad. Sci. U.S.A. 88:6560–6564.

Inoue, M., K. Okajima, and Y. Morino. 1981. Renal transtubular transport of mercapturic acid in vivo. Biochim. Biophys. Acta 641:122–128.

Inoue, M., K. Okajima, and Y. Morino. 1984. Hepato-renal cooperation in biotransformation, membrane transport, and elimination of cysteine S-conjugates of xenobiotics. J. Biochem. 95:247–254.

Inoue, S., D. Grant, and C.P. Leblond. 1989. Heparin sulfate proteoglycan is present in basement membrane as a double-tracked structure. J. Histochem. Cytochem. 37:597–602.

Inskeep, P., and F.P. Guengerich. 1984. Glutathione-mediated binding of dibromoalkanes to DNA: Specificity of rat glutathione S-transferases and dibromoalkane structure. Carcinogenesis 5:805–808.

Ishikawa, J., H.J. Xu, S.X. Hu, D.W. Yandell, S. Maeda, S. Kamidono, W.F. Benedict,

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

and R. Takahashi. 1991. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res. 51:5736–5743.

Ishikura, K., M. Hasegawa, K. Nomura, T. Okamoto, S. Tanji, T. Abe, T. Fujioka, T. Ohhori, and T. Kubo. 1991. Epidermal growth factor in the urine of patients with renal cell carcinoma and bladder tumor [in Japanese]. Hinyokika Kiyo, (Acta Urol. Jpn.) 37:1229–1234.

Isley, W.L., L.E. Underwood, and D.R. Clemmons. 1983. Dietary components that regulate serum somatomedin-C concentrations in humans. J. Clin. Invest. 71:175–182.

Ito, N., and S. Fukushima. 1989. Promotion of urinary bladder carcinogenesis in experimental animals. Exp. Pathol. 36:1–15.

Ito, H., Y. Nakagami, T.T. Lin, K. Ideda, and F. Oka. 1988. A comparative evaluation of PAP and gamma-Sm as the tumor markers of prostatic cancer. Nippon Ika Daigaku Zasshi 55:217–218.

Ito, N., S. Fukushima, and R. Hasegawa. 1989. Bladder cancers. Their process of development and its modification. Acta Pathol. Japan 39:1–14.


Jacob, A.K., D.J. Thomas, C.A. Reznikoff, T.V. Zenser, and B.B. Davis. 1991. Cyclic AMP response in SV40 immortalized human bladder cells. Carcinogenesis 12:1459–1463.

Jacobs, W.R., M. Sgambati, G. Gomez, P. Vilaro, M. Higdon, P.D. Bell, and L.J. Mandel. 1991. Role of cytosolic Ca in renal tubule damage induced by anoxia. Am. J. Physiol. 260:C545–C554.

Jakoby, W.B., and J.L. Stevens. 1984. Cysteine conjugate b-lyase and the thiomethyl shunt. Biochem. Soc. Trans. 12:33–35.

Jarrett, L., P.E. Lacy, and D.M. Kipnis. 1964. Characterization by immunofluore-scence of an ACTH-like substance in nonpituitary tumors from patients with hyperadrenocorticism. J. Clin. Endocrinol. 24:542–549.

Javadpour, N., and R. Guirguis. 1992. Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer--an update. Eur. Urol. 21 Suppl. 1:1–4.

Johnson, M.D., G.T. Bryan, and C.A. Reznikoff. 1985. Serial cultivation of normal rat bladder epithelial cells in vitro. J. Urol, 133:1076–1086.

Jones, D.P., G.B. Sundby, K. Ormstad, and S. Orrenius. 1979. Use of isolate kidney cells for study of drug metabolism. Biochem. Pharmacol. 28:929–935.

Jones, D.P., S. Orrenius, and S.W. Jakobson. 1980. Cytochrome P-450-linked monooxygenase systems in the kidney. Pp. 123–158 in Extrahepatic Metabolism of Drugs and Other Foreign Compounds , T.E. Gram, ed. New York: Spectrum.

Jones, T.W., A. Wallin, T. Thor, R.G. Gerdes, K. Ormstand, and S. Orrenius. 1986. The mechanism of pentachlorobutadienyl-glutathione nephrotoxicity studied with isolated rat renal epithelial cells. Arch. Biochem. Biophys. 251:504–513.

Jones, T.W., C. Qin, V.H. Schaeffer, and J.L. Stevens. 1988. Immunohistochemical

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

localization of glutarnine transaminase K, a rat kidney cystein conjugate b-lyase, and the relationship to the segment specificity of cysteine conjugate nephrotoxicity. Mol. Pharmacol. 34:621–627.

Jones, P.L., C.M. O'Hare, R.A. Bass, J.Y. Rao, G.P. Hemstreet, and R.E. Hurst. 1990. Quantitative immunofluorescence, anti-ras p21 antibody specificity, and cellular oncoprotein levels. Biochem. Biophys. Res. Comm. 167:464–470.

Jones, C.L., S. Buch, M. Post, L. McCulloch, E. Liu, and A.A. Eddy. 1991. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int. 40:1020–1031.

Jordan, A., J. Weingarten, and W. Murphy. 1987. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? [published erratum appears in Cancer 1988 Apr 1;61(7):1385]. Cancer 60(11):2766–2774.

Jordan, D.K., S.R. Patil, J.E. Divelbiss, S. Vemuganti, C. Headley, M.H. Waziri, and N.J. Gurll. 1989. Cytogenetic abnormalities in tumors of patients with von Hippel-Lindau disease. Cancer Genet. Cytogenet. 42:227–241.


Kadamani, S., N.R. Asal, and R.Y. Nelson, 1989. Occupational hydrocarbon exposure and risk of renal cell carcinoma. Am. J. Ind. Med. 15:131–141.

Kadlubar, F., M. Butler, K. Kaderlik, H. Chou, and N. Lang. 1992. Polymorphisms for aromatic amine metabolism in humans: Relevance for human carcinogenesis. Environ. Health Perspect. 98: 69–74.

Kageyama, Y., M. Katoh, K. Okada, K. Yoshida, and T.T suruo. 1991. Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression . Eur. Urol. 20:58–61.

Kahng, M.W., E.A. Conner, and B.A. Fowler. 1992. Lead-binding proteins (PhBP) in human tissues. The Toxicologist 12:214.

Kaiser, U., M.L. Hansmann, and I. Papadopoulos. 1991. Does the immunophenotype of renal cell carcinoma correlate with its clinical stage? Urol. Int. 47:194–198.

Kakizoe, T., H. Komatsu, T. Niijima, T. Kawachi, and T. Sugimura. 1981. Maintenance by saccharin of membrane alterations of rate bladder cells induced by subcarcinogenic treatment with bladder carcinogens. Cancer Res. 41:4702–4705.

Kaloyanides, G.J. 1991. Metabolic interactions between drugs and renal tubulo-interstitial cells: Role in nephrotoxicity. Kidney Int. 39:531–540.

Kanerva, R.L., M.S. McCracken, C.L. Alden, and L.C. Stone. 1987a. Morphogenesis of decalin-induced renal alterations in the male rat. Food chem. Toxicol. 25:53–61.

Kanfer, A., D. deProst, C. Guettier, D. Nochy, V. LeFloch, N. Hinglais, and P. Druet. 1987. Enhanced glomerular procoagulant activity and fibrin deposition in rats with mercuric chloride-induced autoimmune nephritis. Lab. Invest. 57:38–143.

Kao, C., S. Wu, M. Bhattacharya, L.F. Meisner, and C.A. Reznikoff. 1991. Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes. Cancer 4(2): 1–11, 1001.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Karthaus, H.F., M.J. Bussemakers, J.A. Schalken, K.H. Kurth, W.F. Feitz, F.M. Debruyne, H.P. Bloemers, and W.J. Van de Ven. 1987. Expression of proto-oncogenes in xenografts of human renal cell carcinomas. Urol. Res. 15:349–353.

Kawaguchi, A., M.H. Goldman, R. Shapiro, M. Foegh, P. Ramwell, and R. Lower, 1985. Increase in urinary thromboxane B2 in rats caused by cyclosporine. Transplantation 40:214–216.

Kawamata, H., M. Azuma, S. Kameyama, L. Nan, and R. Oyasu. 1992. Effect of epidermal growth factor/transforming growth factor alpha and transforming growth factor beta I on growth in vitro of rat urinary bladder carcinoma cells. Cell Growth Differ. 3:819–825.

Kelley, V.E., S. Sneve, and S. Musinski. 1986. Increased renal thromboxane production in murine lupus nephritis. J. Clin. Ivest. 77:252–259.

Kerr, L., C. Huntoon, J. Donohue, P.J. Leibson, N.H. Bander, T. Ghose, S.J. Luner, R. Vassella, and D.J. McKean. 1990. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J. Immunol. 144:4060–4067.

Key, G., M.H.G. Becker, B. Baron, M. Duchrow, C. Schluter, and H.D. Flad. 1993. New Ki-67 murine monoclonal antibodies (MIB 1–3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62bp repetitive elements encoding for the Ki-67 epitope. Lab. Invest. 68:629–636.

Kiesewetter, F., O.P. HOrnstein, P. Hermanek, A. Herrlinger, S. Eberhard. 1987. Possibilities of DNA impulse cytophotometry in kidney cancer [in German]. Urologe A. 26:162–167.

Kiley, J.E., S.R. Powers, and R.T. Beebe. 1960. Acute renal failure: Eight cases of renal tubular necrosis. N. Engl. J. Med. 262:481.

Kimball, E.S., W.H. Bohn, K.D. Cockley, T.C. Warren, and S.A. Sherwin. 1984. Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals. Cancer res. 44:3613–3619.

Kinouchi, T., S. Saidi, T. Naoe, A. Uenaka, T. Kotake, H. Shiku, and E. Nakayama. 1989. Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. Cancer Res. 49:3627–3630.

Kleer, E., J.J. Larson-Keller, H. Zincke, and J.E. Oesterling. 1993. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology 41:207–216.

Klingel, R., W. Dippold, S.Storkel, K.H. Meyer zum Buschenfelde, and H. Kohler. 1992. Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma. Am. J. Kidney Dis. 19:22–30.

Klingelhutz, A.J., S.Q. Wu, J. Huang, and C.A. Reznikoff. 1992. Loss of 3p13–p21.2

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

in tumorigenic reversion of a hybrid between isogeneic nontumorigenic and tumorigenic human uroepithelial cells. Cancer Res. 52:1631–6134.

Kloppel, G., W.T. Knofel, H. Baisch, and U. Otto. 1986. Prognosis of renal cell carcinoma related to nuclear grade, DNA content and Robson stage. Eur. Urol. 12:426–431.

Klouda, P.T., J. Manos, and E.J. Acheson. 1979. Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet 2:770–771.

Kluwe, W.M., and J.B. Hook. 1980. Effects of environmental chemicals on kidney metabolism and function. Kidney Int. 18:648–655.

Knudson, A.G. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68:820–823.

Knudson, A.G., and L.C. Strong. 1972. Mutation and cancer: A model for Wilms' tumor of the kidney. J. Nat. Cancer Inst. 48:313–324.

Kochevar, G.J., J.A. Stanek, and E.B. Rucker. 1992. Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. Cancer 69:2311–2315.

Kohler, H., E. Wandel, and B. Brunck. 1991. Acanthocyturia--A characteristic marker for glomerular bleeding. Kidney Int. 40:115–120.

Kohnon, T., T. Sekine, K. Tobisu, M. Oshimura, and J. Yokota. 1993. Chromosome 3p deletion in a renal cell carcinoma cell line established from a patient with von Hippel-Lindau disease. Jpn. J. Clin. Oncol. 23:226–231.

Koide, T. 1992. The clinical significance of tissue, blood and urine polyamine in renal cell carcinoma [in Japanese]. Nippon Hinvokika Gakkai Zasshi (Jpn. J. Urol.) 83:1228–1237.

Kolonel, L.N., A.M.Y. Nomura, M.W. Hinds, T. Hirohata, J.H. Hankin, and J. Lee. 1983. Role of diet in cancer incidence in Hawaii. Cancer Res. (Suppl.) 43:2397s–2402s.

Konchuba, A.M., M.C. Clements, P.F. Schellhammer, S. M. Schlossberg, and G.L. Wright. 1992. Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer. Cancer 70: 2879–2884.

Konen, J.C., L.G. Curtis, Z.K. Shihabi, and M.B. Dignan. 1990. Screening diabetic patients for microalbummuria. J. Fam. Pract. 31:505–510.

Koo, C., B. Pauli, G. Friedell, and R.S. Weinstein. 1979. Induction of proliferative activity in urinary bladder epithelium by cystoscopy fluids. Lab. Invest. 40:265.

Koo, A.S., C. Armstrong, B. Bochner, T. Shimabukuro, C.L. Tso, J.B. deKernion, A Belldegrum. 1992. Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol. Immunother. 35:97–105.

Koob, M., and W. Dekant. 1990. Metabolism of hexafluorpropene. Evidence for bioactivation by glutathione conjugate formation in the kidney Drug etab. Dispos. 18:911–922.

Koopman, M.G., R.T. Krediet, F.M.J. Zuijderhoudt. E.A.M. deMoor, and L. Arisz.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1987. Circadian rhythm or urinary beta2-microglobulin excretion in patients with a nephrotic syndrome. Nephron. 45:140–146.

Koss, L.G., and B. Czerniak. 1992. Image analysis and flow cytometry of tumors of prostate and bladder; with a comment on molecular biology of urothelial tumors. Monogr. Pathol. (34):112–128.

Kotake, T., and T. Kinouchi. 1994. Characterization of renal cell carcinoma: Current topics [review][in Japanese]. Gan to Kagaku Ryoho 21:5–11.

Kotake, T, S. Saiki, T. Kinouchi, H. Shiku, and E. Nakayama. 1990. Detection of the c-myc gene product in urinary bladder cancer. Jpn. J. Cancer Res. 81:1198–1201.

Kovacs, G. 1989. Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am. J. Pathol. 134:27–34.

Kovacs, G., S. Szucs, W. deRiese, and H. Baumgartel. 1987. Specific chromosome aberration in human renal cell carcinoma. Int. J. Cancer 40:171–178.

Kovacs, G., P. Brusa, and W. deRiese. 1989. Tissue-specific expression of a constitutional 3;6 translocation: Development of multiple bilateral renal-cell carcinomas. Int. J. Cancer 43:422–427.

Kovacs, G., C. Welter, L. Wilkens, N. Blin, and W. deRiese. 1989. Renal oncocytorna. A phenotypic and genotypic entity of renal parenchymal tumors. Am. J. Pathol. 134:967–971.

Kovacs, G., L. Fuzesi, A. Emanuel, and H.F. Kung. 1991. Cytogenetics of papillary renal cell tumors. Genes Chromosom. Cancer 3:249–255.

Kovacs, G., A. Emanuel, H. Neumann, and H. King. 1991. Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer 3:256–262.

Koziol, J.A., D.C. Clark, R.F. Gittes, and E.M. Tan. 1993. The natural history of interstitial cystitis: A survey of 374 patients. J. Urol. 149:465–469.

Kreisberg, J.I., G. Sachs, T.G. Pretlow, and R.A. McGuire. 1977a. Separation of proximal tubule cells from suspensions of rat kidney cells by free-flow electrophoresis. J. Cell. Physiol. 93:169–172.

Kreisberg, J.I., A.M. Pitts, and T.G. Pretlow. 1977b. Separation of proximal tubule cells from suspensions of rat kidney cells in density gradients of Ficoll in tissue culture medium. Am. J. Pathol. 86:591–602.

Kujubu, D.A., J.T. Norman, H.R. Herschman, and L.G. Fini. 1991. Primary gene expression in renal hypertrophy: Evidence for different growth initiation processes. Am. J. Physiol. 260:F823–F827.

Kumar, D., and S. Kumar. 1993. Adrenal cortical adenoma and adrenal metastasis of renal cell carcinoma: Immunohistochemical and DNA ploidy analysis. Mod. Pathol. 6:36–41.

Kumar, S., and A. Muchmore. 1990. Tamm-Horsfall protein--uromodulin (1950–1990). Kidney Int. 37:1395–1401.

Kumar, S., S.M. Jakate, H.B. Marsden, P. Kumar, and B. Jasani. 1988. Tamm-

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Horsfall protein is a marker of renal and extra-renal rhabdoid tumors. Int. J. Cancer 41:386–389.

Kumar, S., P.H. Hand, H.B. Marsden, P. Kumar, and A. Thor. 1991. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumors. Anticancer Res. 11: 1657–1662.

Kunes, J., K. Capek, J. Stejskal, and J. Jelinek. 1978. Age-dependent difference of kidney response to temporary ischernia in the rat. Clin. Sci. Mol. Med. 55:365–368.

Kurnick, N.B., and P.A. Lindsay. 1968. Nucleic acids in compensatory renal hypertrophy. Lab. Invest. 18:700–708.

Kurokawa, Y., A. Maekawa, M. Takahashi, and Y. Hayashi. 1990. Toxicity and carcinogenicity of potassium bromate--a new renal carcinogen [review] . Environ. Health Perspect. 87:309–335.

Kvist, N., and E. Nexo. 1989. Epidermal growth factor in urine after kidney transplantation in humans. Urol. Res. 17:225–228.


Lajara, R., P. Rotwein, J. Bortz, V. Hansen, J.L. Sadow, C.R. Betts, S.A. Rogers, and M.R. Hammerman. 1989. Dual regulation of insulin-like growth factor I expression during renal hypertrophy. Am. J. Physiol. 257:F252–F261.

Landberg, G., and G. Roos. 1991. Antibodies to proliferating cell nuclear antigent as S-Phase probes in flow cytometric cell cycle analysis. Cancer Res. 51:4570–4574.

Landrigan, P.J., R.A. Goyer, T.W. Clarkson, D.P. Sandler, J.H. Smith, M.J. Thun, and R.P. Wedeen. 1984. The work-relatedness of renal disease. Arch. Environ. Health 39:225–230.

Langkilde, N.C., H. Wolf, P. Meldgard, and T.F. Orntoft. 1991a. Frequency and mechanism of Lewis antigen expression in human urinary bladder and colon carcinoma patients. Br. J. Cancer 63:583–586.

Langkilde, N.C., H. Wolf, and T.F. Orntoft. 1991b. Lewis antigen expression in benign and malignant tissues from RBC Le(a-b-) cancer patients. Br. J. Haematol. 79:493–499.

Lanigan, D., P.A. McLean, B. Curran, and M. Leader. 1993. Comparison of flow and static image cytometry in the determination of ploidy. J. Clin. Pathol. 46:135–139.

Lanzafame, S., L. Puzzo, C. Di Naso, G. Di Marco, S. Ranno, and G. Minardi. 1986. Carcinoembryonic antigen (CEA) in carcinoma of the upper urinary tract and bladder. Immunohistochemical study [in Italian]. Pathologica 78:451–458.

Larsen, G.L. 1985. Distribution of cysteine conjugate b-lyase in gastrointestinal bacteria and in the environment. Xenobiotica 15:199–209.

Larsson, P., G. Roos, R. Stenling, and B. Ljungberg. 1993. Tumor-cell proliferation and prognosis in renal-cell carcinoma. Int. J. Cancer 55:566–570.

Lash, L.H. 1989. Isolated kidney cells in the study of chemical toxicity. Pp. 231–262 in In Vitro Toxicology: Model Systems and Methods, C.A. McQueen, ed. Caldwell, N.J.: Telford Press.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Lash, L.H. 1990. Susceptibility to toxic injury in different nephron cell populations. Toxicol. Lett. 53:97–104.

Lash, L.H. 1992. Nephrotoxicity studies with freshly isolated cells from rat kidney. Pp. 115–122 in In Vitro Methods of Toxicology, R.R. Watson, ed. Boca Raton, Fla: CRC Press.

Lash, L.H. 1993. Purification of renal cortical cell populations by Percoll density-gradient centrifugation. Pp. 397–410 in In Vitro Biological Systems: Preparation and Maintenance Methods in Toxicology, Vol. 1., Part A, C.A. Tyson, and J.M. Frazier, eds. San Diego: Academic.

Lash, L.H. 1994. Patterns of chemical-induced injury in primary cultures of rat renal proximal tubular (PT) and distal tubular (DT) cells. Toxicologist 14:168.

Lash, L.H., and M.W. Anders. 1986. Cytotoxicity of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine in isolated rat kidney cells. J. Biol. Chem. 261:13076–13081.

Lash, L.H., and M.W. Anders. 1989. Uptake of nephrotoxic S-conjugates by isolated rat renal proximal tubular cells. J. Pharmacol. Exp. Ther. 248:531–537.

Lash, L.H., and D.P. Jones. 1983. Transport of glutathione by renal basal-lateral membrane vesicles. Biochem. Biophys. Res. Commun. 112:55–60.

Lash, L.H., and D.P. Jones. 1984. Renal glutathione transport: Characteristics of the sodium-dependent system in the basal-lateral membrane. J. Biol. Chem. 259:14508–14514.

Lash, L.H., and D.P. Jones. 1985. Uptake of the glutathione conjugate S-(1,2-dichlorovinyl)glutathione by renal basal-lateral membrane vesicles and isolated kidney cells. Mol. Pharmacol. 28:278–282.

Lash, L.H., and J.J. Tokarz. 1989. Isolation of two distinct populations of cells from rat kidney cortex and their use in the study of chemical-induced toxicity. Anal. Biochem. 182:271–279.

Lash, L.H., and J.J. Tokarz. 1990. Oxidative stress in isolated rat renal proximal and distal tubular cells. Am. J. Physiol. 259:F338–F347.

Lash, L.H., and E.B. Woods. 1991. Cytotoxicity of alkylating agents in isolated rat kidney proximal tubular and distal tubular cells . Arch. Biochem. Biophys. 286:46–56.

Lash, L.H., and R.K. Zalups. 1992. Mercuiric chloride-induced cytotoxicity and compensatory hypertrophy in rat kidney proximal tubular cells. J. Pharmacol. Exp. Ther. 261:819–829.

Lash, L.H., and R.K. Zalups. 1994. Activities of enzymes involved in renal cellular glutathione metabolism after urinephrectomy in the rat. Arch. Biochem. Biophys. 309:129–138.

Lash, L.H., A.A. Elfarra, and M.W. Anders. 1986a. S-(1,2-Dichlorovinyl-L-homocysteine-induced cytotoxicity in isolated rat kidney cells. Arch. Biochem. Biophys. 251:432–439.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Lash, L.H., T.M. Hagen, and D.P. Jones. 1986b. Exogenous glutathione protects intestinal epithelial cells from oxidative injury. Proc. Natl. Acad. Sci. U.S.A. 83:4641–4645.

Lash, L.H., A.A. Elfarra, and M.W. Anders. 1986c. Renal cysteine conjugate b-lyase: Bioactivation of nephrotoxic cysteine S-conjugates in mitochondrial outer membrane. J. Biol. Chem. 261:5930–5935.

Lash, L.H., D.P. Jones, and M.W. Anders. 1988. Glutathione homeostasis and glutathione S-conjugate toxicity in the kidney. Rev. Biochem. Toxicol. 9:29–67.

Lash, L.H., R.M. Nelson, R.A. Van Dyke, and M.W. Anders. 1990, Purification and characterization of human kidney cytosolic cysteine conjugate b-lyase activity. Drug Metab. Dispos. 18:50–54.

Lash, L.H., R.M. Nelson, R.A. Van Dyke, and M.W. Anders. 1990a. Purification and characterization of human kidney cytosolic cysteine conjugate b-lyase activity. Drug Metab. Dispos. 18:50–54.

Lash, L.H., A.A. Elfarra, D. Rakiewicz-Nemeth, and M.W. Anders. 1990b. Bioactivation mechanism of cvtotoxic homocysteine S-conjugates. Arch. Biochem. Biophys. 276:322–330.

Lash, L.H., J.J. Tokarz, E.B. Woods, and B.M, Pedrosi. 1993. Hypoxia and oxygen dependence of cytotoxicity in renal proximal tubular and distal tubular cells. Biochem. Pharmacol. 45:191–200.

Lash, L.H., P.J. Sausen, R.J. Duescher, A.J. Cooley, and A.A. Elfarra. 1994. Roles of cysteine conjugate β-lyase and S-oxidase in nephrotoxicity: Studies with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinvl)-L-cysteine sulfoxide. J. Pharmacol. Exp. Ther. 269:374–383.

Latif, F., K. Tory, J. Gnarra, M. Yao, F.-M. Duh, M.L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, L. Schmidt, F. Zhou, H. Li, M.H. Wei, G. Glenn, F.M. Richards, P.A. Crossey, M.A. Ferguson-Smith, D. Le Pasher, I1. Chumakov, D. Cohen, C.A. Chinault, E.R. Maher, W.M. Linehan, B. Zbar, and M.I. Lerman. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320.

Lauwerys, R., A. Bernard, C. Viau, and J.P. Buchet. 1985. Kidney disorders and haematotoxicity from organic solvent exposure. Scand. J. Work Environ. Health 11 (Suppl. 1):83–90.

le Coutre, P., S. Bock, G. Jakse, and P.E. Petrides. 1992. Immunoreactive low-molecular-weight epidermal growth factor in urine of patients with renal cell carcinoma. Urol. Res. 20:293–296.

Lefkowith, J.B., J. Pippin, T. Nagamatsu and V. Lee. 1992. Urinary eicosanoids and the assessment of glomerular inflammation. J. Am. Soc. Nephrol. 2:1560–1567.

Lehman, McKeeman, L.D., and D. Caudill. 1992. Biochemical basis for mouse resistance to hyaline droplet nephropathy: Lack of relevance of the α2u-globulin

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

protein superfamily in this male rat-specific syndrome. Toxicol. Appl. Pharmacol. 116:170.

Lehman-McKeeman, L.D., P.A. Rodriguez, R. Takigiku, D. Caudill, and M.L. Fey. 1989. d-Limonene-induced male rat-specific nephrotoxicity: Evaluation of the association between d-limonene and α2u-globulin. Toxicol. Appl. Pharmacol. 99:250–259.

Lehman-McKeeman, L.D., D. Caudill, R. Takigiku, R.E. Schneider, and J.A. Young. 1990a. Comparative disposition of d-limonene in rats and mice: Relevance to male-rat-specific nephrotoxicity. Toxicol. Lett. 53:193–195.

Lehman-McKeeman, L.D., M.I. Rivera-Torres, and D. Caudill. 1990b. Lysosomal degradation of α2u-globulin-xenobiotic conjugates. Toxicol. Appl. Pharmacol. 103:539–548.

Levin, I., T. Klein, J. Goldstein, O. Kuperman, J. Kanetti, and B. Klein. 1991. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 68:2591–2594.

Levin, I., B. Klein, S. Segal, A. Eyal, J. Gopas, et al. 1992. Expression of HLA class I-encoded cell surface antigens in transitional cell carcinoma of the urinary bladder. Tissue Antigens 39(1):19–22.

Lewis, R.A., R.H. Schwartz, and E.A. Schenk. 1972. Tamm-Horsfall mucoprotein. II. Ontogenetic development. Lab. Invest. 26(6):728–730.

Leyh, H., A. Lehmer, and R. Hartung. 1992. Patterns of ploidy in renal cell carcinoma. Prog. Clin. Biol. Res. 378:187–193.

Liang P., and A.B. Pardee. 1992. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967–971.

Liang P., L. Averboukh, and A.B. Pardee. 1993. Distribution and cloning of eukaryotic mRNAs by means of differential display: Refinements and optimization. Nucleic Acids Res. 21:3269–3275.

Lianos E.A., and A. Zanglis. 1990. Glomerular platelet-activating factor levels and origin in experimental glomerulonephritis. Kidney Int. 37:736–740.

Lianos, E., G.A. Andres, and M.J. Dunn. 1983. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. J. Clin. Invest. 72:1439–1448.

Lianos, E., M.A. Rahman, and M.J. Dunn. 1985. Glomerular arachidonate lipoxygenation in rat nephrotoxic serum nephritis. J. Clin. Invest. 76:1355–1359.

Lianos, E.A., B. Bresnahan, and C. Pan. 1991. Mesangial cell immune injury: Synthesis, origin and role of eicosanoids. J. Clin. Invest. 88:623–631.

Libertino, J.A., L. Zinman, and E. Watkins. 1987. Long-term results of resection of renal cell cancer with extension into inferior vena cava. J. Uro. 137:21–24.

Liebert, M., G.A. Wedemeyer, J.A. Stein, R.W. Washington, A. Flint, L. Ren, and H.B. Grossman. 1989. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cell. Cancer Res. 49:6720–6726.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Liebert, M., G. Wedemeyer, J.A. Stein, R. Washington, G. Faerber, A. Fling, and H.B. Grossman. 1993. Evidence for urotlielial cell activation in interstitial cystitis. J. Urol. 149:470–475.

Lilja, H., A.T.K. Cockett, and P.-A. Abrahamsson. 1992. Prostate specific antigen predominantly forms a complex with α1-antichymotrypsin in blood. Cancer (Suppl) 70:230–234.

Limas, C. 1990. A,B blood group antigens ill tissues of AB heterozygotes. Emphasis on normal and neoplastic urothelium. Am. J. Pathol. 137:1157–1162.

Limas, C. 1991. Quantitative interrelations of Lewis antigens in normal mucosa and transitional cell bladder carcinomas, J. Clin. Pathol. 44:983–989.

Limon, J., K. Mrozek, S. Heim, P. Elfving, B. Nedoszytko, M. Babinska, N. Mandahl, R. Lundgren, and F. Mitelman. 1990. On the significance of trisomy 7 and sex chromosome loss in renal cell carcinoma. Cancer Genet. Cytogenet. 49:259–263.

Lin, C.-W., D.A. Young, S.D. Kirley, A.-H. Khaw, and G.A. Prout. 1988. Detection of tumor cells in bladder washings by a monoclonal antibody to human bladder tumor-associated antigen. J. Urol. 140:672–677.

Lipponen, P., M. Eskelinen, K. Hietala, K. Syrjanen, and R.A. Gambetta. 1994. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int. J. Cancer 57:275–280.

Lipponen, P., and M. Eskelinen. 1990. Nuclear morphometry in grading transitional cell bladder cancer compared with subjective histological grading. Anticancer Res. 10(6):1725–1730.

Lipponen, P., M. Eskelinen, and S. Nordiing. 1991 a. Relationship between DNA flow cytometric data, nuclear morphometric variables and volume-corrected mitotic index in transitional cell bladder tumors. Eur. Urol. 19(4):327–331.

Lipponen, P., M. Eskelinen, and S. Nordling. 1991b. Progression and survival in transitional cell bladder cancer: A comparison of established prognostic factors, S-phase fraction and DNA ploidy. Eur. J. Cancer 27(7):877–881.

Lipponen, P., M. Eskelinen, K. Jauhiainen, E. Harju, R. Terho, and H. Haapasalo. 1992. Prediction of superficial bladder cancer by nuclear image analysis. Eur. J. Cancer 29A(1):61–65.

Lizard, G., P. Roignot, L. Dusserre-Guion, F. Morlevat, D. Michiels-Marzais, N. Ferry, and J.C. Tremeaux. 1992. Characterization of seven kidney tumors by flow cytometry: Analysis of cell cycle, DNA content and P-glycoprotein expression. Eur. Urol. 21 (Suppl. 1):39–42.

Ljungberg, B., R. Stenling, and G. Roos. 1956. DNA content in renal cell carcinoma with reference to tumor heterogeneity. Cancer 56:503–508.

Ljungberg, B., I. Nordenson, and G. Roos. 1991. Cytogenetic and flow cytometric DNA analysis in renal cell carcinoma. Eur. Urol. 19:59–64.

Lloyd, S.N., I.L. Brown, and R.E. Leake. 1992. Transforming growth factor-alpha

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

expression in benign and malignang human prostatic disease. Int. J. Biol. Markers 7:27–34.

Lock, E.A., and J. Ishmael. 1985. Effect of the organic acid transport inhibitor probenecid on renal cortical uptake and proximal tubular toxicity of hexachloro-1,3-butadiene and its conjugates. Toxicol. Appl. Pharmacol. 81:32–42.

Lock, E.A., and R.G. Schnellman. 1990. The effect of haloalkene cysteine conjugates on rat renal glutathione reductase and lipoyl dehydrogenase activities. Toxicol. Appl. Pharmacol. 104:180–190.

Lock, E.A., J. Odum, and P. Ormond. 1986. Transport of N-acetyl-S-pentachloro-1, 3-butadienyl-cysteine by rat renal cortex. Arch. Toxicol. 59:12–15.

Longin, A., A. Huazi, N. Berger-Dutrieux, et al. 1989. A monoclonal antibody (BL2-10D1) reacting with a bladder cancer associated antigen. Int. J. Cancer 43:183–189.

Lopez-Rivas, A.E., A. Adelberg, and E. Rozengurt. 1982. Intracellular K+ and the mitogenic response of 3T3 cells to peptide factors in serum-free medium. Proc. Natl. Acad. Sci. U.S.A. 79:6275–6279.

Lose, G., and B. Frandsen. 1989. Eosinophil cationic protein in urine in patients with urinary bladder tumors. Urol. Res. 17:295–297.

Lovern, W.J., B.L. Fariss, J.N. Wettlaufer, and S. Hane. 1975. Ectopic ACTH production in disseminated prostatic adenocarcinoma. Urology 5:817–820.

Lower, G.M., T. Nilsson, C.E. Nelson, H. Wolf, T.E. Gamsky, and G.T. Bryan. 1979. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29:71–79.

Lunec, J., C. Challen, C. Wright, K. Mellon, and D.E. Neal. 1992. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder [letter] . Lancet 339:439–440.

Lynn, K.L., A. Shenkin, and R.D. Marshall. 1982. Factors affecting excretion of human urinary Tamm-Horsfall glycoprotein. Clin. Sci. 62:21–26.


Maack, T. 1986. Renal clearance and isolated kidney perfusion techniques. Kidney Int. 30:142–151.

Maack, T., C.Y. Park, M.S.F. Camargo. 1985. Renal filtration, transport and metabolism of proteins. Pp. 1773–1803 in The Kidney: Physiology and Pathophysiology. D.W. Seldin, and G. Giebisch, eds. New York: Raven Press.

MacDermott, J.P., C.H. Miller, N. Levy, and A.R. Stone. 1991. Cellular immunity in interstitial cystitis. J. Urol. 145:274–278.

MacFarlane, M., J.R. Foster, G.G. Gibson, L.J. King, and E.A. Lock. 1989. Cysteine conjugate b-lyase of rat kidney cytosol: Characterization, immunohistochemical localization, and correlation with hexachlorobutadiene nephrotoxicity. Toxicol. Appl. Pharmacol. 98:185–197.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

MacInnes, J.I., E.S. Nozik, and D.T. Kurtz. 1986. Tissue-specific expression of the rat α2u-globulin gene family. Molec. Cell. Biol. 6:3563–3567.

MacMahon, B., and T.F. Pugh. 1970. Pp. 261–262 in Epidemiology: Principals and Methods. Boston: Little, Brown.

Maddy, S.Q., G.D. Chisholm, A. Busuttil, and F.K. Habib. 1989. Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumour. Br. J. Cancer 60:41–44.

Madrenas, J., N.A. Parfrey, and P.F. Halloran. 1991. Interferon gamma-mediated renal MHC expression in mercuric chloride-induced glomerulonephritis. Kidney Int. 39:273–281.

Mahadevia, P.S., A. Ramaswamy, E.S. Greenwald, D.I. Wollner, and D. Markham. 1983. Hypercalcimia in prostatic carcinoma: report of eight cases. Arch. Intern. Med. 143:1339–1342.

Maiter, D., M. Maes, L.E. Underwood, T. Fliesen, G. Gerard, and J.M. Ketelslegers. 1988. Early changes in serum concentrations of somatomedin-C induced by dietary protein deprivation in rats: Contributions of growth hormone receptor and post-receptor defects. J. Endocrinol. 118:113–120.

Malmstrom, P.U., J. Vasko, K. Wester, and C. Busch. 1991. Determination of DNA ploidy and ABH antigen reactivity in both frozen and formalin-fixed bladder tumor tissue. Urol. Res. 19:357–359.

Malmstrom, P.U., K. Wester, J. Vasko, and C. Busch. 1992. Expression of proliferative cell nuclear antigen (PCNA) in urinary bladder carcinoma. Evaluation of antigen retrieval methods. Acta Pathol. Microbiol. Immunol. Scand. Sect. A,B or C 100:988–992.

Maloney, K.E., R.W. Norman, C.L. Lee, O.H. Millard, and J.P. Welch. 1991. Cytogenetic abnormalities associated with renal cell carcinoma. J. Urol. 146:692–696.

Mandal, A.K. 1986. Transmission electron microscopy of urinary sediment in renal disease. Semin. Nephrol. 6:346–370.

Mandal, A.K., and W. Bennett. 1988. Transmission electron microscopy of urinary sediment in the assessment of aminoglycoside nephrotoxicity in the rat. Nephron 49:67–73.

Mandal, A.K., G.N. Mize, and D.B. Birnbaum. 1987. Transmission electron microscopy of urinary sediment in aminoglycoside nephrotoxicity. Renal Failure 10:63–81.

Mannens, M., R.M. Slater, C. Heyting, A. Geurts van Kessel, E. Goedde-Salz, R.R. Frants, G.J. Van Ommen, and P.L. Pearson. 1987. Regional localization of DNA probes on the short arm of chromosome 11 using aniridia-Wilms' tumor-associated deletions. Hum. Genet. 75:180–187.

Manteuffel-Cymborowska, M. 1993. Differential role of polyamines in hyperplasia and hypertrophy. Acta Biochim. Pol. 40:383–388.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Marcias-Nunez, J.E., and J.S. Cameron. 1987. Pp. 503 in Renal Function and Disease in the Elderly. Butterworth, London, Boston, Durban, Singapore, Sydney, Toronto, Wellington.

Martin, B.F. 1962. The effect of distension of the urinary bladder on the lining epithelium and on its histochemical reaction for alkaline phosphatase. Ann. Histochim. 1:51–.

Martin, E.W., W.E. Kibbey, L. DiVecchia, G. Anderson, P. Catalano, and J.P. Minton. 1976. Carcinoembryonic antigen: Clinical and historical aspects. Cancer 37:62–81.

Martinerie, C., and B. Perbal. 1991. Expression of a gene encoding a novel potential IGF binding protein in human tissues. Comptes Rendus de l Academie des Sciences-Serie Iii, Sciences de la Vie 313:345–351.

Martinerie, C., E. Viegas-Pequignot, I. Guenard, B. Dutrillaux, V.C. Nguyen, A. Bernheim, and B. Perbal. 1992. Physical mapping of human loci homologous to the chicken nov proto-oncogene. Oncogene 7:2529–2534.

Marx, J. 1991. How the retinoblastoma gene may inhibit cell growth. Science 252:1492.

Masters, J.R., R.S. Camplejohn, M.C. Parkinson, C.R. Woodhouse, and S.M. O'Reilly. 1992. Does DNA flow cytometry give useful prognostic information in renal parenchymal adenocarcinoma?. Br. J. Urol. 70:364–369.

Masuko, T., H. Gaigita, and Y. Hashimoto. 1984. Monoclonal antibodies against cell surface antigens present on human urinary bladder cancer cells. J. Natl. Cancer Inst. 72:523–530.

Masuko, T., K. Sugahara, T. Kamiya, and Y. Hashimoto. 1989. Increase in murine monoclonal-antibody-defined urinary antigens in patients with bladder cancer and benign urogenital disease. Int. J. Cancer 44:582–588.

Matejka, G.L., and E. Jennische. 1992. IGF-I binding and IGF-I mRNA expression in the post-ischemic regenerating rat kidney. Kidney Int. 42:1113–1123.

Mathiesen, E.R., B. Oxenbøll, K. Johansen, P.A. Svendsen, and T. Deckert. 1984. Incipient nephropathy in type I (insulin-dependent) diabetes. Diabetologia 26:406–410.

Mathiesen, E.R., E. Nexo, E. Hommel, and H. Parving. 1988. Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy. Diabetic Med. 6:121–126.

Matsumoto, K., and M. Hatano. 1989. Production of interleukin 1 in glomerular cell culture from rats with nephrotoxic serum nephritis. Clin. Exp. Immunol. 75:123–128.

Matsumoto, K., J. Dowling, and R.C. Atkins. 1988. Production of interleukin-1 in glomerular cell cultures from patients with rapidly progressive crescentic glomerulonephritis. Am. J. Nephrol. 8:463–470.

Matsusako, T., H. Muramatsu, T. Shirahama, T. Muramatsu, and Y. Ohi. 1991. Expression of a carbohydrate signal, sialyl dimeric Le(x) antigen, is associated with

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

metastatic potential of transitional cell carcinoma of the human urinary bladder. Biochem. Biophys. Res. Commun. 181:1218–1222.

Mattila, A.L., I. Saario, L. Viinikka, O. Ylikorkala, and J. Perheentupa. 1988. Urinary epidermal growth factor concentrations in various human malignancies. Br. J. Cancer 57:139–141.

Maunsbach, A.B. Observations on the segmentation of the proximal tubule in the rat kidney. Comparison of results from phase contrast, fluorescence and electron microscopy. J. Ultrastruct. Res. 16:239–258.

Maw, M.A., P.E. Grundy, L.J. Millow, M.R. Eccles, R.S. Dunn, P.J. Smith, A.P. Feinberg, D.J. Law, M.C. Paterson, P.E. Telzerow, et al. 1992. A third Wilms' tumor locus on chromosome 16q. Cancer Res. 52:3094–3098.

McCormick, D., and P.A. Hall. 1992. The complexities of proliferating cell nuclear antigen. Histopathology 21:591–594.

McGowan, P., R.E. Hurst, R.A. Bass, G.P. Hemstreet, and R. Postier. 1988. Equilibrium binding of Hoechst 33258 and Hoechst 33342 fluorochromes with rat colorectal cells. J. Histochem. Cytochem. 36:757–762.

McKeehan, W.L., and P.S. Adams. 1988. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev. Biol. 24:243–246.

McKinney, L.L., F.B. Weakley, A.C. Eldridge, R.G. Campbell, J.C. Cowan, J.C. Picken, and H.C. Beister. 1957. S-(dichlorovinyl)-L-cysteine: An agent causing fatal aplastic anemia in calves. J. Am. Chem. Soc. 79:3932–3933.

McKinney, L.L., J.C. Picken, F.B. Weakley, A.C. Eldridge, R.G. Campbell, J.C. Cowan, and H.E. Beister. 1959. Possible toxic factor of trichloroethylene-extracted soybean oil. J. Am. Chem. Soc. 81:909–915.

McLachlan, M.S.F., J.C. Guthrie, C.K. Anderson, and M.J. Fulker. 1977. Vascular and glomerular changes in the aging kidney. J. Pathol. 121:65–78.

McManus, L.M., M.A. Naughton, and A. Martinez-Hernandez. 1976. Human chorionic gonadotropin in human neoplastic cells. Cancer Res. 36:3476–3481.

McNeal, J.E., and D.G. Bostwick. 1986. Intraductal dysplasia: A premalignant lesion of the prostate. Hum. Pathol. 17:64–71.

McNeal, J.E., D.G. Bostwick, R.A. Kindrachuk, E.A. Redwin, F.S. Freiha, and T.A. Stamey. 1986. Patterns of progression in prostate cancer. Lancet 1:60–63.

McNeal, J.E., E.A. Redwine, F.S. Freiga, and T.A. Stamey. 1988a. Zonal distribution of prostatic adenocarcinoma. Am. J. Surg. Pathol. 12:897–.

McNeal, J.E., J. Alroy, I. Leav, E.A. Redwine, F.S. Freiha, and T.A. Stamey. 1988b. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am. J. Clin. Path. 90:23–32.

McNichols, D.W., J.W. Segura, and J.H. DeWeerd. 1981. Renal cell carcinoma: Long-term survival and late recurrence. J. Urol. 126:17–23.

McQueen, E.G. 1962. The nature of urinary casts. J. Clin. Pathol. 15:367–373.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Medeiros, L.J., A.B. Gelb, and L.M. Weiss. 1988. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 61:1639–1651.

Medeiros, L.J., and L.M. Weiss. 1990. Renal adenocarcinoma. Pp. 35–70 in Tumors and Tumor-like Conditions of the Kidneys and Ureters, J.N. Eble, ed. New York: Churchill Livingstone, Inc.

Meisner, L.F., S.-Q. Wu, B.J. Christian, and C.A. Reznikoff. 1988. Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uroepithelial cell line. Cancer Res. 48:3215–3220.

Mellon, K., S. Thompson, R.G. Charlton, C. Marsh, M. Robinson, D.P. Lane, A.L. Harris, C.H. Horne, and D.E. Neal. 1992. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol. 147:496–499; 1992.

Melnick, R.L. 1992. An alternative hypothesis on the role of chemically induced protein droplet (α2u-globulin) nephropathy in renal carcinogenesis. Reg. Tox. Pharmacol. 16:111–125.

Merritt, S., P.D. Killen, S.H. Phan, and R.C. Wiggins. 1990. Analysis of α 1 (I) procollagen, α 1 (IV) collagen and β-actin mRNA in glomerulus and cortex of rabbits with experimental antiglomerular basement membrane disease. Lab. Invest. 63:762–769.

Merz, V.W., G.J. Miller, T. Krebs, T.L. Timme, D. Kadmon, S. Park, S. Egawa, P. Scardino, and T. Thompson. 1991. Elevated transforming growth factor-β 1 and β 3 mRNA levels are associated with ras + myc -induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol. Endocrinol. 5:503–513.

Messing, E.M. 1989. Interstitial Cystitis and Related Syndromes. Pp. 982–1005 in Campbell's Urology, 6th Edition. P.C. Walsh, A.B. Retik, T.A. Stamey, and E.D. Vaughan, eds. Philadelphia, PA: W.B. Saunders Company.

Messing, E.M., and A. Vaillancourt. 1990. Hematuria screening for bladder cancer. J. Occup. Med. 32:838–845.

Messing, E.M., J.E. Bubbers, K.E. Whitmore, J.B. de Kernion, M.S. Nestor, and J.L. Fahey. 1984. Murine hybridoma antibodies against human transitional carcinoma-associated antigens. J. Urol. 132:167–172.

Messing, E.M., P. Hanson, P. Ulrich, and E. Erturk. 1987. Epidermal growth factor--interactions with normal and malignant urothelium: In vivo and in situ studies . J. Urol. 138:1329–1335.

Messing, E.M., P. Hanson, and C.A. Reznikoff. 1988. Normal and malignant human urothelium: In vitro response to blockade of polyamine synthesis and interconversion. Cancer Res. 48:357–361.

Messing, E.M., T.B. Young, V.B. Hunt, E.B. Roecker, A.M. Vaillancourt, W.J. Hisgen, E.B. Greenberg, M.E. Kuglitsch, and J.D. Wegenke. 1992. Home screening for hematuria: Results of a multi-clinic study. J. Urol. 148:289–292.

Miao, T.J., Z. Wang, and N. Sang. 1991. Correlation between the expression of the

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

P21 ras oncogene product and the biological behavior of bladder tumors. Eur. Urol. 20:307–310.

Michael, A.F., E. Blau, and R.L. Vernier. 1970. Glomerular polyanion: Alteration in aminonucleoside nephrosis. Lab. Invest. 23:649–657.

Miki, T., M. Kuroda, H. Kiyohara, M. Usami, T. Nakamura, and T. Kotake. 1980. Primary carcinoid tumor fo the prostate: Report of a case. Cancer 45:2580–2592.

Miki, S., M. Iwano, Y. Miki, M. Yamamoto, B. Tang, K. Yokokawa, T. Sonoda, T. Hirano, and T. Kishimoto. 1989. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250:607–610.

Milani, M., R. Tacconi, G. Marsili, A. Trognoni, G. Centioni, T. Leoni, and A. Fumarola. 1986. Critical-laboratoristic correlation of the diagnostic importance of prostate specific antigen compared with prostatic acid phosphatase and carcinoembryonic antigen in the prostatic cancer. Quad. Sclavo Diagn. Clin. Lab. 22:428–432.

Miles, J., K. Michalski, M. Kouba, D.J. Weaver. 1988. Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. Cancer Genet. Cytogenet. 34:135–142.

Miller, W.L., and B.J. McCarthy. 1979. Gene expression in normal and regenerating mouse kidney . J. Biol. Chem. 254:742–748.

Miller, E.C., and J.A. Miller. 1985. Some historical perspectives on the metabolism of xenobiotic chemicals to reactive electrophiles. Pp. 3–28 in Bioactivation of Foreign Compounds, M.W. Anders, ed. Orlando, Fla: Academic Press.

Miller, C.H., J.P. MacDermott, K.B. Quattrocchi, G.A. Broderick, and A.R. Stone. 1992. Lymphocyte function in patients with interstitial cystitis. J. Urol. 147:592–595.

Mogensen, C.E. 1987. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 31:673–689.

Mogensen, C.E., A. Chachati, C.K. Christensen, et al. 1985–86. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest. 9:85–95.

Moll, R., J. Laufer, X.R. Wu, and T.T. Sun. 1993. Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas [in German]. Verh. Dtsch. Ges. Pathol. 77:260–265.

Molland, E.A. 1978. Prostatic adenocarcinoma with ectopic ACTH production. Br. J. Urol. 50:358.

Moller, E., J.F. McIntosh, and D.D. Van Slyke. 1929. Relationship between urine volume and the rate of urea excretion by normal adults. J. Clin. Invest. 6:427–465.

Monks, T.J., and S.S. Lau. 1987. Commentary: Renal transport processes and glutathione-mediated nephrotoxicity. Drug Metab. Dispos. 15:437–441.

Montironi, R., M. Scarpelli, S. Sisti, G. Ansuini, E. Pisani, and G. Mariuzzi. 1987. Prognostic value of computerized DNA analysis of noninvasive papillary carcinomas of the urinary bladder. Tumori 73:567–574.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Montironi, R., M. Scarpelli, S. Sisti, A. Braccischi, P. Gusella, E. Pisani, R. Alberti, and G.M. Mariuzzi. 1990. Quantitative analysis of prostatic intraepithilial neoplasia on tissue sections. Anal. Quant. Cytol. Histol. 12:366–372.

Moore, R.D., C.R. Smith, J.J. Lipsky, E.D. Mellitus, and P.S. Lietman. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann. Inter. Med. 100:352–373.

Morita, R., S. Saito, J. Ishikawa, O. Ogawa, O. Yoshida, K. Yamakawa, Y. Nakamura. 1991. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res. 51:5817–5820.

Moriyama, M., T. Akiyama, T. Yamamoto, T. Kawamoto, T. Kato, K. Sato, T. Watanuki, T. Hikage, N. Katsuta, and S. Mori. 1991a. Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol. 145:423–427.

Moriyama, M., I. Sugawara, H. Hamada, T. Tsuruo, T. Kato, K. Sato, T. Hikage, T. Watanuki, and S. Mori. 1991b. Elevated expression of P-glycoprotein in kidney and urinary bladder cancers. Tohoku J. Exp. Med. 164:191–201.

Moriyama-Gonda, N., H. Sumi, H. Shiina, Y. Himeno, and T. Ishibe. 1991. Unstable chromosome aberrations in bladder and renal cell carcinoma. Cancer Genet. Cytogenet. 56:65–72.

Morkve, O., and J. Hostmark. 1991. Influence of tissue preparation techniques on p53 expression in bronchial and bladder carcinomas, assessed by immunofluorescence staining and flow cytometry. Cytometry 12:622–627.

Morote Robles, J., and A. Ruibal Morell. 1987. Is the prostate-specific antigen useful in the detection of prostatic cancer? [letter] [in Spanish]. Med. Clin. 89(15):663–.

Morote, J., A. Ruibal, J. Palou, J.A. de Torres, and A. Soler-Rosello. 1986. Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer. Int. J. Biol. Markers 3(1):23–28.

Morote, J., M.A. Lopez-Pacios, G. Encabo, J.A. de Torres. 1990. Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms [letter] [in Spanish]. Med. Clin. 95:119–.

Motwani, N.M., D. Caron, W.F. Demuan, B. Chatterjee, S. Hunter, M.D. Poulik, and A.K. Roy. 1984. Monoclonal antibodies to α2u-globulin and immunocytofluorometric analysis of α2u-globulin-synthesizing hepatocytes during androgenic induction and aging. J. Biol. Chem. 259:3653–3657.

Muchmore, A.V., and J.M. Decker. 1985. Uromodulin: A unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science 229:479–481.

Muchmore, A.V., and J.M. Decker. 1987. Evidence that recombinant IL-1a exhibits lectin-like specificity and binds to homogeneous uromodulin via N-linked oligosaccharides. J. Immunol. 138:2541–2546.

Muchmore, A.V., S. Shifrin, and J.M. Decker. 1987. In vitro evidence that carbohydrate moieties derived from uromodulin, and 85,000 dalton

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

immunosuppressive glycoprotein isolated from human pregnancy urine, are immunosuppressive in the absence of intact protein. J. Immunol 138:2547–2553.

Mudge, G.H. 1980. Nephrotoxicity of urographic radiocontrast drugs. Kid. Internat. 18:540–562.

Muggia, F.M., H.O. Heinemann, M. Farhangi, and E.F. Osserman. 1969. Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am. J. Med. 47:351–366.

Mulder, A., J. Van Hooteg, R. Sylvest, F. ten Kate, K. Kurth, et al. 1992. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J. Pathol. 166(1):37–43.

Müller, C.A., J. Markovic-Lipkovski, T. Risler, A. Bohle, and G.A. Müller. 1989. Expression of HLA-DQ,-DR and -DP antigens in normal kidney and glomerulonephritis. Kidney Int. 35:116–124.

Murakami, T., and H. Kawakami. 1990. The clinical significance of asymptomatic low molecular weight proteinuria detected on routine screening of children in Japan: A study of 53 patients. Clin. Nephrol. 33:12–19.

Muraki, J., and M. Nakazano. 1992. Establishment of a new human renal cancer cell line (TC-1) and its productivity of interleukin-6 (IL-6) [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 83:1882–1889.

Murty, C.V.R., M.J. Olson, B.D. Garg, and A.K. Roy. 1988. Hydrocarbon-induced hyaline droplet nephropathy in male rats during senescence. Toxicol. Appl. Pharmacol. 96:380–392.

Mutti, A., R. Alinova, E. Bergamaschi, C. Biagini, S. Cavazzini, I. Franchini, R.R. Lauwerys, A.M. Bernard, H. Roels, E. Gelpi, J. Rosello, I. Ramis, R.G. Price, S.A. Taylor, M. DeBroe, G.D. Nuyts, H. Stolte, L.M. Fels, and C. Herbort. 1992. Nephropathies and exposure to perchloroethylene in dry-cleaners. Lancet 340:189–193.

Mutti, A. 1989. Detection of renal diseases in humans: Developing markers and methods. Toxicol. Lett. 46:177–191.

Mutti, A., S. Lucertini, P.P. Valcavi, T.M. Neri, M. Fornari, R. Alinova, and I. Franchini. 1985. Urinary excretion of brush-border antigen revealed by monoclonal antibody: Early indicator of toxic nephropathy. Lancet 2:914–917.

Mutti, A., R. Alinova, E. Bergamaschi, M. Fornari, and I. Franchini. 1988. Monoclonal antibodies to brush-border antigens for the early diagnosis of nephrotoxicity. Arch. Toxicol. (Supplement) 12:162–165.

Mydlo, J.H., J. Michaeli, C. Cordon-Cardo, A.S. Goldenberg, W.D. Heston, and W.R. Fair. 1989. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res. 49:3407–3411.


Nabi, I.R., H. Watanabe, S. Silletti, and A. Raz. 1991. Tumor cell autocrine motility factor receptor. EXS. 59:163–177.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Nabi, I.R., H. Watanabe, and A. Raz. 1992. Autocrine motility factor and its receptor: Role in cell locomotion and metastasis. Cancer Metastasis Rev. 11:5–20.

Nagata, Y., M. Abe, K. Kobayashi, S. Saiki, T. Kotake, K. Yoshikawa, R. Ueda, E. Nakayama, and H. Shiku. 1990. Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn. J. Cancer Res. 81:22–27.

Nagata, M. 1993. Expression on major histocompatibility complex antigen and effect of IFN-alpha on renal cell carcinoma [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 84:814–821.

Nagle, R.B., M.K. Brawer, J. Kittleson, and V. Clark. 1991. Phenotypic relationships of prostatic intraepithilial neoplasia to invasive prostatic carcinoma. Am. J. Pathol. 138:119–128.

Nakagawa, Y., M. Netzer, E.K. Michaels, F. Suzuki, and H. Ito. 1994. Nephrocalcin in patients with renal cell carcinoma [see comments]. J. Urol. 152:29–34.

Nakamura, T., I. Ebihara, I. Shirato, Y. Tomino, and H. Koide. 1991. Increased steady-state levels of mRNA coding for extracellular matrix components in kidneys of NZB/W F1 mice. Am. J. Pathol. 139:437–450.

Nakamura, T., I. Ebihara, I. Nagaoka, Y. Tomino, and H. Koide. 1992. Renal platelet-derived growth factor gene expression in NZB/W F1 mice with lupus and ddY mice with IgA nephropathy. Clin. Immunol. Immunopathol. 63:173–181.

Nanus, D.M., S.A. Ebrahim, N.H. Bander, F.X. Real, L.M. Pfeffer, J.R. Shapiro, and A.P. Albino. 1989. Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression. J. Exp. Med. 169:953–972.

Nanus, D.M., S.A. Lynch, P.H. Rao, S.M. Anderson, S.C. Jhanwar, A.P. and Albino, A.P. 1991. Transformation of human kidney proximal tubule cells by a src-containing retrovirus. Oncogene 6:2105–2111.

Narayan, S., and D. Roy. 1992. Enhanced expression of membrane phosphoproteins tyrosine phosphorylation in estrogen-induced kidney tumors. Biochem. Biophys. Res. Comm. 186:228–236.

Narvarte J., S.R. Saba, and G. Ramirez. 1989. Occupational exposure to organic solvents causing chronic tubulointerstitial nephritis. Arch. Intern. Med. 149:154–158.

Nathan, C., and M. Sporn. 1991. Cytokines in context. J. Cell Biol. 113:981–986.

Neal, D.E., K. Smith, J.A. Fennelly, M.K. Bennett, R.R. Hall, and A.L. Harris. 1989. Epidermal growth factor receptor in human bladder cancer: A comparison of immunohistochemistry and ligand binding. J. Urol. 141:517–521.

Neal, D.E., L. Sharples, K. Smith, J. Fennelly, R.R. Hall, and A.L. Harris. 1990. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619–1625.

Nelson, N.A., T.G. Robins, and F.K. Port. 1990. Solvent nephrotoxicity in humans and experimental animals. Am. J. Nephrol. 10:10–20.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Nemoto, R., K. Hattori, K. Uchida, T. Shimazue, Y. Nishijima, K. Doiso, and M. Harada. 1990. S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling. Cancer 66:509–516.

Neuhauss, O.W., and D.S. Lerseth. 1979. Dietary control of the renal reabsorption and excretion of α2u-globulin. Kidney Int. 16:409–415.

Neuhauss, O., W. Flory, N. Biswas, and C.E. Hollerman. 1981. Urinary excretion of α 2u-globulin by adult male rats following treatment with nephrotoxic agents. Nephron 28:133–140.

Newmark, S.R., R.G. Dluhy, and A.H. Bennett. 1973. Ectopic adenocorticotropin syndrome with prostatic carcinoma. Urology 2:666–668.

Newton, J.F., W.E. Braselton, C.-H. Kuo, W.M. Kluwe, M.W. Gemborys, G.H. Mudge, and J.B. Hook. 1982. Metabolism of acetaminophen by the isolated perfused kidney. J. Pharmacol. Exp. Ther. 221:76–79.

Nickel, J.C., L. Emerson, and J. Cornish. 1993. The bladder mucus (glycosaminoglycan) layer in interstitial cystitis. J. Urol. 149:716–718.

Nielsen, K., H. Colstrup, T. Nilsson, and H. Gundersen. 1988. Stereological estimates of nuclear volume correlated with histopathological grading and prognosis of bladder tumour. Virchows Arch. B.: Cell Pathol. 52(1):41–54.

Nielson, S., E. Nexo., and E.I. Christenson. 1989. Absorption of epidermal growth factor and insulin in rabbit renal proximal tubules. Am. J. Physiol. 256(9):E55–E63.

NIH (National Institutes of Health). 1990. National Kidney and Urologic Diseases Advisory Board 1990 Long-Range Plan. U.S. Department of Health and Human Services, Public Health Service, NIH Publication Number 90–583.

NIH (National Institutes of Health). 1991. U.S. Renal Data System 1991 Annual Data Report. U.S. Department of Health and Human Services, Public Health Service, NIH Publication No. 91–3176.

NIH (National Institutes of Health). 1992. U.S. Renal Data System 1992 Annual Data Report. U.S. Department of Health and Human Services, Public Health Service, NIH Publication No. 92–3176.

NIH (National Institutes of Health), 1993. U.S. Renal Data System 1993 Annual Data Report. U.S. Department of Health and Human Services, Public Health Service, NIH Publication No. 93–3176.

Noble, B., K. Ren, J. Taverne, J. DiPirro, J. Van Liew, C. Dijkstra, G. Janossy, and L.W. Poulter. Mononuclear cells in glomeruli and cytokines in urine reflect the severity of experimental proliferative immune complex glomerulonephritis. Clin. Exp. Immunol. 80:281–287.

Noh, J.W., R.C. Wiggins, and S.H. Phau. 1991. Transforming growth factor β (TGF-β) in urine predicts renal cortical scarring in rabbit anti-GBM disease. J. Am. Soc. Nephrol. 2:556.

Nonclereq, D., G. Toubeau, P. Lambrecht, J-A. Henson-Stiennon, and G. Laurent.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1991. Redistribution of epidermal growth factor immunoreactivity in renal tissue after nephrotoxin-induced tubular injury. Nephron 57:210–215.

Nordenson, I., B. Ljungberg, and G. Roos. 1988. Chromosomes in renal carcinoma with reference to intratumor heterogeneity. Cancer Genet. Cytogenet. 32:35–41.

Noris, M., A. Benigni, E. Gotti, P. Boccardo, S. Aiello, and G. Remuzzi. 1991. Urinary excretion of platelet activating factor (PAF) in patients with immune-mediated glomerulonephritis. Am. J. Nephrol. 2:601.

Norman, J.T. 1991. The role of angiotensin II in renal growth. Renal Physiol. Biochem. 14:175–185.

Norman, J.B., B. Badie-Dezfooly, E.P. Nord, I. Kurtz, J. Schlosser, A. Chaudhari, and L.G. Fine. 1987. EGF-induced initogenesis in proximal tubular cells: Potentiation by angiotensin II. Am. J. Physiol. 253(2 Pt 2):F299–F309.

Norman, J.T., R.E. Bohman, G. Fischmann, et al. 1988. Patterns of mRNA expression during early cell growth differ in kidney epithelial cell destined to undergo compensatory hypertrophy versus regenerative hyperplasia. Proc. Natl. Acad. Sci. 85:6768–6772.

Norming, U., C. Nyman, and B. Tribukait. 1989. Comparative flow and cytometric deoxyribonucleic acid studies on exophytic tumor and random mucosal biopsies in untreated carcinoma of the bladder. J. Urol. 142:1442–1447.

Norming, U., B. Tribukait, H. Gustafson, C.R. Nyman, N. Wang, and H. Wijkstrom. 1992. Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: A study of 63 patients with grade 3 lesions. J. Urol. 147:11–15.

Nouri, A.M., M.E. Smith, D. Crosby, and R.T. Oliver. 1990. Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma. Br. J. Cancer 62:603–606.

NRC (National Research Council). 1981. Aromatic Amines: An Assessment of the Biological and Environmental Effects. Washington, D.C.: National Academy Press. 319 pp.

NRC (National Research Council). 1983. Risk Assessment in the Federal Government: Managing the Process. Washington, D.C.: National Academy Press, 191 pp.

NRC (National Research Council). 1989a. Biologic Markers in Reproductive Toxicology. Washington, D.C.: National Academy Press. 395pp.

NRC (National Research Council). 1989b. Biologic Markers in Pulmonary Toxicology. Washington, D.C.: National Academy Press. 179pp.

NRC (National Research Council). 1991. Human Exposure Assessment for Airborne Pollutants: Advances and Opportunities. Washington, D.C.: National Academy Press. 321 pp.

NRC (National Research Council). 1992. Biologic Markers in Immunotoxicology. Washington, D.C.: National Academy Press. 206 pp.

NTP (National Toxicology Program). 1989. Toxicology and Carcinogenesis Studies of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Hexachloroethane (CAS No. 67-72-1) in F344/N rats (Gavage Studies). NTP Technical Report 361. Research Triangle Park, N.C.: National Toxicology Program.

NTP (National Toxicology, Program). 1990. Toxicology and Carcinogenesis Studies of D-limonene (CAS No. 5989-27-5) in F344/N rats and B6C3F1 mice (Gavage Studies). NTP Technical Report 347. Research Triangle Park, N.C.: National Toxicology Program.

Nutting, C., and J. Chowaniec. 1992. Evaluation of the actions and interactions of retinoic acid and epidermal growth factor on transformed urothelial cells in culture: Implications for the use of retinoid therapy in the treatment of bladder cancer patients . Clin. Oncol. 4:51–55.


Oberle, G.P., J. Niemeyer, F. Thaiss, W. Schoeppe, and R.A.K. Stahl. 1992. Increased oxygen radical and eicosanoid formation in immune-mediated mesangial cell injury. Kidney Int. 42:69–74.

Odum, J., and T. Green. 1984. The metabolism and nephrotoxicity of tetrafluoroethylene in the rat. Toxicol. Appl. Pharmacol. 76:306–318.

Oesterling, J.E. 1991. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:907–923.

Ogawa, O., T. Habuchi, Y. Kakehi, M. Koshiba, T. Sugiyama, O. Yoshida. 1992. Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. Cancer Res. 52:1881–1885.

Ohashi, T., T. Akagi, S. Irie, T. Obama, Y. Nasu, S. Tohjoh, K. Takeda, J. Yoshimoto, Y. Matsumura, and H. Ohmori. 1987. Clinical study on PAP, gamma-Sm and PA as tumor markers in prostatic cancer patients [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 78:1403–1408.

Ohgaki, H., P. Kleihues, and G.C. Hard. 1991. Ki-ras mutations in spontaneous and chemically induced renal tumors of the rat. Mol. Carcinog. 4:455–459.

Ohkubo, S., K. Ogi, M. Hosoya, H. Matsumoto, N. Suzuki, C. Kimura, H. Ondo, M. Fujino. 1990. Specific expression of human endothelin-2 (ET-2) gene in a renal adenocarcinoma cell line. Molecular cloning of cDNA encoding the precursor of ET-2 and its characterization. FEBS Lett. 274:136–140.

Ohta, K., Y. Hirata, M. Schichiri, K. Kanno, T. Emori, K. Tomita, and F. Marumo. 1991. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 39:307–311.

Oka, K., J. Ishikawa, J.M. Bruner, R. Takahashi, and H. Saya. 1991. Detection of loss of heterozygosity in the p53 gene in renal cell carcinoma and bladder cancer using the polymerase chain reaction . Mol. Carcinog. 4:10–13.

Okuda, S., L. Languino, E. Ruoslahti, and W. Border. 1990. Elevated expression of transforming growth factor β and proteoglycan production in experimental glomerulonephritis. J. Clin. Invest. 86:453–462.

Oliver, J., and M. MacDowell. 1958. Cellular mechanisms of protein metabolism in the nephron, VII. The characteristics and significance of the protein absorption

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

droplets (hyaline droplets) in epidemic hemorrhagic fever and other renal diseases. J. Exp. Med. 107:731–754.

Olsen, P.S., E. Nexo, S.S. Poulsen, H.F. Hansen, and P. Kierkegaard. 1984. Renal origin of rat urinary epidermal growth factor. Regul. Pept. 10:37–43.

Olson, M.J., J.T. Johnson, and C.A. Reidy. 1990. A comparison of male rat and human urinary proteins: Implications for human resistance to hyaline droplet nephropathy. Toxicol. Appl. Pharmacol. 102:524–536.

Olson, M.J., J.C. Parker, and C.H. Ris. 1991.

Olumi, A.F., Y.C. Tsai, P.W. Nichols, D.G. Skinner, D.R. Cain, L.I. Bender, and P.A. Jones. 1990. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50:7081–7083.

Omichinski, J.G., G. Brunborg, E.J. Søderlund, J.E. Dahl, J.A. Bausano, J.A. Holme, S.D. Nelson, and E. Dybing. 1987. Renal necrosis and DNA damage caused by selectively deuterated and niethylated analogs of 1,2-dibromo-3-chloropropane in the rat. Toxicol. Appl. Pharmacol. 91:358–370.

Onda, H., S. Ohkubo, T. Kosaka, T. Yasuhara, K. Ogi, M. Hosoya, H. Matsumoto, N. Suzuki, C. Kitada, Y. Ishibashi, et al. 1991. Expression of endothelin-2 (ET-2) gene in a human renal adenocarcinoma cell line: Purification and cDNA cloning of ET-2. J. Cardiovas. Pharmacol 17(Suppl. 7):S39–S43.

Oosterwijk, E., S.O. Warnaar, J. Zwartendijk, E.A. van der Velde, G.J. Fleuren, and C.J. Cornelisse. 1988. Relationship between DNA ploidy, antigen expression and survival in renal cell carcinoma. Int. J. Cancer 42:703–708.

Orntoft, T.F., S.E. Petersen, and H. Wolf. 1988. Dual-parameter flow cytometry of transitional cell carcinomas. Quantitation of DNA content and binding of carbohydrate ligands in cellular subpopulations. Cancer 61:963–970.

Ouelette, A.J. 1983. Messenger RNA regulation during compensatory renal growth. Kidney Int. 23:575–580.

Ouelette, A.J., and R.A. Malt. 1979. Noncoordinate regulation of cytoplasmic RNA in compensatory renal hypertrophy. Am. J. Physiol. 237:R360–R365.

Ouellette, A.J., and C.P. Ordahl. 1981. Extensive homology between poly(A)-containing mRNA and purified nominal poly(A)-lacking mRNA in mouse kidney. J. Biol. Chem. 256:5104–5108.

Ouellette, A.J., R. Moonka, A.D. Zelenetz, and R.A. Malt. 1987. Regulation of ribosome synthesis during compensatory renal hypertrophy in mice. Am. J. Physiol. 253:C506–C513.

Ouellette, A.J., R.A. Malt, V.P. Sukhatme and J.V. Bonventre. 1990. Expression of two ''immediate early'' genes, Ega-1 and c-fos, in response to renal ischemia and during compensatory renal hypertrophy in mice. J. Clin. Invest. 85:766–771.


Papapetrou, P.D., N.P. Sakalerou, H. Braouzi, and P.H. Fessas. 1980. Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: The value of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

measurements of immunoreactive hCG in the urine as a screening procedure. Cancer 45:2583–2592.

Parshad, R., F.M. Price, M. Oshimura, J.C. Barrett, H. Satoh, B.E. Weissman, E.J. Stanbridge, K.K. Sanford. 1992. Complementation of a DNA repair deficiency in six human tumor cell lines by chromosome 11. HUM. Genet. 88:524–528.

Park, Y., H. Kiwarnoto, T. Nishioka, H. Tsujihashi, S. Mitsubayashi, et al. 1987. Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer [in Japanese]. Hinvokika Kiyo (Acta Urol. Jpn.) 33(6):883–888.

Parker, J.C., M.J. Olson, and C.H. Ris. 1992. Hazard evaluation issues associated with chloroalkene-induced renal carcinogenesis in male rats. The Toxicologist 12:426.

Parry, W.L., and G.P. Hemstreet. 1988. Cancer detection by quantitative fluorescence image analysis. J. Urol. 139:270–274.

Parsons, C.L., J.D. Lilly, and P. Stein. 1991. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J. Urol. 145:732–735.

Partin, A.W., A.C. Walsh, R.V. Pitcock, J.L. Mohler, J.I. Epstein, and D.S. Coffey. 1989. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in Stage A2 prostate cancer: A critical analysis. J. Urol. 142:1254–.

Partin, A.W., R.H. Getzenberg, M.J. CarMichael, D. Vindivich, J. Yoo, J.I. Epstein, and D.S. Coffey. 1993. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:744–746.

Patrono, C., G. Ciabattoni, G. Remuzzi, E. Gotti, S. Bombardieri, O. di Munno, G. Tartarelli, G.A. Cinotti, B.M. Simonetti and A. Pierucci. 1985. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J. Clin. Invest. 76:1011–1018.

Pelletier, L., F. Hirsch, J. Rossert, E. Druet, and P. Druet. 1987. Experimental mercury-induced glomerulonephritis. Springer Semin. Immunopathol. 9:359–369.

Pelletier, L., R. Pasquier, J. Rossert, M.C. Viol, C. Mandet, and P. Druet. 1988. Autoreactive T cells in mercury-induced autoimmunity. J. Immunol. 140:750–755.

Perlman, E.J., and J.I. Epstein. 1990. Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am. J. Surg. Pathol. 14:810–818.

Pertoft, H., and T.C. Laurent. 1982. Sedimentation of cells in colloidal silica (Percoll). Pp. 115–152 in Cell Separation: Methods and Selected Applications, Vol. 1. T.G. Pretlow, and T.P. Pretlow, eds. New York: Academic Press.

Pervaiz, S., and K. Brew. 1987. Homology and structure-function correlations between β1-acid glycoprotein and serum retiriol-binding protein and its relatives. FASEB J. 1:209–214.

Peter, S. 1991. Oncogenes and growth factors in renal cell carcinoma. Urol. Int. 47:199–202.

Peterson, P.A., and I. Berggard. 1971. Isolation and properties of a human retinol-transporting protein. J. Biol. Chem. 246:25–33.

Peterson, P.A., P.E. Evrin, and I. Berggard. 1969. Differentiation of glomerular,

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

tubular, and normal proteinuria: Determinations of urinary excretion of b2-microglobulin, albumin, and total protein. I. Clin. Invest. 48:1889–1198.

Petrides, P.E., S. Bock, J. Bovens, R. Hofmann, and G. Jakse. 1990. Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res. 50:3934–3939.

Pevsner, J., R.R. Reed, P.G. Feinstein, and S.H. Snyder. 1988. Molecular cloning of odorant-binding protein: Member of a ligand carrier family. Science 241:336–339.

Phan, S.H., B.M. McGarry, and R. Wiggins. 1990. Characterization of the collagen synthesis stimulatory activity in renal cortical conditioned media and its role in renal fibrosis (abstract). Kidney Int. 37:426.

Piana, P., G. Caetta, A. Cavallini, P. Piantino, and A. Tizzani. 1991. Urinary evaluation of tumor-associated antigens in Urothelial bladder tumors. Prog. Clin. Biol. Res. 370:179–184.

Pienta, K.J., A.W. Partin, and D.S. Coffey. 1989. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 49:2525–2532.

Pirani, C.L., F.G. Silva, and G.B. Appel. 1983. Tubulointerstitial disease in multiple myeloma and other nonrenal neoplasias. Pp. 287–334 in Tubulointerstitial Nephropathies, R.S. Cotran, B.M. Brenner, and J.H. Stein, eds. New York: Churchill Livingstone.

Pitha, J.V., G.P. Hemstreet, N.R. Asal, R.L. Petrone, B.F. Trump, and F.G. Silva. 1987. Occupational hydrocarbon exposure and renal histopathology . Toxicol. Ind. Health 3:491–506.

Plummer, D.R., S. Noorazar, D.K. Obatomi, and J.D. Haslan. 1985. Assessment of renal injury by urinary enzymes. Uremia Invest. 9:97–102.

Pogue, V.A., and H.M. Nurse. 1989. Cocaine-associated acute myoglobinuric renal failure. Am. J. Med. 86:183–186.

Pollak, VE., and C. Arbel. 1969. The distribution of Tamm-Horsfall protein (uromucoid) in the human nephron. Nephron 6:667–672.

Pollak, M.N., C. Polychronakos, and H. Guyda. 1989. Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 9:889–891.

Pollock, C., L. Pei-Ling, A.Z. Györy, R. Grigg, E.D.M. Gallery, R. Caterson, L. Ibels, J. Mahony, and D. Waugh. 1989. Dysmorphism of urinary red blood cells—Value in diagnosis. Kidney Int. 36:1045–1049.

Polychronakos, C., H.J. Guyda, and B.I. Posner. 1985. Increase in the type 2 insulin-like growth factor receptors in the rat kidney during compensatory growth. Biochem. Biophys. Res. Comm. 132:418–423.

Polychrenakos, C., U. Janthly, J.G. Lehoux, and M. Koutsilieris. 1991. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

adenocarcinoma cells: Characterization of the receptors involved. Prostate 19:313–321.

Poortmans, J., and R.W. Jeanloz. 1976. Urinary excretion of total protein, albumin, and β2-microglobulin during exercise in adolescent diabetics. Biomedicine 25:273–274.

Popper, H., G. Wirnsberger, H. Hoefler, and H. Denk. 1987. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas. Cancer Detect. Prev. 10: 167–174.

Porter, G.A. 1989. Risk factors for toxic nephropathies. Toxicol. Lett. 46:269–279.

Portila, D., L.J. Mandel, D. Bar-Sagi, and D.S. Millington. 1992. Anoxia induces phospholipase A2 activation in rabbit renal proximal tubules. Am. J. Physiol. 262:F354–F360.

Pratt, C.I., C. Kao, S.-Q. Wu, K.W. Gilchrist, R. Oyasu, and C.A. Reznikoff. 1992. Neoplastic progression by Ej/ras at different steps of transformation in vitro of human uroepithelial cells. Cancer Res. 52:688–695.

Presti, J.C., P.H. Rao, Q. Chen, V.E. Reuter, F.P. Li, W.R. Fair, and S.C. Jhanwar. 1991. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res. 51:1544–1552.

Presti, J.C., V.E. Reuter, C. Cordon-Cardo, M. Mazumdar, W.R. Fair, and S.C. Jhanwar. 1993. Allelic deletions in renal tumors: Histopathological correlations. Cancer Res. 53:5780–5783.

Pretl, K. 1944. Zur frage der endokrinie der menschlichen vorsteherdruse. Virchows Arch. A: 312:392–404.

Prewitt, T.E., A.J. D'Ercole, B.R. Switzer, and J.J. Van Wyk. 1982. Relationship of serum immunoreactive somatomedin-C to dietary protein and energy in growing rats. J. Nutr. 112:144–150.

Price, R.G. 1982. Urinary enzymes, nephrotoxicity and renal disease. Toxicology 23:99–134.

Proctor, A., L. Coombs, J. Cairns, and M. Knowles. 1991. Amplification at chromosome llql3 in transitional cell tumours of the bladder. Oncogene 6(5):789–795.

Pruchno, C.J., M.W. Burns, M. Schulze, R.J. Johnson, P.J. Baker, and W.G. Couser. 1989. Urinary excretion of C5b-9 reflects disease activity in passive Heymann nephritis. Kidney Int. 36:65–71.

Purnell, D.M., B.M. Heatfield, and B.F. Trump. 1984. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, β-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res. 44:285–292.


Quamme, G.A., and J.H. Dirks. 1986. Micropuncture techniques. Kidney Int. 30:152–165.


Racusen, L.C., B.A. Fivush, T-L. Li, I. Slatnik, and K. Solez. 1991. Dissociation of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

tubular cell detachment and tubular cell death in clinical and experimental "acute tubular necrosis," Lab. Invest. 64:546–556.

Rahman, M.A., C.N. Lui, M.J. Dunn and S.N. Emancipator. 1988a. Complement and leukocyte independent proteinuria and eicosanoid synthesis in rat membranous nephropathy. Lab. Invest. 59:477–483.

Rahman, M., M. Nakazana, S.N. Emancipator, and M.J. Dunn. 1988b. Increased leukotriene B4 synthesis in immune injured rat glomeruli. J. Clin. Invest. 81:1945–1952.

Rainwater, L.M., Y. Hosaka, G.M. Farrow, and M.M. Lieber. 1987. Well differentiated clear cell renal carcinoma: Significance of nuclear deoxyribonucleic acid patterns studied by flow cytometry. J. Urol. 137:15–20.

Rainwater, L.M., H. Zincke, G.M. Farrow, and N.J. Gonchoroff. 1991. Renal cell carcinoma in young and old patients. Comparison of prognostic pathologic variables (cell type, tumor grade and stage, and DNA ploidy pattern) and their impact on disease outcome. Urology 38:1–5.

Rall, L.B., J. Scott, G.I. Bell, R.J. Crawford. 1985. Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. Nature 313:228–231.

Rao, J.Y., R.E. Hurst, W.D. Bales, P.L. Jones, R.A. Bass, L.T. Archer, P.B. Bell, and G.P. Hemstreet. 1990. Cellular f-actin levels as a marker for cellular transformation: Relationship to cell division and differentiation. Cancer Res. 50:2215–2220.

Rao, J.Y., G.P. Hemstreet, R.E. Hurst, R.B. Bonner, K.W. Min, and P.L. Jones. 1991. Cellular F-actin levels as a marker for cellular transformation: Correlation with bladder cancer risk. Cancer Res. 51:2762–2767.

Rao, J.Y., G. Hemstreet, R.E. Hurst, R.B. Bonner, P.L. Jones, K.W. Min, Y.A. Fradet. 1993. A strategy for individual bladder cancer risk assessment based upon progressive alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 90:8287–8291.

Raska, I., K. Koberna, M. Jarnik, V. Petrasovicova, J. Bednar, I. Raska, and R. Bravo. 1989. Ultrastructural immunolocalization of cyclin/PCNA in synchronized 3T3 cells. Exp. Cell Res. 184:81–89.

Rasmussen, H.H., and L.S. Ibels. 1982. Acute renal failure: Multivariate analysis of causes and risk factors. Am. J. Med. 73:211–218.

Ravery, V., J. Jouanneau, S. Gil Diez, C. Abbou, J. Caruelle, et al. 1992. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol. Res. 20:211–214.

Ravnskov, U. 1986. Influence of hydrocarbon exposure on the course of glomerulonephritis. Nephron. 42:156–160.

Reddy, M.V., R.C. Gupta, E. Randerath, and K. Randerath. 1984. 32P-Postlabeling

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

test for covalent DNA binding of chemicals in vivo: Application to a variety of aromatic carcinogens and methylating agents. Carcinogenesis 5:31–243.

Rehn, L. 1895. Blasigeschwülste bei Fuchsin arbeitern. Arch. Klin. Chir. 50:588–600.

Reichert, D., S. Schultz, and M. Metzler. 1985. Excretion pattern and metabolism of hexachlorobutadiene in rats: Evidence for metabolic activation by conjugation reactions. Biochem. Pharmacol. 34:499–505.

Reiter, R.E., P. Anglard, S. Liu, J.R. Gnarra, and W.M. Linehan. 1993. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 53:3092–3097.

Rennie, I.D.B., and H. Keen. 1967. Evaluation of clinical methods for detecting proteinuria. Lancet 2:489–492.

Rew, D.A., D.J. Thomas, M. Coptcoat, and G.D. Wilson. 1991. Measurement of in vivo urological tumour cell kinetics using multiparameter flow cytometry. Preliminary study. Br. J. Urol. 68:44–48.

Reznikoff, C.A., M.D. Johnson, D.H. Norback, and G.T. Bryan. 1983. Growth and characterization of normal human urothelium in vitro. In Vitro Cell. Dev. Biol. 19:326–343.

Reznikoff, C.A., L.J. Loretz, M.D. Johnson, and S. Swaminathan. 1986. Quantitative assessments of the cytotoxicity of bladder carcinogens towards cultured normal human uroepithelial cells. Carcinogenesis 7:1625–1632.

Reznikoff, C.A., L.J. Loretz, B.J. Christian, S.-Q. Wu, and L.F. Meisner. 1988. Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene. Carcinogenesis 9:1427–1436.

Ridder, G.M., E.C. Von Bargen, C.L. Alden, and R.D. Parker. 1990. Increased hyaline droplet formation in male rats exposed to decalin is dependent on the presence of α2u-globulin. Fundam. Appl. Toxicol. 15:732–743.

Rifkin, D.B., and D. Moscatelli. 1989. Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. 109:1–6.

Rigatti, P., F. Montorsi, G. Guazzoni, G. Viale, G. Bulfamante, and G. Coggi. 1990. Adult nephroblastoma induced erythrocytosis. Report of a case and review of the literature. Scand. J. Urol. Nephrol. 24:159–161.

Rindler, J.J., S.S. Naik, N. Li, T.C. Hoops, and M.N. Peraldi. 1990. Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J. Biol. Chem. 265:20784–20789.

Ring, K.S., F. Karp, and M.C. Benson. 1990. Enhanced detection of bladder cancer using the epithelial Surface marker epithelial membrane antigen: A preliminary report. J. Occup. Med. 32:904–909.

Robson, C.J., B.M. Churchill, and W. Anderson. 1969. The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101:297–301.

Rochlitz, C.F., H. Lobeck, S. Peter, J. Reuter, B. Mohr, E. de Kant, D. Huhn, and R.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Herrmann. 1992. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. Cancer 69:2993–2998.

Rogers, S.A., S.B. Miller, and M.R. Hammerman. 1991. Insulin-like growth factor I gene expression in isolated rat renal collecting duct is stimulated by epidermal growth factor . J. Clin. Invest. 87:347–351.

Rojas-Corona, R.R., L. Chen, and P.S. Mahadevia. 1987. Prostatic carcinoma with endocrine features: A report of a neoplasm containing multiple immunoreactive hormonal substances. Am. J. Clin. Path. 88:759–762.

Rosa, R.M., and R.S. Brown. 1983. Acute renal failure associated with heavy metals and organic solvents. Pp. 321–332 in Acute Renal Failure, B.M. Brenner, and J.M. Lazarus, eds. Saunders.

Rosalki, S.B., and J.H. Wilkinson. 1959. Urinary lactic dehydrogenase in renal disease. Lancet 2:327–328.

Rosenberg, M.E., and M.S. Paller. 1991. Differential gene expression in the recovery from ischemic renal injury. Kidney Int. 39:1156–1161.

Rostand, S.G. 1992. U.S. minority groups and end-stage renal disease: A disproportionate share, Am. J. Kidney Dis. 19:411–413.

Rostand, S.G., K.A. Kirk, E.A. Rutsky, and B.A. Pate. 1982. Racial differences in the incidence of treatment for end-stage renal disease. N. Engl. J. Med. 306:1276.

Rotter, M., T. Block, R. Busch, S. Thanner, and H. Hofler. 1992. Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. Int. J. Cancer 52:213–217.

Roy, A.K., and O.W. Neuhaus. 1967. Androgenic control of a sex-dependent protein in the rat. Nature 214:618–620.

Roy, A.K., and B. Chatterjee. 1983. Sexual dimorphism in the liver. Ann. Rev. Physiol. 45:37–50.

Roy, A.K., T.S. Nath, N.M. Motwani, and B. Chatterjee. 1983. Age-dependent regulation of the polymorphic forms of α2u-globulin. J. Biol. Chem. 258:10123–10127.

Royer-Pokora, B., B. Fleischer, S. Ragg, U. Loos, and D. Williams. 1989. Molecular cloning of the translocation breakpoint in T-ALL 11;14 (p13;q11): Genomic map of TCR alpha and delta region on chromosome 14q11 and long-range map of region 11p13. Hum. Genet.82:264–270.

Rozengurt, E. 1980. Stimulation of Na influx, Na-K pump activity and DNA synthesis in quiescent cultured cells . Adv. Enzyme Regul. 19:61–85.

Rozengurt, E., and L.A. Heppel. 1975. Serum rapidly stimulates ouabain-sensitive 86Rb+ influx in quiescent 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 72:4492–4495.

Rozengurt, E., T.D. Gelehrter, A. Legg, and P. Pettican. 1981. Mellitin stimulates Na entry, Na-K pump activity and DNA synthesis in quiescent cultures of mouse cells. Cell 23:781–788.

Rubber, H., W. Lutzeyer, and D.M.A. Wallace. 1985. The epidemiology and

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

aetiology of bladder cancer. Pp. 1–21 in Bladder Cancer. E.J. Zingg, and D.M.A. Wallace, eds. New York: Springer-Verlag.

Rubenstein, M., P.D. Guinan, C.F. McKiel, and A. Dubin. 1988. Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers. Clin. Phys. Biochem. 6:241–252.

Ruder, A.M., L.J. Fine, and J.D. Sundin. 1990. National estimates of occupational exposure to animal bladder tumorigens. J. Occup. Med. 32:797–805.

Rush, G.F., and J.B. Hook. 1986. The kidney as a target organ for toxicity. Pp. 1–18 in Target Organ Toxicity, Vol. 2, G.M. Cohen, ed. Boca Raton, Fla: CRC Press.

Rush, G.F., J.H. Smith, J.F. Newton, and J.B. Hook. 1984. Chemically induced nephrotoxicity: Role of metabolic activation. CRC Crit. Rev. Toxicol. 13:99–160.

Rutecki, G.J., C. Goldsmith, and G.E. Schreiner. 1971. Characterization of proteins in urinary casts: Flourescent-antibody identification of Tamm-Horsfall mucoprotein in matrix and serum protein in granules. N. Engl. J. Med. 284:1049–1052.


Sabatier, L., F. Hoffschir, W.A. al Achkar, C. Turleau, J. de Grouchy, and B. Dutrillaux. 1989. The decrease of catalase or esterase D activity in patients with microdeletions of 11p or 13q does not increase their radiosensitivity. Ann. Genet. 32:144–148.

Sacks, S.A., D.B. Rhodes, D.R. Malkasian, and A.A. Rosenbloom. 1975. Prostatic carcinoma producing syndrome of inappropriate secretion of antidiuretic hormone. Urology 6:489–492.

Sade, M.V., and E.R. Barrack. 1991. Determination of growth factor in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67:3065–3071.

Safirstein, R. 1994. Gene expression in nephrotoxic and ischemic acute renal failure. J. Am. Soc. Nephrol. 4:1387–1395.

Safirstein, R., A.Z. Zelent, and P.M. Price. 1989. Reduced renal prepro-epidermal growth factor mRNA and decreased EGF excretion in ARF. Kidney Int. 36:810–815.

Safirstein, R., P.M. Price, S.J. Saggi, and R.C. Harris. 1990. Changes in gene expression after temporary renal ischemia. Kidney Int. 37:1515–1521.

Safirstein, R., J. Megyesi, S.J. Saggi, P.M. Price, M. Poon, B. Rollins, and M.B. Taubman. 1991. Expression of cytokine-like genes JE and KC is increased during renal ischemia. Am. J. Physiol. 261:F1095–F1101.

Saito, S. 1992. Detection of H-ras gene point mutations in transitional cell carcinoma of human urinary bladder using polymerase chain reaction. Keio J. Med. 41:80–86.

Salido, E.C., L. Barajas, J. Lechago, N.P. Laborde, and D.A. Fisher. 1986. Immunocytochemical localization of epidermal growth factor in mouse kidney. J. Histochem. Cytochem. 34:1155–1160.

Salido, E.C., P.H. Yen, L.J. Shapiro, D.A. Fischer, and L. Barajas. 1989. In situ hybridization of prepro-epidermal growth factor mRNA in the mouse kidney. Am. J. Physiol. 256(4 Pt 2):F632–F638.

Sanchez-Fernandez de Sevilla, M., L. Morell-Quadreny, M. Gil-Salom, M.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Perez-Bacete, and A. Llombart-Bosch. 1992. Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions. Eur. Urol. 21 (Suppl 1):5–9.

Sanders, H., P. McCue, and S.D. Graham. 1991. ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin. Cancer 67:3024–3028.

Sandgren, E.P., N.C. Luetteke, R.D. Palmiter, R.L. Brinster, and D.C. Lee. 1990. Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121–1135.

Sandler, D.P. 1987. Epidemiology in the assessment of nephrotoxicity. Pp. 847–883 in Nephrotoxicity in the Experimental and Clinical Situation, P.H. Bach, and E.A. Lock, eds. Martinus Nijhoff Publ. Dordricht, Boston, Lancaster.

Sandler, D.P., and J.C. Smith. 1991. Chronic renal disease risk associated with employment in industries with potential solvent exposure. Pp. 261–266 in Nephrotoxicity, Mechanisms, Early Diagnosis, Therapeutic Management, P.H. Bach, N.J. Gregg, M.F. Wiks, and L. Delacrluz, eds. New York, Basel, Hong Kong: Marcel Dekker Inc.

Sarkar, F., W. Sakr, S. Drozdowicz, P. Sreepathi, and J. Crissman. 1992. Measurement of cellular proliferation in human prostate by AgNOR, PCNA and SPF. Mod. Pathol. 5:59A.

Sassine, A.M., and C. Schulman. 1992. Value of PSA in the staging of prostatic cancer [in French]. Acta Urol. Belg. 60:49–59.

Sato, T., Y. Sakata, and K. Tamura. 1990. Inflammatory reaction and laboratory tests: IAP (immunosuppressive acidic protein) [review] [in Japanese]. Rinsho Byori 38:255–259.

Sausen, P.J., and A.A. Elfarra. 1990. Cysteine conjugate S-oxidase: Characterization of a novel enzymatic activity in rat hepatic and renal microsomes. J. Biol. Chem. 265:6139–6145.

Sawczuk, I.H., G. Hoke, C.A. Olsson, J. Connor, and R. Buttyan. 1989. Gene expression in response to acute unilateral ureteral obstruction. Kidney Int. 35:1315–1319.

Sawczuk, I.H., C.A. Olsson, G. Hoke, and R. Buttyan. 1990. Immediate induction of c-fos and c-myc transcripts following unilateral nephrectomy. Nephron. 55:193.

Scandinavian Committee on Enzymes, Scandinavian Prostatic Cancer Group. 1985. Acid phosphatases and other tumor markers in the management of prostatic cancer. Workshop. Copenhagen, March 1985. Scand. J. Clin. Lab. Invest. Suppl. 179:1–117.

Schaafsma, H.E., F.C. Ramaekers, G.N. van Muijen, E.B. Lane, I.M. Leigh, H. Robben, A. Huijsmans, E.C. Ooms, and D.J. Ruiter. 1990. Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am. J. Pathol. 136:329–343.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Schaeffer, V.H., and J.L. Stevens. 1987. Mechanism of transport for toxic cysteine conjugates in rat kidney cortex membrane vesicles. Mol. Pharmacol. 32:293–298.

Schardijn, G.H.C., and L.W. Statius van Eps. 1987. β2-microglobulin: Its significance in the evaluation of renal function. Kidney Int. 32:635–641.

Schenk, E.A., R.H. Schwartz, and R.A. Lewis. 1971. Tamm-Horsfall mucoprotein. I. Localization in the kidney. Lab. Invest. 25:92–95.

Schentag et al., 1978.

Schiebler, M., B. Yankaskas, C. Tempany, P. Holtz, and E. Zerhouni. 1992. Efficacy of prostate-specific antigen and magnetic resonance imaging in staging stage C adenocarcinoma of the prostate. Invest. Radiol. 27:575–577.

Schimamuria, T., and A.B. Morris. 1975. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomy. Am. J. Pathol. 79:95.

Schlondorff, D. 1986. Isolation and use of specific nephron segments and their cells in biochemical studies. Kidney Int. 30:201–207.

Schmid, H., A. Mall, and H. Backhorn. 1986. Catalytic activity of alkaline phosphatase and N-acetyl-beta-D-glucosaminidase in human cortical nephron segments: Heterogenous changes in acute renal failure and acute rejection following kidney allotransplantation. J. Clin. Chem. Clin. Biochem. 24:961–970.

Schoel, B., and G. Pfleiderer. 1987. The amount of Tamm-Horsfall protein in the human kidney, related to its daily excretion. J. Clin. Chem. Clin. Biochem. 25:681–682.

Schoenig, G.P., and R.L. Anderson. 1985. The effects of high dietary levels of sodium saccharin on mineral and water balance and related parameters in rats. Fd. Chem. Toxic 23:465–474.

Scholer, D.W., and I.S. Edelman. 1979. Isolation of rat kidney cortical tubules enriched in proximal and distal segments. Am. J. Physiol. 237:F350–F359.

Schreiner, G.F., R.S. Cohan, and E.R. Unanue. 1984. Modulation of Ia and leukocyte common antigen expression in rat glomeruli during the course of glomerulonephritis and aminonucleoside nephrosis. Lab. Invest. 51:524–531.

Schroder, S., B.C. Padberg, E. Achilles, K. Holl, H. Dralle, and G. Kloppel. 1992. Immunocytochemistry in adrenocortical tumours: A clinicomorphological study of 72 neoplasms. Virchows Arch. A: Pathol. Anat. Histopathol. 420:65–70.

Schuldiner, S., and E. Rozengurt. 1982, Na+/H+ antiport in Swiss 3T3 cells: Mitogenic stimulation leads to cytoplasmic alkalinization. Proc. Natl. Acad. Sci. U.S.A. 79:7778–7782.

Schulte, P.A. 1987. Methodologic issues in the use of biologic markers in epidemiologic research. Arch. Environ. Health 43:83–89.

Schulte, P.A., and W.E. Kaye. 1988. NIOSH exposure registries [review]. Arch. Environ. Health 43:155–161.

Schulte, et al. 1987. Occupational cancer of the urinary tract [review]. Occupational Medicine: State of the Art Reviews 2:85–107.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Schulte, P.A., W.E. Halperin, E.M. Ward, and A.M. Ruder. 1990. Bladder cancer screening in high-risk groups. J. Occup. Med. 32:787–945.

Schultz, M.O., P. Klubes, V. Perman, W.S. Mizuno, F.W. Bates, and J.H. Sautter. 1959. Blood dyscrasia in calves induced by S-(dichlorovinyl)-L-cysteine. Blood 14:1015–1025.

Schulze, M., J.V. Donadio, C.J. Pruchno, P.J. Baker, R.J. Johnson, R.A.K. Stahl, S. Watkins, D.C. Martin, R. Wurzner, O. Gotze, and W.G. Couser. 1991. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int. 40:533–538.

Schumann, G. 1986. Cytodiagnostic Urinalysis for the Nephrology Practice. Semin. Nephrol. 6:308–345.

Scott, J., S. Patterson, L. Rall, G.I. Bell, R. Crawford, J. Penschow, H. Niall, and J. Coghlan. 1985. The structure and biosynthesis of epidermal growth factor precursor. J. Cell Sci. (suppl.) 3:19–28.

Scott, R.J., P.A. Hall, J.S. Haldane, S. van Noorden, Y. Price, D.P. Lane, and N.A. Wright. 1991. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J. Pathol. 165:173–178.

Scrivner, D.L.; Meyer, J.S.; Rujanavech, N.; Fathman, A.; Scully, T. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies. J. Urol. 146:1034–1039; 1991.

See, W.A. 1992. Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence. Clin. Exp. Metastasis 10:99–109.

Selli, C., W.M. Hinshaw, B.H. Woodard, and D.F. Paulson. 1983. Stratification of risk factors in renal cell carcinomas. Cancer 52:899–903.

Sellwood, R.A., J. Spencer, J.G. Azzopardi, S. Wapnick, R.B. Welbourn, and A.E. Kulatilake. 1969. Inappropriate secretion of antidiuretic hormone by carcinoma of the prostate. Br. J. Surg. 56:933–935.

Serio, G. 1991. c-erbB-2 gene product-like expression in urothelial carcinomas of the human bladder. Its value as a prognostic indicator in superficial tumors. Pathologica 83:413–420.

Sesterhenn, I.A., R.L. Becker, F.A. Avallolne, F.K. Mostofi, T.H. Lin, Davis. 1991. Image analysis of nucleoli and nucleolar organizer regions in prostatic hyperplasia, PIN and prostatic carcinoma. J. Urogenital Pathol. 1:42–51.

Shah, V.M., J. Newman, J. Crocker, G.N. Antonakopoulos, C.K. Chapple, and M.J. Collard. 1987. Production of beta-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. Br. J. Exp. Pathol. 68:871–878.

Shah, I. A., M.-O. Schlageter, P. Stinnett, and J. Lechago. 1991. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod. Pathol. 4:220–224.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Shalitin, C., R. Epelbaum, C. Valansi, R. Segal, T. Mekori, et al. 1991. A novel 21-kDa protein as a serum marker for benign and malignant urogenital tumors: Preliminary, communication. Int. J. Cancer 49:861–866.

Shapiro, L.E., and J. Sachchidananda. 1982. Regulation of proteins by thyroid hormone and glucocorticoid: The responses of hepatic α 2u-globulin and pituitary growth hormone differ in adult male hypothyroid rats. Endocrinology 111:653–660.

Shaw, A.B., P. Risdon, and J.D. Lewis-Jackson. 1983. Protein creatinine index and Albustix in assessment of proteinuria. Br. Med. J. 287:929–932.

Sherif, M., A.S. Ibrahim, and A.A. El-Aaser. 1980. Prostatic Carcinoma in Egypt: Epidemiology and etiology. Scand. J. Urol Nephrol., Suppl. 55:25–26.

Sherwood, E.R., L.A. Berg, N.J. Mitchell, J.E. McNeal, J.M. Kozlowski, and C. Lee. 1990. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J. Urol. 143:167–171.

Sherwood, E.R., G. Theyer, G. Steiner, L.A. Berg, J.M. Kozlowski, and C. Lee. 1991. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate 18:303–314.

Sherwood, E., C. Fong, C. Lee, and J. Kozlowski. 1992. Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 130:2955–2963.

Shibata, M.-A., A. Hagiwara, S. Tamano, S. Ono, and S. Fukushima. 1989. Lack of a modifying effect by the diuretic drug furosemide on the development of neoplastic lesions in rat two-stage urinary bladder carcinogenesis. J. Tox. Environ. Health 26:255–265.

Shinmi, O., K. Yorimitsu, K. Moroi, M. Nishiyama, Y. Sugita, T. Saito, Y. Inagaki, T. Masaki, and S. Kimura. 1993. Endothelin-2-converting enzyme from human renal adenocarcinoma cells is a phosphoramidon-sensitive, membrane-bound metalloprotease. J. Cardiovas. Pharmacol. 22(Suppl. 8):S61–S64.

Shinoda, I., M. Kuriyama, T. Takeuchi, Y. Takahashi, Y. Ban, and Y. Kawada. 1988. Clinical studies on tumor markers in prostate cancer; the evaluation of PA (prostate specific antigen) and comparison with PAP and gamma-Sm [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 79:635–642.

Short, B.G., V.L. Burnett, M.G. Cox, J.S. Bus, and J.A. Swenberg. 1987. Site-specific renal cytotoxicity and cell proliferation in male rats exposed to petroleum hydrocarbons. Lab. Invest. 57:564–577.

Short, B.G., V.L. Burnett, and J.A. Swenberg. 1989. Elevated proliferation of proximal tubule cells and localization of accumulated α2u-globulin in F344 rats during chronic exposure to unleaded gasoline or 2,2,4-trimethylpentane. Toxicol. Appl. Pharmacol. 101:414–431.

Shoskes, D., N.A. Parfrey, and P.F. Halloran. 1990. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation 49:201–207.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Shulkes, A., D.R. Fletcher, C. Rubinstein, P.R. Ebeling, T.J. Martin. 1991. Production of calcitonin gene related peptide, calcitonin and PTH-related protein by a prostatic adenocarcinoma.. Clin. Endocrinol. 34:387–393.

Shull, M.M., I. Ormsby, A.B, Kier, S. Pawlowski, R.J. Diebold, M. Yin, R, Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta I gene results in multifocal inflammatory disease. Nature 359:693–699.

Sidransky, D., A. Von Eschenbach, Y.C. Tsai, P. Jones, 1. Summerhayes, F. Marshall, M. Paul, P. Green, S.R. Hamilton, P. Frost, and B. Vogelstein. 1991. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706–709.

Sigler, M.H. 1975. The mechanism of the natriuresis of fasting. J. Clin. Invest. 55:377.

Sikri, K.L., C.L. Foster, N. MacHugh, and R.D. Marshall. 1981. Localization of Tamm-Horsfall glycoprotein in the human kidney using immunoflourescence and immuno-electron microscopical techniques. J. Anat. 132:597–605.

Silverman, D.T., L.I. Levin, R.N. Hoover, and P. Hartge. 1989a. Occupational Risks of bladder cancer in the United States. I. White men. J. Nat. Cancer Inst. 81:1472–1480.

Silverman, D.T., L.I. Levin, and R.N. Hoover. 1989b. Occupational risks of bladder cancer in the United States. II. Nonwhite men. J. Nat. Cancer Inst. 81:1480–1483.

Silverman, D.T., L.I. Levin, and R.N. Hoover. 1990. Occupational risks of bladder cancer among white women in the United States. Am. J. Epidemiol. 132:453–461.

Silverman, D.T., P. Harge, A. Morrison, and S. Devesa. 1992. Epidemiology of bladder cancer. Hematol. Oncol. Clin. NorthAm. 6:1–3.

Singhal, P.C., R.B. Rubin, A. Peters, H. Santiago, and J. Neugarten. 1990. Rhabdomyolysis and acute renal failure associated with cocaine abuse. J. Toxicol. Clin. Toxicol. 28:321–330.

Sippel, A.E., P. Feigelson, and A.K. Roy. 1975. Hormonal regulation of the hepatic messenger RNA levels for α2u globulin. Biochemistry 14:825–829.

Skinner, D.G., R.B. Colvin, C.D. Vermillion, R.C. Pfister, and W.F. Leadbetter. 1971. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28:1165–1177.

Smart, C.R. 1990. Bladder cancer survival statistics. J. Occup. Med. 32:926–928.

Smith, J.H. 1986. Role of renal metabolism in chloroform nephrotoxicity. Comments Toxicol. 1: 124–144.

Smith, J.B., and E. Rozengurt. 1978. Serum stimulates the Na+, K+ pump in quiescent fibroblasts by increasing Na+ entry. Proc. Natl. Acad. Sci. U.S.A. 75:5560–5564.

Smith, M. A., D. Acosta, and J. V. Bruckner. 1986. Development of a primary culture system of rat kidney cortical cells to evaluate the nephrotoxicity of xenobiotics. Food Chem. Toxicol. 24:551–556.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Smith, K., J.A. Fennelly, D.E. Neal, R.R. Hall, and A.L. Harris. 1989. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors . Cancer Res. 49:5810–5815.

Snyder, S.H., P.B. Sklar, and J. Pevsner. 1988. Molecular mechanisms of olfaction. J. Biol. Chem. 263:13971–13974.

Solet, D., and T.G. Robins. 1991. Renal function in dry-cleaning workers exposed to perchloroethylene. Am. J. Ind. Med. 20:601–614.

Soloway, M.S., and S.W. Hardeman. 1990. Animal models in bladder cancer research. Pp 567–575 in Scientific Coundation of Urology, 3rd Ed. G.D. Chisholm, and W.R. Fair, eds. Oxford: Hineman Medical Books.

Spark, R.F. 1975. Renain, aldosterone and glucogon in the natriuresis of fasting. New Engl. J. Med. 292:1335.

Spitz, M.R., R.D. Currier, J.J. Fueger, R.J. Babaian, and G.R. Newell. 1991. Familial patterns of prostate cancer: A case-control analysis. J. Urol. 146:1305–1307.

Spitzer, A., ed. 1982. The Kidney During Development: Morphology and Function . Masson.

Sporn, M. Retinoids, TGF-beta and prostate carcinogenesis. Society for basic urological research, annual meeting, Washington DC 1992.

Spry, L.A., T.V. Zenser, and B.B. Davis. 1986. Bioactivation of xenobiotics by prostaglandin H synthase in the kidney: Implications for therapy. Comments Toxicol. 1: 109–123.

Spurney, R.F., P. Ruiz, D.S. Pisetsky, and T.M. Coffmann. 1991. Enhanced renal leukotriene production in murine lupus: Role of lipoxygenase metabolites. Kidney Int. 39:95–102.

Staessen, J., W.B. Yeoman, A.E. Fletcher, H.L.J. Markowe, M.G. Marmot, G. Rose, A. Semmence, M.J. Shipley, and C.J. Bulpitt. 1990. Blood lead concentration, renal function and blood pressure in London civil servants. Br. J. Ind. Med. 47:442–447.

Staessen, J.A., R.R. Lauwerys, J.P. Buchet, C.J. Bulpitt, D. Rondia, Y. Vanrenterghem, and A. Amery. 1992. Cadmibel study group: Impairment of renal function with increasing blood lead concentrations in the general population. N. Eng. J. Med. 237:151–156.

Staffa, J.A., and M.A. Mehlman. 1980. J. Environ. Path. Toxicol. 3:1-.

Stahl, R.A.K., F. Thaiss, S. Kahf, W. Schoeppe, and U.M. Helmchen. 1990. Immune-mediated mesangial cell injury—Biosynthesis and function of prostanoids. Kidney Int. 38:273–281.

Stamey, T.A., N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine. 1987. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 317:909–916.

Steel, G.G. 1977. Growth Kinetics of Tumours. Oxford: Clarendon Press.

Steenland, N.K., M.J. Thun, C.W. Ferguson, and F.K. Port. 1990. Occupational and

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

other exposures associated with male end-stage renal disease: A case/control study. Am. J. Public Health 80: 153–159.

Steenland, K., S. Selevan, and P.J. Landrigan. 1992. The mortality of lead smelter workers: An update. Am. J. Public Health 82:1641–1644.

Steffes, M.W., B.M. Chavers, R.W. Bilous, and S.M. Mauer. 1989. The predictive value of microalbuminuria. Am. J. Kidney Dis. 13:25–28.

Stege, R., B. Tribukait, B. Lundh, K. Carlstrom, A. Pousette, and M. Hasenson. 1992. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J. Urol. 148:833–837.

Stein, P., and C.L. Parsons. 1991. Animal model of interstitial cystitus. J. Urol. 145:258A.

Steiner, M.S., and E.R. Barrack. 1992. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endicrol. 6:15–25.

Stevens, J.L. 1985a. Isolation and characterization of a rat liver enzyme with both cysteine conjugate b-lyase and kynureninase activity. J. Biol. Chem. 260:7945–7950.

Stevens, J.L. 1985b. Cysteine conjugate b-lyase activities in rat kidney cortex: Subcellular localization and relationship to the hepatic enzyme. Biochem. Biophys. Res. Commun. 129:499–504.

Stevens, J.L., and D.P. Jones. 1989. The mercapturic acid pathway: Biosynthesis, intermediary metabolism, and physiological disposition. Pp. 45–84 in Glutathione: Chemical, Biochemical, and Medical Aspects. Part B: Coenzymes and Cofactors. Vol. III, D. Dolphin, R. Poulson, and O. Aramovic, eds. New York: John Wiley & Sons.

Stevens, J.L., J.D. Robbins, and R.A. Byrd. 1986. A purified cysteine conjugate b-lyase from rat kidney cytosol: Requirement of an a-keto acid or an amino acid oxidase for activity and identity with soluble glutamine transaminase K. J. Biol. Chem. 261:15529–15537.

Stevens, J.L., N. Ayoubi, and J.D. Robbins. 1988. The role of mitochondrial matrix enzymes in the metabolism and toxicity of cysteine conjugates. J. Biol. Chem. 263:3395–3401.

Stevens, J.L., P.B. Hatzinger, and P.J. Hayden. 1989. Quantitation of multiple pathways for the metabolism of nephrotoxic cysteine conjugates using selective inhibitors of L-a-hydroxy acid oxidase (L-amino acid oxidase) and cysteine conjugate b-lyase. Drug Metab. Dispos. 17:297–303.

Stiles, A., I. Sosenko, A.J. D'Eicole, and H. Smith, 1985. Relation of kidney tissue somatomedin-C/insulin-like growth factor I to postnephrectomy renal growth in the rat. Endocrinology 117: 2397–2401.

Storch, S., S. Saggi, I. Megyesi, P.M. Price, and R. Safirstein. 1992. Ureteral

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

obstruction decreases renal prepro-epidermal growth factor and Lamm-Horsfall expression. Kidney Int. 42:89–94.

Story, M., K. Hopp, D. Meier, F. Begun, and R. Lawson. 1993. Influence of transforming growth factor β—and other growth factors on basic fibroblast growth factor level and proliferation of Cultured human prostate-derived fibroblasts. Prostate 23:183–195.

Stracke, M.L., S.A. Aznavoorian, M.E. Beckner, L.A. Liotta, and E. Schiffmann. 1991. Cell motility, a principal requirement for metastasis. EXS. 59:147–162.

Strong, L.C. 1993. Genetic implications for long-term survivors of childhood cancer. Cancer 71:3435–3440.

Stula, E.F., J.R. Barnes, H. Sherman, C.F. Reinhardt, and J.A. Zapp. 1978. Urinary bladder tumors in dogs from 4,4'-methylene-bis (2-chloroaniline) (MOCA). J. Env. Pathol. Toxicol. 1:31–50.

Sugao, H., T. Seguchi, E. Nakano, M. Matsuda, T. Sonoda, M. Nakamura, and T. Goto. 1992, Cytogenetics of tumor cells from patients with nonfamilial renal cell carcinomas. Urol. Int. 48:138–143.

Sukumar, S., B. Armstrong, J. Bruyntjes, I. Leav, and M. Bosland. 1991. Frequent activation of the Ki-ras oncogene at codon 12 in N-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Mol. Carcinog. 4:362–368.

Sumi, S., K. Kihara, Y. Kageyama, Y. Higashi, I. Fukui, and H. Oshima. 1990. A study of cytokeratin in human normal bladder epithelium and bladder carcinoma cell lines. [in Japanese]. Hinyokika Kiyo (Acta Urol. Jpn.) 36:903–906. Discussion 906.

Summerhayes, I.C., R.A.J. Mcllhinney, B.A.J. Ponder, R.J. Shearer, and R.D. Pocock. 1985. Monoclonal antibodies raised against cell membrane components of human bladder tumor tissue recognizing subpopulations in normal urothelium. J. Natl. Cancer Inst. 75:1025–1038.

Sunderman, F.W., S.M. Hopfer, W.W. Nichols, J.R. Selden, H.L. Allen, C.A. Anderson, R. Hill, C. Bradt, and C.J. Williams. 1990. Chromosomal abnormalities and gene amplification in renal cancers induced in rats by nickel subsulfide. Ann. Clin. Lab. Sci. 20:60–72.

Suzuki, Y., and G. Tamura. 1993. Mutations of the p53 gene in carcinomas of the urinary system. Acta. Pathol. Jpn. 43:745–750.

Suzuki, Y., G. Tamura, R. Satodate, and T. Fujioka. 1992. Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn. J. Cancer Res. 83:233–235.

Swan, R.C., and J.P. Merrill. 1953. The clinical course of acute renal failure. Medicine 32:215.

Swenberg, J.A., B.G. Short, S.J. Borghoff, J. Strasser, and M. Charbonneau. 1989. The comparative pathobiology of α2u-globulin nephropathy. Toxicol. Appl. Pharmacol. 97:35–46.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Szymanski, S.C., H. Hummerich, F. Latif, M.I. Lerman, G. Rohrborn, and E. Schroder. 1993. Long range restriction map of the von Hippel-Lindau gene region on human chromosome 3p. Hum. Genet. 92:282–288.


Takashi, M., J. Tanaka, H. Mitsuya, T. Murase, H. Haimoto, and K. Kato. 1988. Serum gamma-enolase as a marker for renal cell carcinoma [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 79:220–226.

Takenawa, J., Y. Kaneko, M. Fukumoto, A. Fukatsu, T. Hirano, H. Fukuyama, H. Nakayama, J. Fujita, and O. Yoshida. 1991. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl. Cancer Inst. 83:1668–1672.

Talaska, G., M. Schamer, P. Skipper, S. Tannenbaum, N. Caporaso, F. Kadlubar, H. Bartsch, and P. Vineis. 1993. Carcinogen-DNA adducts in exfoliated urothelial cells: Techniques for noninvasive human monitoring. Environ. Health. Perspect. 99:289–291.

Tamm, I., and F.L. Horsfall. 1950. Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc. Soc. Exp. Biol. Med. 74:108–114.

Tanioka, F., M. Hiroi, T. Yamane, and H. Hara. 1993. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma. Zentral. Pathol. 139:185–193.

Tannenbaum, M. 1971. Ultrastructural pathology of human renal cell tumors. Pathol. Annu. 6:249–277.

Tarle, M., and N. Rados. 1991. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: Comparative study of a multiple tumor marker assay. Prostate 19:23.

Tarnowski, B.I., D.A. Sens, J.H. Nicholson, D.I. Hazen-Martin, A.J. Garvin , and M.A. Sens. 1993. Automatic quantitation of cell growth and determination of mitotic index using DAPI nuclear staining. Pediatr. Pathol. 13:249–265.

Taub, M.L., I.S. Yang, and Y. Wang. 1989. Primary rabbit kidney proximal tubule cell cultures maintain differentiated functions when cultured in a hormonally defined serum-free medium. In Vitro Cell. Dev. Biol. 25:770–775.

Tawfic, S., S.A. Goueli, M.O.J. Olson, and K. Ahmed. 1993. Androgenic Regulation of the expression and phosphorylation of prostatic nucleolar protein-B23. Cell Mol. Biol. Res.39:43–51.

Terracini, B., and V.H. Parker, 1965. A pathological study on the toxicity of S-Dichlorovinyl-L-cysteine. Food Cosmet. Toxicol. 3:67–74.

Tetu, B., J.Y. Ro, A.G. Ayala, N.G. Ordonez, C.J. Logotheis, and A.C. von Eischenbach. 1989. Small cell carcinoma of the prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology 33:148–152.

Teyssier, J.R., and D. Ferre. 1990. Chromosomal changes in renal cell carcinoma. No evidence for correlation with clinical stage. Cancer Genet. Cytogenet. 45:197–205.

Thaete, L., D. Ahnen, and A. Malkinson. 1989. Proliferating cell nuclear antigen

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

(PCNA/Cyclin) immunocytochemistry as a labeling index in mouse lung tissues. Cell Tissue Res. 256:167–173.

Thalacker, F.W., and M. Nilsen-Hamilton. 1987. Specific induction of secreted proteins by transforming growth factor-beta and 12-O-tetradecanoylphorbol-13-acetate. Relationship with an inhibitor of plasminogen activator. J. Biol. Chem. 262:2283–2290.

Theodorescu, D., I. Cornil, C. Sheehan, M.S. Man, and R.S. Kerbel. 1991. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res. 51:4486–4491.

Thiel, G., J. Torhorst, and F.P. Brunner. 1980. Renal toxicity of cyclosporin A in the rat. Proc. Clin. Dial. Transplant Forum.

Thompson, T.C. 1990. Growth factors and oncogenes in prostate cancer. Cancer Cells 2:345–354.

Thompson, W.M., W.L. Foster, R.A. Halvorsen, N.R. Dunnick, A. Rommel, and M. Bates. 1984. Iopamidol: New, nonionic contrast agent for excretory urography. Am. J. Roentgenol. 142:329–332.

Threfall, G.D., M. Taylor, and A.T. Buck. 1967. Studies of the changes in growth and DNA synthesis in rat kidney during experimentally induced renal hypertrophy. Am. J. Physiol. 50:1–14.

Tichy, M., V. Ticha, P. Jansa, V. Student, and J. Vanak. 1991. Blood group H antigen in transitional carcinoma of the urinary bladder. Acta Univ. Palacki. Olomuc. Fac. Med. 130:157–162.

Tinari, N., C. Natoli, D. Angelucci, R. Tenaglia, B. Fiorentino, P. Di Stefano, C. Amatetti, A. Zezza, M. Nicolai, and S. Iacobelli. 1993. DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer 71:1289–1296.

Tipping, P.G., L.A. Worthington, and S. Holdsworth. 1987. Quantitation and characterization of glomerular procoagulant activity in experimental glomerulonephritis. Lab. Invest. 56:155–159.

Tipping, P.G., J.P. Dowling, and S.R. Holdsworth. 1988. Glomerular procoagulant activity in human proliferative glomerulonephritis. J. Clin. Invest. 81:119–125.

Tipping, P.G., T.W. Leong, and S.W. Holdsworth. 1991a. Tumor necrosis factor production by glomerular macrophages in antiglomerular basement membrane glomerulonephritis in rabbits. Lab. Invest. 65:272–279.

Tipping, P.G., M.G. Lowe, and S.R. Holdsworth. 1991b. Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis. Kidney Int. 39:103–110.

Toback, F.G. 1980. Induction of growth in kidney epithelial cells in culture by Na+. Cell Biol. 11:6654–6656.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Toback, F.G., and L.M. Lowenstein. 1974. Thymidine metabolism during normal and compensatory renal growth. Growth 38:35–44.

Tokarz, J.J., and L.H. Lash. 1993. Primary cultures of isolated rat kidney proximal tubular (PT) and distal tubular (DT) cells for study of cell type-specific chronic injury. The Toxicologist 13:453.

Tokito, F., N. Suzuki, M. Hosoya, H. Matsumoto, S. Ohkubo, and M. Fujino. 1991. Epidermal growth factor (EGF) decreased endothelin-2 (ET-2) production in human renal adenocarcinoma cells. FEBS Lett. 295:17–21.

Tokoff-Rubin, N.E. 1986. Diagnosis of tubular injury in renal transplant patients by urinary assay for proximal tubular antigen, the adenosine-deaminase-binding protein. Transplantation 41:593–599.

Tomisawa, H., H. Fukazawa, S. Ichihara, and M. Tateishi. 1986. A novel pathway for formation of thiol-containing metabolites from cysteine conjugates. Biochem. Pharmacol. 35:2270–2272.

Tomita, Y., Y. Matsumoto, T. Nishiyama, and M. Fujiwara. 1990. Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma. J. Pathol. 162:157–164.

Tosi, P., P. Luzi, and J.P.A. Baak. 1986. Nuclear morphometry as an important prognostic factor in stage I renal cell carcinoma. Cancer 58:2511-2512.

Toyoshima, K. 1990. Proto-oncogene C-erbB-2 and human cancer [in Japanese] . Gan to Kagaku Ryoho 17:309–314.

Trapman, J. 1992. The molecular biology of urological tumors. Prostate Suppl. 4:159–169.

Trifillis, A.L., A.L. Regec, and B.F. Trump. 1985. Isolation, culture and characterization of human renal tubular cells. J. Urol. 133:324–329.

Trump, B.F., M.M. Lipsky, T.W. Jones, B.M. Heatfield, J. Higginson, K. Endicott, and H.B. Hess. 1984a. An evaluation of the significance of experimental hydrocarbon toxicity to man. Pp. 273–288 in Advances in Modern Environmental Toxicology, Vol. VII, Renal Effects of Petroleum Hydrocarbons, M.A. Mehlman, G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton, N.J.: Princeton Scientific Publishers, Inc.

Trump, B.F., T.W. Jones, and B.M. Heatfield. 1984b. The biology of the kidney. Pp. 27–49 in Advances in Modern Environmental Toxicology, Vol. VII, Renal Effects of Petroleum Hydrocarbons, M.A. Mehlman, G.P. Hemstreet, J.J. Thorpe, and N.K. Weaver, eds. Princeton, N.J.: Princeton Scientific Publishers, Inc.

Truong, L., D. Kadmon, B. McCune, K. Flanders, P. Scardino, and T. Thompson. 1993. Association of transforming growth factor-β1, with prostate cancer: An immunohistochemical study. Hum. Pathol. 24:4–9.

Tsai, Y.C., P.W. Nichols, A.L. Hiti, Z. Williams, D.G. Skinner, and P.A. Jones. 1990. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res. 50:44–47.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Tsau, Y.K., J.T. Norman, and L.G. Fine. 1989. Epidermal growth factor (EGF) enhances renal regeneration and accelerates recovery, from ischemic acute renal failure [abstract]. Kidney Int. 35:420.

Tsukamoto, T., Y. Kumamoto, K. Yamazaki, T. Umehara, N. Miyao, K. Ohmura, and M. Iwazawa. 1988. Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm) [in Japanese] Hinyokika Kiyo (Acta Urol. Jpn.) 34:987–995.

Tucker, B.J. and Blantz. 1977. Factors determining superficial nephron filtration in the mature, growing rat. Am. J. Physiol. 232:F97.

Tune, B.M. 1986. The nephrotoxicity of cephalosporin antibiotics-Structure-activity relationships. Comments Toxicol. 1:145–170.

Tupper, J.T., F. Zorgniotti, and B. Mills. 1977. Potassium transport and content during G1 and S phase following serum stimulation of 3T3 cells. J. Cell Physiol. 91:429–440.

Turbat-Herrera, E.A., G.A. Herrera, I. Gore, R.L. Lott, W.E. Grizzle, and J.M. Bonnin. 1988. Neuroendocrine differentiation in prostatic carcinomas: A retrospective autopsy study. Arch. Pathol. Lab. Med. 112:1100–1106.

Tyson, C.K., and J.C. Mirsalis. 1985. Measurement of unscheduled DNA synthesis in rat kidney cells following in vivo treatment with genotoxic agents. Environ. Mutagen. 7:889–899.


Uchida, T., K. Shinohara, K. Kobayashi, N. Honda, T. Ao, T. Omata, K. Odajima, and K. Koshiba. 1986. Tumor markers in renal cell carcinoma [in Japanese] . Hinyokika Kiyo, (Acta Urol. Jpn.) 32:929–940.

Ullrich, K.J., and G. Rumrich. 1993. Renal transport mechanisms for xenobiotics: Chemicals and drugs. Clin. Invest. 71:843–848.

Ulrich, K.J., G. Rumrich, T. Wieland, and W. Dekant. 1989. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of rat kidney. VI. Specificity: Amino acids, their N-methyl-, N-acetyl-, and N-benzoyl derivatives; glutathione-and cysteine conjugates, di-and oligopeptides. Pflfgers Arch. 415:342–350. (Chapter 3)

Umbas, R., J.A. Schalken, T.W. Aalders, B.S. Carter, H.F.M. Karthaus, H.E. Schaafsma, F.M.J. Debruyne, and W.B. Isaacs. 1992. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52:5104–5109.

Unger, P.D., C.W. Watson, Z. Liu, and J. Gil. 1993. Morphometric analysis of neoplastic renal aspirates and benign renal tissue. Anal. Quant. Cytol. Histol. 15:61–66.

USRDS (United States Renal Data System). 1991, United States Renal Data System, USRDS 1991 Annual Report, Bethesda, MD , The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, August 1991.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

USRDS (United States Renal Data System). 1993. Annual Report.


Valles, A., G. Tucker, J. Thiery, and B. Boyer. 1990. Alternative patterns of mitogenesis and cell scattering induced by acidic FGF as a function of cell density in a rat bladder carcinoma cell line. Cell Regul. 1:975–988.

Vamvakas, S., A. Küchling, K. Berthold, and W. Dekant. 1989a. Cytotoxicity of cysteine S-conjugates: Structure-activity relationships. Chem.-Biol. Interact. 71:79–90.

Vamvakas, S., W. Dekant, and M.W. Anders. 1989b. Mutagenicity of benzyl S-haloalkyl and S–74 haloalkenyl Sulfides in the Ames test. Biochem. Pharmacol. 38:935–939.

Vamvakas, S., W. Dekant, and D. Henschler. 1989c. Assessment of unscheduled DNA synthesis in a cultured line of renal epithelial cells exposed to cysteine S-conjugates of haloalkanes and haloalkenes. Mutation Res. 222:329–335.

Vamvakas, S., M. Herkenhoff, W. Dekant, and D. Henschler. 1989d. Mutagenicity of tetrachloroethene in the Ames test--metabolic activation by conjugation with glutathione. J. Biochem. Toxicol. 4:21–27.

van Dalen, A., D.H. Helmhout, and R.D. van Caubergh. 1988. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer. Int. J. Biol. Markers 3:123–126.

vanden Houte, K., R. Kiss, C. de Prez, A. Verhest, J.L. Pasteels, and R. Van Velthoven. 1991. Use of computerized cell image analysis to characterize cell nucleus populations from normal and neoplastic renal tissues. Eur. Urol. 19:155–164.

van der Hout, A.H., E. van den Berg, P. van der Vlies, T. Dijkhuizen, S. Storkel, J.W. Oosterhuis, B. de Jong, and C.H. Buys. 1993. Loss of heterozygosity at the short arm of chromosome 3 in renal-cell cancer correlates with the cytological tumour type. Int. J. Cancer 53:353–357.

van der Poel, H., M. Boon, L. Kok, E. van der Meulen, R. van Caubergh, et al. 1991. Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial) cell carcinoma of the bladder. Anal. Quant. Cytol. Histol. 13:307–315.

van Dierendonck, J., J. Wijsman, R. Keijzer, C.H. van de Velde, and C. Cornelisse. 1991. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am. J. Pathol. 138:1165–1172.

Vandoren, G., B. Mertens, W. Heyns, H. Van Baelen, W. Rombauts, and G. Verhoeven. 1983. Different forms of α2u-globulin in male and female rat urine. Eur. J. Biochem. 134:175–181.

van Leeuwen, E.H., A. Postma, J.W. Oosterhuis, A. Meiring, C.J. Cornelisse, J. Koudstaal, W.M. Molenaar. 1987. An analysis of histology and DNA-ploidy in primary wilms tumors and their metastases and a study of the morphological effects of therapy. Virchows Arch. A: Pathol. Anat. Histopathol. 410:487–494.

van Weerden, W.M., E.P. Moerings, A. van Kreuningen, F.H. de Jong, G.J. van

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Steenbrugge, and F.H. Schroeder. 1993. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif. 26:67–75.

Vancura, P., L. Miller, J.W. Little, and R.A. Malt. 1970. Contribution of glomerular and tubular RNA synthesis to compensatory renal growth. Am. J. Physiol. 219:78–83.

Veloso, J.D., O.G. Solis, J.H. Barada, H.A. Fisher, and J.S. Ross. 1992. DNA ploidy of oncocytic-granular renal cell carcinomas and renal oncocytomas by image analysis. Arch. Pathol. Lab. Med. 116:154–158.

Verpooten, G.F., E.J. Nouwen, M.F. Hoylaerts, P.G. Hendrix, and M.E. De Broe. 1989. Segment-specific localization of intestinal-type alkaline phosphatase in human kidney. Kidney Int. 36:617–625.

Verstrepen, W., E.J. Nouwen, Y. Ziaosheng, and M. De Broe. 1991. Expression of EGF, TGF-alpha, and PDGF-A in the rat kidney during regeneration after acute aminoglycoside toxicity. JASN 2:447A.

Viau, C., A. Bernard, R. Lauwerys, J.P. Buchet, L. Quaeghebeur, M.E. Cornu, S.C. Phillips, A. Mutti, S. Lucertini, and 1. Franchini. 1987, A cross sectional survey of kidney function in oil refinery employees. Am. J. Ind. Med. 11:177–187.

Vinay, P., A. Gougoux, and G. Lemieux. 1981. Isolation of a pure suspension of rat proximal tubules. Am. J. Physiol. 241: F403-F411.

Visakorpi, T., O.P. Kallioniemi, I.Y. Paronen, J.J. Isola, A.I. Heikkinen, and T.A. Koivula. 1991. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy. Br. J. Cancer 64:578–582.

Voeller, H., G. Wilding, and E. Gelmann. 1991. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endicrol 5:209–216.

Volm, M., and T. Efferth. 1990. Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests. Cytometry 11:406–410.

Volm, M., M. Kastel, J. Mattern, and T. Efferth. 1993. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas . Cancer 71:3981–3987.

Vonder Hude, W., A. Basler, R. Mateblowski, and G. Obe. 1989. Genotoxicity of epoxides II. In vitro investigations with the sister chromatid exchange (SCE) test and the unscheduled DNA synthesis (UDS) test. Mutagenesis 4:323.

Vuitch, M.F.; Mendelsohn, G. Relationship of ectopic ACTH production to tumor differentiation: a morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome.. Cancer 47:296–299; 1981.


Waber, P.G., J. Chen, and P.D. Nisen. 1993. Infrequency of ras, p53, WTI, or RB gene alterations in Wilms tumors. Cancer 72:3732–3738.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Wade, T.P., L.G. Comelia, E.R. Sargent, P. Anglard, A. Kasid, and W.M. Linehan. 1989. Southern blot analysis of transformed growth factor alpha and beta DNA in normal kidney and in renal cell carcinoma. Curr. Surg. 46:401–403.

Waldmann, T.A., W. Strober, and R.P. Mogielnicki. 1972. The renal handling of low molecular weight proteins. J. Clin. Invest. 51:2162.

Waldman, F.M., P.R. Carroll, R. Kerschmann, M.B. Cohen, F.G. Field, and B.H. Mayall. 1991. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 51:3807–3813.

Waldman, F.M., P.R. Carroll, M.B. Cohen, R. Kerschmann, K. Chew, and B.H. Mayall. 1993. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder. Mod. Pathol. 6:20–24.

Walker, R.J., and G.G. Duggin. 1988. Drug nephrotoxicity. Annu. Rev. Pharmacol. Toxicol. 28:331–345.

Walker, K.Z., P.J. Russell, E.A. Kingsley, J. Philips, and D. Raghavan. 1989. Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J. Urol, 142:1578–1583.

Walker, C., L. Recio, K. Funaki, and J. Everitt. 1992. Cytogenetic and molecular correlates between rodent and human renal cell carcinoma [review] . Prog. Clin. Biol. Res. 376:289–302.

Wallace, A.C., and R.C. Nairn. 1972. Renal tubular antigens in kidney tumors. Cancer 29:977–981.

Wallin, A., R.G. Gerdes, R. Morgenstern, T.W. Jones, and K. Ormstad. 1988. Features of microsomal and cytosolic glutathione conjugation of hexachlorobutadiene in rat liver. Chem.-Biol. Interact. 68: 1–11.

Wallin, A., G. Zhang, T. Jones, S. Jaken, and J. Stevens. 1992. Mechanism of the nephrogenic repair response. Lab. Invest. 66:474–484.

Walzer, M. 1982. Delay of progression of renal failure. Pp. 23–30 in Prevention of Kidney Disease and Long-Term Survival, M.M. Avram, ed. New York: Plenum.

Wang, Z. 1991. Oncogene ras P 21 expression and DNA ploidy in human bladder tumor [in Chinese]. Zhonghua Zhongliu Zazhi 13:245–248.

Wang, T., and T. Kawaguchi. 1987. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann. Clin. Lab. Sci. 16:461–466.

Wang, M.C., L.A. Valenzuela, G.P. Murphy, and T.M. Chu. 1979. Purification of a human prostate specific antigen. Invest. Urol. 17:159–63.

Watanabe, T., A. Hiratusuka, M. Isobe, and N. Ozawa. 1980. Metabolism of d-Limonene by hepatic microsoms to monmutagenic epoxides toward salmonella typhimurium. Biochem. Pharmacol. 29:1068.

Watanabe, M., Y. Kitamura, S. Komatsubara, and Y. Sakata. 1988. Role of

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer [in Japanese]. Hinyokika Kiyo (Acta Urol. Jpn.) 34:2135–2141.

Waters, W.B., and J.P. Richie. 1979. Aggressive surgical approach to renal cell carcinoma. Review of 130 cases. J. Urol. 122:306–309.

Weaver, M.G., F.W. Abkul-Karim, J. Strigley, D.G. Bostwick, J.Y. Ro, and A.G. Ayala. 1992. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am. J. Surg. Pathol. 16:62–68.

Weaver, D.J., K. Michalski, and J. Miles. 1988. Cytogenetic analysis in renal cell carcinoma: Correlation with tumor aggressiveness. Cancer Res. 48:2887–2889.

Webb, D.R., G.M. Ridder, and C.L. Alden. 1989. Acute and subchronic nephrotoxicity of d-limonene in Fischer 344 rats. Food Chem. Toxicol. 27:639–649.

Weber, P., and J. Rohner. 1987. Importance of acid phosphatase in response criteria for prostate cancer. Urology 30:316–317.

Webster, K.D., and M.W. Anders. 1989. Bioactivation mechanism of L-thiomorpholine-3-carboxylic acid. Arch. Biochem. Biophys. 273:562–571.

Webster, G.D., J.C. Touchstone, and M. Suzuki. 1959. Adenocortical hyperplasia occurring with metastatic carcinoma of the prostate: Report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. J. Clin. Endocrinol. 19:967–979.

Weghorst, C.M., K.H. Dragnev, G.S. Buzard, K.L. Thorne, G.F. Vandeborne, K.A. Vincent, and J.M. Rice. 1994. Low incidence of point mutations detected in the p53 tumor suppressor gene from chemically induced rat renal mesenchymal tumors. Cancer Res. 54:215–219.

Weidner, U., S. Peter, T. Strohmeyer, R. Hussnatter, R. Ackermann, and H. Sies. 1990. Inverse relationship of epidermal growth factor receptor and HER-2/neu gene expression in human renal cell carcinoma. Cancer Res. 50:4504–4509.

Weinberg, J.M., J.A. Davis, M. Abarzua, T. Kiani, and R. Kunkel. 1990. Glycine-dependent protection of proximal tubules against lethal cell injury due to inhibitors of mitochondrial ATP production. Am. J. Physiol. 258:C1127–C1140.

Weiss, R. 1989. Predisposition and prejudice. Sci. News 135:40–42.

Weiss, L.M., M.J. Gaffey, M.J. Warhol, P. Mehta, S.M. Bonsib, E. Bruder, E. Santos, and L.J. Mederios. 1991. Immunocytochemical characterization of a monoclonal antibody directed against mitochondria reactive in paraffin-embedded sections . Mod. Pathol. 4:596–601.

Wells, D., B. Bennett, and W.J. Gardner. 1985. Uses and limitations of prostate-specific antigen in the laboratory, diagnosis of prostate cancer. South. Med. J. 81

Wenk, R.E., B.S. Bhagavan, R. Levy, D. Miller, and W. Weisburger. 1977. Ectopic

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 40:773–778.

Werber, A., S.N. Emancipator, M.L. Lykocinski, and J.R. Sedor. 1987. The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J. Immunol. 138:3207–3212.

Wernert, N., M.B. Raes, P. Lassalle, M.P. Dehouck, B. Gosselin, B. Vandenbunder, and D. Stehelin. 1992. c-etsl proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am. J. Pathol. 140:119–127.

West, S.S. 1970. Biophysical Cytochemistry. Page 451 in Introduction to Quantitative Cytochemistry , Vol. II, G.L. Weid, and G.F. Bahr, eds. New York: Academic Press.

West, S.S., G.P. Hemstreet, R.E. Hurst, et al. 1987. Detection of DNA aneuploidy by quantitative fluorescence image analysis: Potential in screening for occupational bladder cancer. Pp. 327–341 in Biological Monitoring of Exposure to Chemicals, Vol. I. Organic Chemicals, H.K. Dillon, and M. Ho, eds. New York: Wiley.

Wheeless, L.L., J. Coon, C. Cox, A. Deitch, R.W. DeVere White, et al. 1991. Precision of DNA flow cytometry in inter-institutional analyses. Cytometry 12:405–412.

Wheeless, L.L., R.A. Badalament, R.W. DeVere White, Y. Fradet, and B. Tribukait. 1993. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 14:478–481.

Wibel, L., and A. Karlsson. 1976. Urinary excretion of β2-microglobulin after the induction of a diuresis. A study in healthy subjects. Nephron 17:343–352.

Wiggins, R.C., A. Glatfelter, and J. Brukman. Procoagulant activity in glomeruli and urine of rabbits with nephrotoxic nephritis. Lab. Invest. 53:156–165.

Wille, J.J., J. Park, and A. Elgavish. 1992. Effects of growth factors, hormones, bacterial lipopolysaccharides, and lipotechoic acids on the clonal growth of normal ureteral epithelial cells in serum-free culture. J. Cell Physiol. 150:52–58.

Willems, M., H. Musilova, and R.A. Malt. 1969. Giang nucleoplasmic RNA in ''switch on'' of compensatory renal growth, Proc. Natl. Acad. Sci. U.S.A. 62:1189–1194.

Wilson, C.B. 1982. Drug-and toxin-induced nephrotodes: Anti-kidney antibody and immune complex mediation. Pp. 383–392 in Nephrotoxic Mechanisms of Drugs and Environmental Toxins, G.A. Porter, ed. New York: Plenum.

Wilson, P.D., R.J. Anderson, R.D. Breckon, W. Nathrath, and R.W. Schrier. 1987. Retention of differentiated characteristics by cultures of defined rabbit kidney epithelia. J. Cell. Physiol. 130:245–254.

Wise, H.M., A.L. Fohl, A. Gazzaniga, J.H. Harrison. 1965. Hyperadrenocorticism associated with "reactivated" prostatic carcinoma. Surgery 57:655–664.

Wolf, G., and E.G. Neilson. 1990. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am. J. Physiol. 259:F768–F777.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

Wolf, G., and E.G. Neilson. 1991. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int. 39:401–420.

Wolff, G., P.D. Killen, and E.G. Neilson. 1990. Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J. Am. Soc. Nephrol. 1:918–922.

Wolfgang, G.H.I., A.J. Gandolfi, J.L. Stevens, and K. Brendel. 1989, N-Acetyl S-(1,2-dichlorovinyl)-L-cysteine produces a similar toxicity to S-(1,2-dichlorovinyl)-L-cysteine in rabbit renal slices: Differential transport and metabolism. Toxicol. Appl. Pharmacol. 101:205–219.

Wood, D.P., D.D. Wartinger, V. Reuter, C. Cordon-Cardo, W.R. Fair, and R.S. Chaganti. 1991. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J. Urol. 146:1398–1401.

Wood, D.P., W.R. Fair, and R.S. Chaganti. 1992. Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. J. Urol. 147:274–277.

Woolf, C.M. 1960. An investigation of the familial aspects of carcinoma of the prostate. Cancer 13:739–744.

Woolhandler, S., R.J. Pels, D.H. Bor, D.U. Himmelstein, and R.S. Lawrence. 1989. Dipstick urinalysis of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 262:1214–1219.

Wright, C., K. Mellon, P. Johnston, D.P. Lane, A.L. Harris, C.H. Horne, and D.E. Neal. 1991. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer 63:967–970.

Wu, S.-Q., B.E. Storer, E.A. Bookland, A.J. Klingelhutz, K.W. Gilchrist, L.F. Meisner, R. Oyasu, and C.A. Reznikoff. 1991. Nonrandom chromosome losses in stepwise neoplastic transformation in vitro of human uroepithelial cells. Cancer Res. 51:3323–3326.

Wuthrich, R., M.A. Yui, G. Mazoujian, N. Nabavi, L.H. Glimcher, and V.E. Kelley. 1989. Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am. J. Path. 134:45–51.

Wuthrich, R.P., A.M. Jevnikar, F. Takei, L.H. Glimcher, and V.E. Kelley. 1990. Intercellular adhesion molecule-1 (ICAM-l) expression is preregulated in autoimmune murine lupus nephritis. Am. J. Path. 136:441–450.


Yagoda, A., and N.H. Bander. 1989. Failure of cytotoxic chemotherapy, 1983–1988, and the emerging role of monoclonal antibodies for renal cancer [review]. Urol. Int. 44:338–345.

Yamada, T., I. Fukui, T. Kobayashi, H. Sekine, M. Yokogawa, and H. Oshima. 1991. The relationship of ABH(O) blood group antigen expression in intraepithelial

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder. Cancer 67:1661–1666.

Yamakawa, K., R. Morita, E. Takahashi, T. Hori, J. Ishikawa, and Y. Nakamura. 1991. A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res. 51:4707–4711.

Yamamoto et al. 1994.

Yamazaki, K., Y. Kumamoto, T. Tsukamoto, K. Ohmura, N. Miyao, and T. Yoshioka. 1988. The clinical investigation of tumor markers for renal cell carcinoma--a comparison among TPA, ferritin and immunosuppressive substance [in Japanese]. Nippon Hinyokika Gakkai Zasshi (Jpn. J. Urol.) 79:28–34.

Yamazaki, K., Y. Kumamoto, T. Tsukamoto, K. Ohmura, N. Miyao, M. Yoshioka, A. Iwasawa. 1991. Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma (in Japanese). Hinyokika Kiyo (Acta Urol. Jpn.) 37:467–474.

Yao, M., T. Shuin, H. Misaki, and Y. Kubota. 1988. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 48:6753–6757.

Yaqoob, M., and G.M. Bell. 1994. Occupational factors and renal disease. Renal Failure 16:425–434.

Yaqoob, M., G.M. Bell, D. Perdy, and R. Finn. 1992a. Primary glomerulonephritis and hydrocarbon exposure: A case control study and literature review. Q. J. Med. 301:409–418.

Yaqoob, M., A.W. Patrick, P. McClelland, A. McGregor, H. Mason, M.C. White, and G.M. Bell. 1992b. High hydrocarbon exposure in diabetic nephropathy. Nephrol. Dial. Transplant. 8:1157–1158.

Yaquoob, M., A. Stevenson, H. Mason, and G.M. Bell. 1993. Hydrocarbon exposure and tubular damage: Additional factors in the progression of renal failure in primary glomerulonephritis. Q. J. Med. 86:661–667.

Yogi, S., T. Ikeuchi, H. Yoshikawa, T. Hamashima, H. Sasaki, F. Morikawa, Y. Onodera, K. Matsumoto, and Y. Kai. 1991. Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA" [in Japanese]. Hinyokika Kiyo (Acta Urol. Jpn.) 37:335–339.

Yorimitsu, K., O. Shinmi, M. Nishiyama, K. Moroi, Y. Sugita, T. Saito, Y. Inagaki, T. Masaki, and S. Kimura. 1992. Effect of phosphoramidon on big endothelin-2 conversion into endothelin-2 in human renal adenocarcinoma (ACHN) cells. Analysis of endothelin-2 biosynthetic pathway. FEBS Lett. 314:395–398.

Yoshida, S.O., A. Imam, C.A. Olson, and C.R. Taylor. 1986. Proximal renal tubular surface membrane antigens identified in primary and metastatic renal cell carcinomas. Arch. Pathol. Lab. Med. 110:825–832.

Yoshida, M.A., T. lkeuchi, Y. Tachibana, K. Takagi, M. Moriyama, and A. Tonomura.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

1988. Rearrangements of chromosome 3 in nonfamilial renal cell carcinomas from Japanese patients. Jpn. J. Cancer Res. 79:600–607.

Yoshiki, T., K. Okada, K. Oishi, and O. Yoshida. 1987. Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein [in Japanese] . Hinyokika Kiyo, (Acta Urol. Jpn.) 33:2044–2049.

Yoshimura, A., K. Gordon, C.E. Alpers, J. Floege, P. Pritzl, R. Ross, W.G. Couser, D.F. Bowen-Pope, and R.J. Johnson. 1991. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 40: 470–476.

Yoshioka, K., T. Takemura, M. Tohda, N. Akano, H. Miyamoto, A. Ooshima, and S. Maki. 1989. Glomerular localization of type III collagen inhuman kidney disease. Kidney Int. 35:1203–1211.

Young, D.A., G.R. Prout, and C.-W. Lin. 1985. Production and characterization of mouse monoclonal antibodies to human bladder-tumor associated antigens. Cancer Res. 45:4439–4446.

Young, E.W., E.A. Mauger, K-H. Jiang, F.K. Port, and R.A. Wolfe. 1994. Socioeconomic status and end-stage renal disease in the United States. Kidney Int. 45:907–911.

Yu, D.S., J. Wang, S.Y. Chang, and C.P. Ma. 1991. Flow cytometric analysis of DNA ploidy, cell cycle and cytomorphometry in sarcomatoid renal cell carcinoma. Eur. Urol. 20:227–231.

Yu, D.S., C.M. Hsu, W.H. Lee, S.Y. Chang, and C.P. Ma. 1993. Flow cytometric DNA and cytomorphometric analysis in renal cell carcinoma: Its correlation with histopathology and prognosis. J. Surg. Res. 55:480–485.

Yun, S.K., D.J. Laub, D.L. Weese, P.M. Lad, G.E. Leach, and P.E. Zimmern. 1992. Stimulated release of urine histamine in interstitial cystitis. J. Urol. 148:1145–1148.

Yura, Y., O. Hayashi, M. Kelly, and R. Oyasu. 1989. Identification of epidermal growth factor as a component of the rat urinary bladder tumor-enhancing urinary fractions. Cancer Res. 49:1548–1553.


Zager, R.A. 1988. Gentamicin nephrotoxocity in the setting of renal hypoperfusion. Am. J. Physiol. 254:F574–F581.

Zager, R.A., and H.M. Sharma. 1983. Gentamicin increases renal susceptibility to an acute ischemic insult. J. Lab. Clin. Med. 101:670.

Zager, R.A., and M.A. Venkatachalam. 1983. Potentiation of ischemic renal injury by amino acid infusion. Kidney Int. 24:620–625.

Zalups, R.K., and L.H. Lash. 1990. Effects of uninephrectomy and mercuric chloride on renal glutathione homeostasis. J. Pharmacol. Exp. Ther. 254:962–970.

Zalups, R.K., and J.C. Veltman. 1988. Renal glutathione homeostasis in compensatory renal growth. Life Sci. 42:2171–2176.

Zalups, R.K., K.L. Knutson, and R.G. Schnellmann. 1993. In vitro analysis of the

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

accumulation and toxicity of inorganic mercury in segments of the proximal tubule isolated from the rabbit kidney. Toxicol. Appl. Pharmacol. 119:1–7.

Zenser, T.V., and B.B. Davis. 1984. Enzymes systems involved in the formation of reactive metabolites in the renal medulla: Cooxidation via prostaglandin H synthase. Fund. Appl. Toxicol. 4:922–929.

Zhang, G., and J.L. Stevens. 1989. Transport and activation of S-(1,2-dichlorovinyl)-L-cysteine and N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine in rat kidney proximal tubules. Toxicol. Appl. Pharmacol. 100:51-61.

Zimmerman, S.W., K. Groehler, and G.J. Beirne, 1975. Hydrocarbon exposure and chronic glomerulonephritis. Lancet 2:199–202.

Zoja, C., N. Perico and G. Remuzzi. 1989. Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. Toxicol. Lett. 46:65–75.

Zumkeller, W., J. Schwander, C.D. Mitchell, D.J. Morrell, P.N. Schofield, and M.A. Preece. 1993. Insulin-like growth factor (IGF)-I,-II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur. J. Cancer 29A: 1973–1977.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×

There was a problem loading page 310.

Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 227
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 228
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 229
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 230
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 231
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 232
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 233
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 234
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 235
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 236
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 237
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 238
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 239
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 240
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 241
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 242
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 243
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 244
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 245
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 246
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 247
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 248
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 249
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 250
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 251
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 252
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 253
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 254
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 255
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 256
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 257
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 258
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 259
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 260
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 261
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 262
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 263
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 264
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 265
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 266
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 267
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 268
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 269
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 270
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 271
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 272
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 273
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 274
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 275
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 276
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 277
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 278
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 279
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 280
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 281
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 282
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 283
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 284
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 285
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 286
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 287
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 288
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 289
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 290
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 291
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 292
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 293
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 294
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 295
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 296
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 297
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 298
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 299
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 300
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 301
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 302
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 303
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 304
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 305
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 306
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 307
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 308
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 309
Suggested Citation:"REFERENCES." National Research Council. 1995. Biologic Markers in Urinary Toxicology. Washington, DC: The National Academies Press. doi: 10.17226/4847.
×
Page 310
Biologic Markers in Urinary Toxicology Get This Book
×
Buy Paperback | $55.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Diseases of the kidney, bladder, and prostate exact an enormous human and economic toll on the population of the United States. This book examines prevention of these diseases through the development of reliable markers of susceptibility, exposure, and effect and the promise that new technologies in molecular biology and sophisticated understanding of metabolic pathways, along with classical approaches to the study of nephrotoxicants and carcinogens, can be developed and prevention of the diseases achieved. The specific recommendations included in this book complement those made in the previous three volumes on biomarkers, Biologic Markers in Reproductive Toxicology (1989), Biologic Markers in Pulmonary Toxicology (1989), and Biologic Markers in Immunotoxicology (1991).

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!